As filed with the Securities and Exchange Commission on April 10, 2023

Registration No. ____________



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

==================================

WASHINGTON, D.C. 20549

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

==================================
HEALTH REVENUE ASSURANCE HOLDINGS,

AMERIGUARD SECURITY SERVICES, INC.

(Exact Namename of Small Business Issuerregistrant as specified in its Charter)

charter)

Nevada 64117200 99-0363866

(State or other Jurisdictionjurisdiction of

Incorporation)

incorporation or organization)

 

(Primary Standard

Industrial

Classification Code)

Code Number)

 

(IRSI.R.S. Employer


Identification No.)
Number)

8551

5470 W. Sunrise Boulevard, Spruce Avenue, Suite 304

Plantation, Florida 33322
Tel. No.: (954) 472-2340
 (Address102

Fresno, CA

(559)271-5984

(Address, including zip code, and Telephone Numbertelephone number, including area code, of Registrant’s Principal

Executive Officesregistrant’s principal executive offices)

NEVADA AGENCY AND TRANSFER COMPANY

Registered Agent

50 West Liberty Street Suite 880, Reno, NV, 8950

(775)322-0626

(Name, address, including zip code, and Principal Placetelephone number, including area code, of Business)

Copiesagent for service)

With copies to:

Matthew McMurdo

McMurdo Law Group, LLC

1185 Avenue of communications to:

Gregg E. Jaclin, Esq.
Szaferman Lakind Blumstein & Blader, PC
101 Grovers Mill Road
Secondthe Americas, 3rd Floor
Lawrenceville, NJ 08648
Tel. No.: (609) 275-0400
 Fax No.: (609) 555-0969

New York, NY 10036

(917) 318-2865

Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement is declared effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. x

box: ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, of 1933, please check the following box and list the Securities Act registration Statement number of the earlier effective registration statement for the same offering. o

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act of 1933, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

If this Form is a post-effective amendment filed pursuant to Rule 462(d)462(c) under the Securities Act, of 1933, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

 ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large, accelerated filer,” “accelerated filer”filer,” “smaller reporting company,” and “smaller reporting“emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated fileroAccelerated filero
Non-accelerated fileroSmaller reporting companyx
Emerging growth company
 CALCULATION OF REGISTRATION FEE
Title of Each Class Of Securities to be Registered 
Amount to
be
Registered (1)
  
Proposed
Maximum
Aggregate
Offering
Price
per share (2)
  
Proposed
Maximum
Aggregate
Offering
Price
  
Amount of
Registration
fee
 
                 
Common Stock, $0.001 par value per share  
5,125,000
  $0.25  $
1,281,250
  $
165.03
 
(1)       This Registration Statement covers

If an emerging growth company, indicate by check mark if the resale by our selling shareholders of upregistrant has elected not to 5,125,000 shares of common stock previously issueduse the extended transition period for complying with any new or revised financial accounting standards provided pursuant to such shareholders.

Section 7(a)(2)       The offering price has been estimated solely for the purpose of computing the amount(B) of the Securities Act. ☐

The registrant hereby amends this registration feestatement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Rule 457(o)Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the basis of the closing bid price of the common stock of the registrant as reported on the OTCBB on January 31, 2014.

Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

 

THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SUCH SECTION 8(a), MAY DETERMINE.  

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission becomesis effective. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any state where the offer or sale is not permitted.




EXPLANATORY NOTE
This Registration Statement contains one prospectus as set forth below:
Resale Prospectus. A prospectus to be used for the resale by selling stockholders of up to 5,125,000 shares of common stock issued in exchange for compensation to consultants for services performed for the company.
The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the U.S. Securities and Exchange Commission (“SEC”) is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

PRELIMINARY PROSPECTUS   Subject to completion, dated February __, 2014
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
5,125,000 SHARES OF COMMON STOCK
The selling security holders named in this prospectus are offering all of the shares of common stock offered through this prospectus. We will not receive any proceeds from the sale of the common stock covered by this prospectus.

Our common stock is quoted on the Over-The-Counter Bulletin Board (“OTCBB”) under the ticker symbol “HRAA”. The selling security holders have not engaged any underwriter in connection with the sale of their shares of common stock. Common stock being registered in this registration statement may be sold by selling security holders at prevailing market prices or privately negotiated prices or in transactions that are not in the public market. On January 31, 2014, the closing price of our Common Stock was $0.25 per share.
We are an emerging growth company as that term is used in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and are subject to reduced public company reporting requirements.
Investing in our common stock involves a high degree of risk. Before buying any shares, you should carefully read the discussion of material risks of investing in our common stock in “Risk Factors” beginning on page 3 of this prospectus.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the SEC is effective. This preliminary prospectus is not an offer to sell these securities and itCompany is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
HEALTH REVENUE ASSURANCE HOLDINGS,

Selling Shareholder Preliminary Prospectus

Subject to completion April 10, 2023

AMERIGUARD SECURITY SERVICES, INC.

3,585,946 Shares of Common Stock

This prospectus relates to the resale of up to 3,585,946 shares of common stock, $.001 par value, of Ameriguard Security Services, Inc., a Nevada corporation (the “Company” or “AGSS”), by certain shareholders, as described herein (the “Selling Shareholders”), originally issued when Ameriguard Security Services, Inc. (“we”, “AGSS” or the “Company”), entered into a Definitive Share Exchange Agreement (the “Merger Agreement”) with Ameriguard Security Services, Inc., a California corporation, (“Ameriguard”) and Lawrence Garcia (“Garcia”) the majority shareholder of Ameriguard (the “Majority Shareholder”) and the minority shareholders of Ameriguard (“Minority Shareholders”). Under the Merger Agreement, One Hundred Percent (100%) of the ownership interest of Ameriguard was exchanged for an aggregate of 90,000,000 shares of common stock of AGSS issued to the Majority Shareholders and the Minority Shareholders, in accordance with the Merger Agreement (the “Merger”). The former stockholders of Ameriguard acquired a majority of the issued and outstanding common stock as a result of the share exchange transaction.

The total amount of shares of common stock, which may be sold pursuant to this prospectus, would constitute approximately 6.22% of our issued and outstanding common stock as of March 27, 2023.

The Selling Shareholders are selling all the shares of common stock offered by this prospectus. It is anticipated that the Selling Shareholders will sell these shares of common stock from time to time in one or more transactions, in negotiated transactions or otherwise, at prevailing market prices or at prices otherwise negotiated. We will not receive any proceeds from the sale of shares by the Selling Shareholders.

Our common stock is quoted on the OTC Markets Pink under the symbol “AGSS.” On March 27, 2023, the closing price of our common stock was $2.00 per share on the OTC Pink. These prices will fluctuate based on the demand for our common stock.

We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments or supplements carefully before you make your investment decision. The Company is not a blank check company because it has a specific business purpose and has no plans or intention to merge with an operating company. To our knowledge, none of the Company’s shareholders have plans to enter a change of control or change of management. None of our current management has previously been involved with a development stage company that did not implement its business plan, that generated no or minimal revenues or was engaged in a change of control.

The shares being offered. See “Risk Factors” beginning on page 5.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus is February  __, 2014subject to completion April 10, 2023.


PROSPECTUS SUMMARYPAGE1
  1
  25
  3
  711
  7
  712
  8
1013
11
1214
12
  1816
20
2118
21
21
21
2227
37
4128
44
4529
46
4634
  F-1
  II-635
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS36
DESCRIPTION OF SECURITIES37
MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS38
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE40
DISCLOSURE OF COMMISSION POSITION OF INDEMNIFICATION FOR SECURITIES ACT LIABILITIES40
EXPERTS40
WHERE YOU CAN FIND MORE INFORMATION41
FINANCIAL STATEMENTSF-1
Please read this prospectus carefully. It describes our business, our financial condition and results of operations. We have prepared this prospectus so that you will have

You may only rely on the information necessary to make an informed investment decision.

You should rely only on information contained in this prospectus.prospectus or that we have referred you to. We have not authorized any other personanyone to provide you with different information. This prospectus isdoes not constitute an offer to sell nor is it seekingor a solicitation of an offer to buy theseany securities other than the common stock offered by this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any common stock in any state where thecircumstances in which such offer or solicitation is unlawful. Neither the delivery of this prospectus nor any sale is not permitted.  Themade in connection with this prospectus shall, under any circumstances, create any implication that there has been no change in our affairs since the date of this prospectus or that the information incontained by reference to this prospectus is complete and accuratecorrect as of the date on the front cover, but the information may have changed since thatany time after its date.

i

This summary highlights selected information contained elsewhere in this prospectus.Prospectus. This summary does not contain all the information that you should consider before investing in the common stock.stock of Ameriguard Security Services, Inc. (referred to herein as “we,” “our,” “us,” “AGSS” or the “Company”). You should carefully read the entire prospectus,Prospectus, including “Risk Factors”,Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the accompanying financial statements and the related notes to the Financial Statements before making an investment decision. In this Prospectus, the terms “HRAH,” “Company,” “we,” “us” and “our” refer to Health Revenue Assurance Holdings, Inc.

Overview
Health Revenue Assurance Holdings, Inc. (the “Company”)

The information presented is a sourcebrief overview of timely, accuratethe key aspects of the offering. The prospectus summary contains a summary of information contained elsewhere in this prospectus. You should carefully read all information in the prospectus, including the financial statements and critical resources, technology and information that supports the performancenotes to the financial statements under the Financial Statements section beginning on page F-1 prior to making an investment decision.

Corporate History

The Company was incorporated in Nevada on December 13, 2010.

The Company intended to become a provider of revenue integrity in assuring the existencecycle services to a broad range of healthcare organizations. The companyproviders. We offer our customers integrated solutions designed around their specific business needs, including revenue cycle data analysis, contract and its subsidiaries’ products and services include business intelligence technology solutions, contractoutsourced coding, billing, coding and compliance audits, coding education, revenue cyclecoding consulting, physician coding services and ICD-10 education and transition services. The

On February 10, 2012, the Company provides customized solutions to its clientsentered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with the highest regard for ethical standards and responsibility.

Unless the context otherwise requires, all references in this Report to “we,” “us,” “our,” “HRAH” and the “Company” refer collectively to Health Revenue Assurance Holdings, Inc. (formerly known as Anvex International, Inc., “HRAH”), a Nevada corporation,company, and its subsidiaries, includingwholly-owned subsidiary Health Revenue Acquisition Corporation (“Acquisition Sub”), which was treated for accounting purposes as a reverse recapitalization with HRAA, considered the accounting acquirer. Each share of HRAA’s common stock was exchanged for the right to receive approximately 1,271 shares of HRAH’s common stock. Before their entry into the Merger Agreement, no material relationship existed between HRAH and Acquisition Sub or HRAA. On April 27, 2012, the Company completed a 12.98 to 1 forward stock split. On May 2, 2012, the Company changed its ticker symbol from ANVX to HRAA.

The Company then went dormant in August 2014.

On July 14, 2020, as a result of a custodianship in Clark County, Nevada, Case Number: A816259, Custodian Ventures LLC (“Custodian”) was appointed Custodian of the Company.

On July 15, 2020 Custodian appointed David Lazar as the Company’s Chief Executive Officer, President, Secretary, Chief Financial Officer, Chief Executive Officer and Chairman of the Board of Directors.

On September 8, 2021, under the terms of a private stock purchase agreement, 10,000,000 shares of Series A-1 Preferred Stock, $0.001 par value per share (the “Shares”) of the Company, were transferred from Custodian Ventures, LLC to Ameriguard Security Services, Inc. California corporation (Ameriguard). As a result, Ameriguard became holder of approximately 91% of the voting rights of the issued and outstanding share capital of the Company on a fully-diluted basis of the Company, and became the controlling shareholder. The consideration paid for the Shares was $450,000. In connection with the transaction, David Lazar forgave the Company from all debts owed to him and/or Custodian Ventures, LLC.

On September 8, 2021, the Company accepted the resignations from David Lazar as the Company’s Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and as a Member of the Board of Directors. Effective on the same date to fill the vacancies created by Mr. Lazar’s resignations, the Company appointed Lawrence Garcia as the Company’s President, CEO, CFO, Treasurer, Secretary, and Chairman of the Board of Directors. These resignations are in connection with the consummation of the private stock purchase agreement and was not the result of any disagreement with Company on any matter relating to Company’s operations, policies or practices.

On March 11, 2022, the Company, amended its articles of incorporation to change its name to Ameriguard Security Services, Inc. from Health Revenue Assurance Associates,Holdings, Inc. (“HRAA”).The name was deemed effective by FINRA on March 17, 2022.

Pursuant to the Merger Agreement, we acquired the business of Ameriguard and will continue the existing business of Ameriguard as our wholly owned subsidiary.

1


Where You Can Find Us

Ameriguard was formed on November 14, 2002. The corporation was incorporated with the issuance of 1,000 common shares formerly held by Lawrence Garcia, President and CEO with 550 shares and Lillian Flores, former VP of Operations with 450 shares. On July 12, 2022 under the terms of a Settlement Agreement, Flores exchanged her 450 shares for consideration of $3,384,950 and a promissory note in that amount secured by a stock pledge. Ameriguard provides armed guard services as a federal contractor with licenses in 7 states and provides commercial guard services in California.

Ameriguard principally provides guard services to governmental, quasi-governmental and commercial property management. Guard services generated $22 million in revenues for the fiscal year ended December 31, 2021. Guard services include, providing armed and unarmed uniformed security personnel for access control, mobile patrols, traffic control, security console/system operators, fire safety directors, communication, reception, concierge and front desk/doorman operations.

Corporation Information

Our principal executive offices are currently located at 8551 West Sunrise Blvd.,5470 W Spruce Ave Suite 304, Plantation, FL 33322. 102 Fresno CA 93722.

Our telephone number is (954) 472-2340website; www.ameriguardsecurity.com.

Employees

As of December 31, 2022, we had 313 full-time employees, 237 of these employees are represented by collective bargaining agreements and our fax number is (954) 370-0157. the Company considers it relations with its employees to be very good.

Our website is www.healthrevenue.com.


Implications of Being an Emerging Growth Company
We qualify as an emerging growth company as that term is usedIndustry

Security guard and related services in the JOBS Act. An emerging growth company may take advantageUS is a $43 billion industry comprising over 11,000 companies and 900,000 officers. Over 55%, ($24 billion) of specified reduced reportingthis market is serviced by 40 companies, with the top 4 firms, with Allied Universal, Securitas, G4S and other burdens that are otherwise applicable generallyProsegur Security controlling 74% ($31.8 billion), an average revenue of $7.9 billion; the next 21 firms control 8.4% ($3.6billion), an average of 172 million and the next 10 firms control 1% ($550 million) with a range of $20 to public companies. These provisions include:

A requirement to have only two years of audited financial statements and only two years of related MD&A;

Exemption from the auditor attestation requirement in the assessment of the emerging growth company’s internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act of 2002;

Reduced disclosure about the emerging growth company’s executive compensation arrangements; and

No non-binding advisory votes on executive compensation or golden parachute arrangements.
We have already taken advantage$100 million with average of these reduced reporting burdens$50 million. Ameriguard’s approximately $22 million in this prospectus, which are also available to us as a smaller reporting company as defined under Rule 12b-2annual revenue places is within the top 25 firms in the country. The rest of the Securities Exchange Actmarket comprises over 7,900 firms with $19 billion or an average of 1934,$2.5 million in revenue. This consolidation of market share has not been gradual but rather a rapid shift over the last five years in an industry which once was highly fragmented and widely dispersed, from smaller regional and local companies to the largest companies.

We believe that the top 40 companies have the resources to harness technology, to expand their business into related services other than guard services. Companies with over $50 million in revenue have, over the last 10 years, experienced steady growth while those guard companies under $20 million, the remaining 9,900 firms, have experienced declining revenues. We believe that the principal reason for this is the steady diversification of security services away from the traditional guard services to areas of utilization of technology requiring capital. Along with this, we believe that the profitability challenges below $20 million annual sales are much more difficult that above $50 million is sales, largely due to the significant economies of scale achieve at the higher revenue levels.

The proliferation of technology while increasing efficacy in performance and inevitably lower costs in the future, the impact on the contract security industry will likely have mixed results – positive for companies who harness technology into their service delivery strategies – and negative for those companies who fail to invest in or adopt these service-enhancing capabilities. Despite the advances in the U.S. contract guarding business over recent years, there remains a question as amended (the “Exchange Act”).

In addition, Section 107to the industry’s viability in view of the JOBS Act also providesincreasing trend for integrating manned services with security systems (i.e. security video, access control and monitoring) along with the emergence of other new smart technology options and solutions (i.e. robotics, drones, cybersecurity and crowd sharing alert notification).

The recent merger and acquisition trend, primarily by the major national and international security organizations and fueled by investment and funding from private equity firms, is continuing. The underlying reason for this shift is less obvious and suggests an increasing number of sellers who concluded that an emerging growth company can taketheir better option was to exit and sell rather than remain in the marketplace and try to compete and organically grow their market share.

Despite its low barriers of entry and nominal capital requirements, the security guard business has become more challenging for the smaller owner/operator. The traditionally historic advantage of the extended transition period provided in Section 7(a)(2)(B)smaller operator’s ability to offer relationship-driven customized services is no longer totally sufficient for sustainable growth – especially with the increasing regulatory challenges of the SecuritiesAffordable Care Act, federal and state minimum wage laws, Family Medical Leave Act and state laws (i.e. meal and rest break reporting and now, predictive scheduling).

2

Even stronger local and smaller regional companies are finding it more difficult to protect their client base and grow revenues under increasing regulatory as well as competitive pressures. Larger regional and national organizations are dealing with the regulatory climate while growing market share by leveraging infrastructure, technology, economies of 1933, as amended (the “Securities Act”) for complyingscale with new or revised accounting standards. We have electedmore aggressive pricing and better service reliability. This approach appears to useoffer a more compelling value proposition from the extended transition period provided above and therefore our financial statementsclient’s perspective, which seems evident by the higher client retention rates reported by the major security companies.

However, this consolidating trend may not be comparableinevitable for the future as newer, more tech-savvy owner/operators enter the business and recognize how to adopt best practices with a variety of sophisticated third-party software platforms and applications to help level the playing field. These include talent management and on-boarding applications to attract, hire and maintain a more skilled and reliable workforce; integrated labor management platforms to control scheduling, compliance, operations, payroll, billing and financial reporting; and state-of-the-art social media marketing applications.

The contract security industry should now be able to more effectively capitalize on and penetrate opportunities in a $20 billion in-house market – especially for those companies that complywho have invested and integrated technology into a more highly reliable ecosystem of protective services.

For the foreseeable future, the U.S. manned guarding business seems likely for continued sustainable growth. While the technology/manpower ratio may shift the revenue mix going forward, based on today’s currently expanding U.S. economy, the prospects for an aggregate growth rate of four percent or more seem realistic and perhaps even conservative, especially for ownership who have prudently invested in technology enhancements to their core guarding operations.

Providing these strategies can yield an attractive ROI, increase operating profits (EBITDA ranges of four to six percent and higher) and enterprise valuations, this industry seems not only viable but also opportune for further investment consideration.

(The above industry data taken from https://www.nasco.org/wp-content/uploads/2021/08/2021-Bob-Perry-Contract-Security-Industry-White-Paper-1.pdf)

Regulatory Matters/Compliance

Each State has specific licensing requirements companies must meet to perform guard services, especially armed guard services. To date, the Company holds firearm licenses in over twelve States and does not foresee any license or governmental requirements preventing us from continuing to operate in any State a contract is awarded to us. As a company with public company effective dates.

We could remain an emerging growth company for upover 300 employees, we are subject to five years, or until the earliest of (i) the last dayall of the first fiscal yearstandard federal and state labor laws and have consistently met those requirements to date, including ERISA.

Contracting officers have indicated that they believe the government has no concern relating to the merger as long as the responsible person(s) remains.

Properties

The Company’s corporate headquarters is located at 5470 W. Spruce Avenue, Suite 102, Fresno CA. The lease is currently month to month. Landlord has not indicated a desire for a new lease. Our lease payments are a total of $55,767 for the entire term (or, $4,230 per month).

Legal Proceedings

While we have not been involved in whichany litigation related to the performance of our annual gross revenues exceed $1 billion, (ii)guard services, armed or otherwise, to date, as an armed guard Company with contracts with Governmental entities is a possibility of legal proceedings that could be more serious than the dateaverage business. From time to time, the Company is involved in matters relating to claims arising from the ordinary course of business, but those claims have been labor and union related and have been settled on an administrative level not in court.

While the results of such claims and legal actions cannot be predicted with certainty, the Company’s management does not believe that we become a “large accelerated filer” as defined in Rule 12b-2 underthere are claims or actions, pending or threatened against the Exchange Act,Company, the ultimate disposition of which would occur if the market valuehave a material adverse effect on our business, results of our common stock that is held by non-affiliates exceeds $700 million asoperations, financial condition or cash flows.

3

The Terms of the last business day of our most recently completed second fiscal quarter, or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three year period.

For more details regarding this exemption, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies.”
Offering

Securities OfferedBeing Offered:
5,125,0003,585,946 shares of common stock being registered on behalf of Health Revenue Assurance Holdings, Inc., par value $0.001 per share (the “Common Stock”). This number represents approximately 9.36% of our current outstanding common stock).
the Selling Shareholders.
   
Common stock outstanding
beforeOffering Period:
Until all shares are sold by the offering:54,752,294Shareholders or until 12 months from the date that the registration statement becomes effective, whichever comes first.
   
Common stock outstanding
after the offering:
Risk of Factors:
54,752,294
Terms of the Offering
Termination of the Offering:
The selling security holders will determine when and how they will sell the common stock offered in this prospectus.
The offering will conclude upon the earliest of (i) such time as all of the common stock has been sold pursuant to the registration statement or (ii) such time as all of the common stock becomes eligible for resale without volume limitations pursuant to Rule 144 under the Securities Act, or any other rule of similar effect.
OTCBB Trading Symbol:HRAA
Use of proceeds:We are not selling any shares of the common stock covered by this prospectus. As such, we will not receive any of the offering proceeds from the registration of the shares of common stock covered by this prospectus.
Risk Factors:The Common Stock offered hereby involvesinvolve a high degree of risk and should not be purchased by investors who cannot afford the loss of their entire investment. See “Risk Factors” beginning on page 3.Factors.”
Common Stock Issued and Outstanding Before Offering:93,418,291 shares of our common stock are issued and outstanding as of the date of this Prospectus.
Common Stock Issued and Outstanding After Offering:93,418,291 shares of common stock.
Use of Proceeds:We will not receive any proceeds from the sale of the common stock by the Selling Shareholders. See “Use of Proceeds.”

4

The information contained

RISK FACTORS

An investment in this prospectus, includingour securities is highly speculative and subject to numerous and substantial risks. These risks are set forth below. You should not invest in the documents incorporated by reference into this prospectus, includes some statements that are not purely historical and that are “forward-looking statements.” Such forward-looking statements include, but are not limited to, statements regarding our Company and management’s expectations, hopes, beliefs, intentions or strategies regarding the future, including our financial condition, results of operations, and the expected impact of the offering on the parties’ individual and combined financial performance. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipates,” “believes,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “possible,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” “would” and similar expressions, or the negatives of such terms, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements contained in this prospectus are based on current expectations and beliefs concerning future developments and the potential effects on the parties and the transaction. There can be no assurance that future developments actually affecting us will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the parties’ control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.
The shares of our common stock being offered are highly speculative in nature, involve a high degree of risk and should be purchased only by persons whounless you can afford to lose theyour entire amount invested in the common stock. Before purchasinginvestment. Readers are encouraged to review these risks carefully before making any of the shares of common stock, you should carefully consider the following factors relating to our business and prospects. If any of the following risks actually occurs, our business, financial condition or operating results could be materially adversely affected. In such case, you may lose all or part of your investment.  You should carefully consider the risks described below and the other information in this process before investing in our common stock.

investment decision.

Risks Related to Our Corporate Business

Going Concern

:

Concentration of Revenue

The Company’s future success is dependent uponcompany receives over 90% of its ability to achieve profitable operations and generate cashtotal revenue from operating activities, and upon additional financing, Management believesfour Federal contracts. These contracts have specific terms, typically five years with the opportunity for extension, but there are no assurances they can raisewill be extended. Although we have had several extended in the appropriate funds needed to support their business plan and develop an operating company which is cash flow positive. The Company has not been able to generate sufficient cash from operating activities to fund its ongoing operations. Therepast, there is no guarantee this will again happened in the future. However, there are significant direct expenses for each contract that also are removed from operations at the end of a contract. As a result, the revenue lost from a completed contract does not affect the bottom-line profits in an amount equal to the revenue lost. The actual net income impact depends on the contract. To mitigate this risk the company actively pursues additional contracts on an ongoing basis.

Long process in acquiring contracts

The process required to acquire a government contract takes several months to complete prior to delivery of the proposal to the contracting agency. Due to the time span required to prepare a proposal and wining the contract is not guaranteed, the company maintains a department of individuals who monitor and write proposals for all government contracts that fit our operating criteria that become open for bid on a continuing basis. It is important to the company that new contracts are acquired consistently to maintain and grow annual revenue

Transitioning from carve out contracts to open market contracts

Currently the company benefits from several ownership criteria and business size that increases the probability of contract awards. The company meets the contracting qualifications of disabled veteran and minority owned business. Another aspect of contract opportunities is set aside for small businesses. This as defined as those who have operating revenue on average over the past five (5) years under $25.5 million. Currently the company is below this threshold, yet our strategic plan is to move past the average revenue limits within the next 24 months. This should not be seen as a negative in that we will only exceed this limit once we reach annual revenue of $40 million or more during the next 24 months, putting us in an excellent financial position to compete with the much larger companies who operate in the $50-$100 million revenue level. Another aspect of our strategy is to acquire similar guard companies who already have small business contracts with the government which add significantly to our bottom line putting us in even a better position to win additional large government contracts.

Staffing Shortages

Like all industries today, the guard industry is not exempt from staffing shortages. This is an ongoing challenge and in its worst case can impact our ability to meet the requirements of the contracts awarded. The company nor our competitors have discovered a silver bullet to address this challenge. However, we have developed a strategy that we anticipate will help meet the challenge. This strategy does need to remain confidential so as to not tip our hand to our competitors. We will indicate that we have successfully implemented this strategy in the past and it was very successful.

Impact of COVID

Initially the impact of the COVID pandemic was positive for the guard industry. Our industry is considered essential and with less activity at the sites we protect, we were able to meet and exceed the contract requirements with fewer staff and little to no overtime. As a result, each contract became more profitable than normal full operations. The challenges have actually come after the critical year of 2020. As the government began to require vaccinations for all employees and contractors, along with quarantine requirements, staffing became a big problem. Starting in 2021 and continuing to today, these policies implemented by the federal government has made it very difficult for us to meet the staffing needs and thus as increased overtime expenses to levels never before seen. As we discussed regarding staffing shortages this is where COVID has had the greatest impact on us, and it continues. However, during August the CDC released new guideline relating to vaccines, transmission, and quarantines that if implemented by the federal government will help us recover from the staffing shortages. If the federal government adjusts to the new guidelines, we will see individuals returning to their guard positions.

5

Accelerating Inflation

All industries struggle when operating in times of inflation like we are experiencing in 2022. The results are increased pressure on salaries, operational costs increase due to higher fuel prices and the increased cost of all supplies. The one silver lining for the company is that federal contacts require that the Company willsalary increases that we negotiate with the labor union must be able to generate enough revenue and/or raise capital to support its operations. These factors raise substantial doubt aboutcovered by increasing the Company’s ability to continue as a going concern.


monthly contracted rate. This of course is stipulated by contract that we do not exceed what is customary in the area with related contracts. This is significant in that guard salaries account for over 90% of operational costs, reducing the impact of inflation.

Key employees are essential to expanding our business.


Andrea Clark

Lawrence Garcia and Robert Rubinowitzother key employees are essential to our ability to continue to grow and expand our business. Mr. Garcia, as owner, allows the company to bid on the restricted contracts that we discussed earlier regarding transitioning out of the special carveout contracts. Other long-term employees have significant impact on the success of operations and understanding of the industry. They have established relationships within the industry in which we operate. If theyMr. Garcia or any of the long-term employees were to leave us,the company, our growth strategy might be hindered, which could materially affect our business and limit our ability to increase revenue.

However, we are taking steps to implement process and procedure to insure no single person lost would be detrimental to our long- term success.

If we are unable to establish appropriate internal financial reporting controls and procedures, it could cause us to fail to meet our reporting obligations, result in the restatement of our financial statements, harm our operating results, subject us to regulatory scrutiny and sanction, cause investors to lose confidence in our reported financial information and have a negative effect on the market price for shares of our Common Stock.

Effective internal controls are necessary for us to provide reliable financial reports and to effectively prevent fraud. We currently do not maintain a system of internal control over financial reporting, which is defined as a process designed by, or under the supervision of, our principal executive officer and principal financial officer, or persons performing similar functions, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

As a public company, we will have significant requirements for enhanced financial reporting and internal controls. We will be required to implement, document and test our internal control procedures in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act of 2002, which requires annual management assessments of the effectiveness of our internal controls over financial reporting. The process of designing and implementing effective internal controls is a continuous effort that requires us to anticipate and react to changes in our business and the economic and regulatory environments and to expend significant resources to maintain a system of internal controls that is adequate to satisfy our reporting obligations as a public company.

We cannot assure you that we will not, in the future, be able to successfully implement proper internal control over financial reporting. We cannot assure you that the measures we will take to implement in any area of financial reporting in need of internal controls will be successful or that we will implement and maintain adequate controls over our financial processes and reporting in the future as we continue our growth. If we are unable to establish appropriate internal financial reporting controls and procedures, it could cause us to fail to meet our reporting obligations, result in the restatement of our financial statements, harm our operating results, subject us to regulatory scrutiny and sanction, cause investors to lose confidence in our reported financial information and have a negative effect on the market price for shares of our Common Stock.
In order to improve our internal controls and procedures in the area of SEC, generally accepted accounting principles (GAAP) and tax accounting procedures, we realize the importance therefore; we began to take steps to address these matters.  As of the date of this registration statement, we have hired an internal control specialist to assist in the design, implementation, and test of adequate controls. We have made pivotal progress to mitigate internal control weaknesses; however, we must still complete the process of design-specific control procedures and test their effectiveness, and maintaining sufficient personnel to implement these tasks before we can report that this weakness has been fully remediated.
Lack of experience as officers of publicly-traded companies of

Although our management team, may hinder our abilityCEO and CFO, have not specifically managed a publicly traded company, we do have experience with the issues and requirements of Sarbanes-Oxley Act. The company CFO is a California CPA with over 30 years of experience in business operations and has been through multiple financial statement audits that required compliance with the Sarbanes-Oxley Act. Management has already identified individuals and consultants who can support management’s efforts to comply with Sarbanes-Oxley Act.


It may be time consuming, difficult and costly for us to develop and implement theall internal controls and reporting procedures required by the Sarbanes-Oxley Act. We may need to hire additional financial reporting, internal controls and other finance staff or consultants in order to develop and implement appropriate internal controls and reporting procedures.
We compete with many other companies in the market for contract coding and revenue consulting services which may result in lower prices for our services, reduced operating margins and an inability to maintain or increase our market share.

We compete with other companies in a highly fragmented market that includes national, regional and local service providers, as well as service providers with global operations. These companies have services that are similar to ours, and certain of these companies have substantially greater financial resources than we do. There can be no assurance thatrequirements. The company is confident we will be able to compete effectively against our competitors or timely implement new products and services. Many of our competitors attempt to differentiate themselves by offering lower priced alternatives to our outsourced medical transcription services and customers could elect to utilize less comprehensive solutions than the ones we offer due to the lower costs of those competitive products. Some competition may even be willing to accept less profitable business in order to grow revenue. Increased competition and cost pressures affecting the healthcare markets in general may result in lower prices for our services, reduced operating margins and the inability to maintain or increase our market share.

Our growth is dependent on the willingness of new customers to outsource their coding work to us.

We plan to grow, in part, by capitalizing on perceived market opportunities to provide our services to new customers. These new customers must be willing to outsource functions which may otherwise have been performed within their organizations. Many customers may prefer to remain with their current provider or keep their coding in-house rather than outsource such services to us. Also, as the maintenance of accurate medical records is a critical element of a healthcare provider’s ability to deliver quality care to its patients and to receive proper and timely reimbursement for the services it renders, potential customers may be reluctant to outsource or change providers of such an important function.

meet all requirements.

Technology innovations in the markets that we serve may create alternatives to our products and result in reduced sales.


sales.

Technology innovations to which our current and potential customers might have access to, could reduce or eliminate their need for our services. ALike all industries as new or other disruptive technology that reduces or eliminates the use of one or more of our services could negatively impact the need for our services. OurHowever, our management team and board of directors are aware of this challenge and are very innovative and forward thinking. Yet, our failure to develop, introduce or enhance our services able to compete with new technologies in a timely manner could have an adverse effect on our business, results of operation and financial condition. The management team is continually focused on improvements and new technology to insure we are not left behind.

6

We may engage in a business combination that causes tax consequences to us and our shareholders.

Federal and state tax consequences can be a significant factor in considering any business combination that we may undertake. As a result, such transactions may be subject to significant taxation to the buyer and its shareholders under applicable federal and state tax laws. While we intend to structure any business combination so as to minimize the federal and state tax consequences to the extent practicable in accordance with our business objectives, there can be no assurance that any business combination we undertake will meet the statutory or regulatory requirements of a tax-free reorganization or similar favorable treatment or that the parties to such a transaction will obtain the tax treatment intended or expected upon a transfer of equity interests or assets. A non-qualifying reorganization, combination or similar transaction could result in the imposition of significant taxation, both at the federal and state levels, which may have an adverse effect on both parties to the transaction, including our shareholders.

It is unlikely that our shareholders will have any opportunity to evaluate or approve a business combination.

Our growth objectives are largely dependentshareholders will not have the opportunity to evaluate and approve the business combination. In most cases, business combinations do not require shareholder approval under applicable law, and our Articles of Incorporation and Bylaws do not afford our shareholders with the right to approve such a transaction. Further, Mr. Garcia, our Chief Executive Officer and sole director, is the holder of over 86% of the voting rights of the Company on a fully diluted basis. Accordingly, our shareholders will be relying almost exclusively on the timing and market acceptancejudgement of our new product offerings, includingboard of directors (“Board”) and Chief Executive Officer and any persons on whom they may rely with respect to a potential business combination. To develop and implement our abilitybusiness plan, may in the future hire lawyers, accountants, technical experts, appraisers, or other consultants to continually renewassist with determining the Company’s direction’ and consummating any transactions contemplated thereby. We may rely on such persons in making difficult decisions in connection with the Company’s future business and prospects. The selection of any such persons will be made by our pipelineBoard, and any expenses incurred, or decisions made based on any of new products and to bring those products to market.

Our ability to continually renew our pipeline of new products and bring those products to market may be adversely affected by difficulties or delays in product development, such as the inability to identify viable new products, obtain adequate intellectual property protection, or gain market acceptance of new products. There are no guarantees that new products willforegoing could prove to be commercially successful.
The Department of Health and Human Services has announced a delay in initiating the implementation of the ICD-10 system.
In January 2009, the United States Department of Health and Human Services (“HHS”) published a final rule which mandated a change in medical coding in United States health care settings from the current system, International Classification of Diseases, 9th Edition, Clinical Modification (ICD-9-CM),averse to the International ClassificationCompany in hindsight, the result of Diseases, 10th Edition, Clinical Modification/Procedure Coding System (ICD-10-CM/PCS). Compliance with this ruling waswhich could be diminished value to be achieved by October 1, 2013. The new, mandated version expands the number of codes from 24,000 to 155,000, making it more precise and descriptive and more accurately describing the diagnoses and inpatient procedures of care delivered. The transition to ICD-10-CM/PS will require significant business and systems changes throughout the health care industry and will impact all processes and people from finance to compliance to doctors.
On April 9, 2012, as published in the Federal Register, citing concerns about the ability of provider groups to meet the looming compliance deadline to adopt ICD-10-CM/PCS, HHS announced a proposed rule which would delay the implementation date to October 1, 2014. Interested parties had the ability to comment during a period ending 30 days after the date of the announcement. On August 27, 2012, Health and Human Services Secretary Kathleen Sebelius announced the release of a rule that makes final a one-year proposed delay—from October 1, 2013, to October 1, 2014 — in the compliance date for the industry's transition to ICD-10 codes.
our shareholders.

Risks Related to Our SecuritiesStockholders and Purchasing Shares of Common Stock

We have not voluntarily implemented various corporate governance measures.

Federal legislation, including the Sarbanes-Oxley Act of 2002, has resulted in the adoption of various corporate governance measures designed to promote the integrity of the corporate management and the securities markets. Some of these measures have been adopted in response to legal requirements. Others have been adopted by companies in response to the requirements of national securities exchanges, such as the NYSE or The NASDAQ Stock Market, on which their securities are listed. Among the corporate governance measures that are required under the rules of national securities exchanges are those that address board of directors’ independence, audit committee oversight and the adoption of a Code of Ethics. Our Board of Directors expects to adopt a Code of Ethics at its next Board meeting. The Company has not adopted exchange-mandated corporate governance measures and, since our securities are not listed on a national securities exchange, we are not required to do so. It is possible that if we were to adopt some or all these corporate governance measures, stockholders would benefit from somewhat greater assurances that internal corporate decisions were being made by disinterested directors and that policies had been implemented to define responsible conduct. For example, in the absence of audit, nominating and compensation committees comprised of at least most independent directors, decisions concerning matters such as compensation packages to our senior officers and recommendations for director nominees may be made by most directors who have an interest in the outcome of the matters being decided. Prospective investors should bear in mind our current lack of corporate governance measures in formulating their investment decisions.

We may be exposed to potential risks relating to our internal control over financial reporting.

As directed by Section 404 of the Sarbanes-Oxley Act of 2002 (“SOX 404”), the SEC has adopted rules requiring public companies to include a report of management on the Company’s internal control over financial reporting in its annual reports. While we expect to expend significant resources in developing the necessary documentation and testing procedures required by SOX 404, there is a risk that we will not comply with all the requirements imposed thereby. At present, there is no precedent available with which to measure compliance adequately. In the event we identify significant deficiencies or material weaknesses in our internal control over financial reporting that we cannot remediate in a timely manner, investors and others may lose confidence in the reliability of our financial statements and our ability to obtain equity or debt financing could suffer.

7

We have many authorized but unissued shares of our common stock.

We have many authorized but unissued shares of common stock, which our management may issue without further stockholder approval, thereby causing dilution of your holdings of our common stock. Our management will continue to have broad discretion to issue shares of our common stock in a range of transactions, including capital-raising transactions, mergers, acquisitions and other transactions, without obtaining stockholder approval, unless stockholder approval is required. If our management determines to issue shares of our common stock from the large pool of authorized but unissued shares for any purpose in the future, your ownership position would be diluted without your further ability to vote on that transaction.

Shares of our common stock may become illiquidity because our shares may begin to be thinly traded and may never become eligible for trading on a national securities exchange.

While we may at some point be able to meet the requirements necessary for our common stock to be listed on a national securities exchange, we cannot assure you that we will ever achieve a listing of our common stock on a national securities exchange. Our shares are currently only eligible for quotation on the OTC Pink, which is not an exchange. Initial listing on a national securities exchange is subject to a variety of requirements, including minimum trading price and minimum public “float” requirements, and could also be affected by the general skepticism of such markets concerning companies that are the result of mergers with inactive publicly-held companies. There are also continuing eligibility requirements for companies listed on public trading markets. If we are unable to satisfy the initial or continuing eligibility requirements of any such market, then our stock may not be listed or could be delisted. This could result in a lower trading price for our common stock and may limit your ability to sell your shares, any of which could result in you losing some or all your investments.

The market valuation of our business may fluctuate due to factors beyond our control and the value of your investment may fluctuate correspondingly.

The market valuation of emerging growth companies, such as us, frequently fluctuate due to factors unrelated to the past or present operating performance of such companies. Our market valuation may fluctuate significantly in response to several factors, many of which are beyond our control, including:

i.changes in securities analysts’ estimates of our financial performance, although there are currently no analysts covering our stock;

ii.fluctuations in stock market prices and volumes, particularly among securities of emerging growth companies;

iii.changes in market valuations of similar companies;

iv.announcements by us or our competitors of significant contracts, new technologies, acquisitions, commercial relationships, joint ventures or capital commitments;

v.variations in our quarterly operating results;

vi.fluctuations in related commodities prices; and

vii.additions or departures of key personnel.

As a result, the value of your investment in us may fluctuate.

We have never paid dividends on our common stock.

We have never paid cash dividends on our common stock and do not presently intend to pay any dividends in the foreseeable future. Investors should not look to dividends as a source of income.

In the interest of reinvesting initial profits back into our business, we do not intend to pay cash dividends in the foreseeable future. Consequently, any economic return will initially be derived, if at all, from appreciation in the fair market value of our stock, and not because of dividend payments.

8

Future sales or perceived sales of our common stock could depress our stock price.

This resale prospectus covers 3,585,946 shares of common stock underlying the Warrants. If the holders of these shares were to attempt to sell a substantial amount of their holdings at once, the market price of our common stock could decline. Moreover, the perceived risk of this potential dilution could cause shareholders to attempt to sell their shares and investors to short the common stock, a practice in which an investor sells shares that he or she does not own at prevailing market prices, hoping to purchase shares later at a lower price to cover the sale. As each of these events would cause the number of shares of our common stock being offered for sale to increase, our common stock market price would likely further decline. All these events could combine to make it very difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate.

Due to factors beyond our control, our stock price may be volatile.

Any of the following factors could affect the market price of our common stock:

The continued COVID-19 pandemic and its adverse impact upon the capital markets;

The loss of one or more members of our management team;

Our failure to generate material revenues;

Regulatory changes including new laws and rules which adversely affect companies in our line of business;

Our public disclosure of the terms of any financing which we consummate in the future;

An announcement that we have effected a reverse split of our common stock;

Our failure to become profitable;

Our failure to raise working capital; 

Any acquisitions we may consummate;

Announcements by us or our competitors of significant contracts, new services, acquisitions, commercial relationships, joint ventures or capital commitments;

Cancellation of key contracts;

Our failure to meet financial forecasts we publicly disclose;

Short selling activities; or

Changes in market valuations of similar companies.

In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs and divert our management’s time and attention, which would otherwise be used to benefit our business.

Offers or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.

The existence of shares of common stock issuable upon conversion of outstanding shares of Preferred Stock, creates a circumstance commonly referred to as an “overhang” which can act as a depressant to our common stock price. The existence of an overhang, whether sales have occurred or are occurring, also could make our ability to raise additional financing through the sale of equity or equity-linked securities more difficult in the future at a time and price that we deem reasonable or appropriate. If our existing shareholders and investors seek to sell a substantial number of shares of our common stock, such selling efforts may cause significant declines in the market price of our common stock.

9

Because we may issue preferred stock without the approval of our shareholders and have other anti-takeover defenses, it may be more difficult for a third party to acquire us and could depress our stock price.

In general, our Board may issue, without a vote of our shareholders, one or more additional series of preferred stock that have more than one vote per share. Additionally, issuance of preferred stock could block an acquisition resulting in both a drop in our stock price and a decline in interest of our common stock. This could make it more difficult for shareholders to sell their common stock. This could also cause the market price of our common stock shares to drop significantly, even if our business is performing well.

Because certain of our stockholders control a significant number of shares of our voting capital stock, they have effective control over actions requiring stockholder approval.

As of March 27, 2023, Lawrence Garcia, our Chief Executive Officer, effectively held 86.26% of the Company’s issued and outstanding common stock. As a result, Mr. Garcia can control the outcome of matters submitted to our stockholders for approval, including the election of directors and any merger, consolidation or sale of all or substantially all our assets. In addition, Mr. Garcia can control the management and affairs of our company. Accordingly, any investors who purchase shares will be minority shareholders and as such will have little to no say in the direction of us and the election of directors. Additionally, this concentration of ownership might harm the market price of our common stock by:

delaying, deferring or preventing a change in corporate control;

impeding a merger, consolidation, takeover or other business combination involving us; or

discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us

Our common stock is considered a “penny stock.”

The SEC has adopted regulations which generally define “penny stock” to be an equity security that has a market price of less than $5.00 per share, subject to specific exemptions. The market price of our common stock may be volatile.

The market price of our common stock has been and will likely continue to be highly volatile, as is the stock market in general, and the market for OTC Bulletin Board quoted stocks in particular. Some of the factors that may materially affect the market price of our common stock are beyond our control, such as changes in financial estimates by industry and securities analysts, conditions or trends in the industry in which we operate or sales of our common stock. These factors may materially adversely affect the market price of our common stock, regardless of our performance. In addition, the public stock markets have experienced extreme price and trading volume volatility. This volatility has significantly affected the market prices of securities of many companies for reasons frequently unrelated to the operating performance of the specific companies. These broad market fluctuations may adversely affect the market price of our common stock.
Because we were engaged in a reverse merger, it may not be able to attract the attention of major brokerage firms.
Additional risks may exist since we were engaged in a “reverse merger.” Securities analysts of major brokerage firms may not provide coverage of the Company since there is little incentive to brokerage firms to recommend the purchase of the common stock. No assurance can be given that brokerage firms will want to conduct any secondary offerings on behalf of the Company in the future.
Our common stock will be considered a “penny stock” which may be subject to restrictions on marketability, so you may not be able to sell your shares.
If our common stock becomes tradable in the secondary market, we will be subject to the penny stock rules adopted by the Securities and Exchange Commission that require brokers to provide extensive disclosure to their customers prior to executing trades in penny stocks. These disclosure requirements may cause a reduction in the trading activity of our common stock, which in all likelihood would make it difficult for our shareholders to sell their securities.
Penny stocks generally are equity securities with a price ofcurrently less than $5.00 (other than securities registered onper share and therefore may be a “penny stock.” Brokers and dealers effecting transactions in “penny stock” must disclose certain national securities exchanges or quoted on the NASDAQ system). Penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson inconcerning the transaction, and monthly account statements showing the market value of each penny stock held in the customer’s account. The broker-dealer must also makeobtain a special written determination that the penny stock is a suitable investment foragreement from the purchaser and receivedetermine that the purchaser’s written agreementpurchaser is reasonably suitable to purchase the transaction. These requirements may have the effect of reducing the level of trading activity, if any, in the secondary market for a security that becomes subject to the penny stock rules. The additional burdens imposed upon broker-dealers by such requirements may discourage broker-dealers from effecting transactions in our securities, which could severely limit the market price and liquidity of our securities. These requirementsrules may restrict the ability of broker-dealersbrokers or dealers to sell our common stock and may affect your ability to resellsell shares.

10

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus includes forward-looking statements. All statements other than statements of historical facts contained in this prospectus, including statements regarding our common stock.

future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The market for penny stocks has experienced numerous fraudswords “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect” and abuses which could adversely impact investors in our stock.
OTCBB securitiessimilar expressions, as they relate to us, are frequent targets of fraud or market manipulation, both because of their generally low prices and because OTCBB reporting requirements are less stringent than those of the stock exchanges or NASDAQ.

Patterns of fraud and abuse include:
Control of the market for the security by one or a few broker-dealers that are often related to the promoter or issuer;
Manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases;
“Boiler room” practices involving high pressure sales tactics and unrealistic price projections by inexperienced sales persons;
Excessive and undisclosed bid-ask differentials and markups by selling broker-dealers; and
Wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, along with the inevitable collapse of those prices with consequent investor losses.
Our management is aware of the abuses that have occurred historically in the penny stock market.
intended to identify forward-looking statements. We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of our stock.
We have never paid any cash dividendsbased these forward-looking statements largely on our common stockcurrent expectations and do not anticipate paying any cash dividends on our common stock in the foreseeableprojections about future events and any return on investment may be limited to the value of our common stock. We plan to retain any future earning to finance growth.
We are an “Emerging Growth Company,” and any decision on our part to comply only with curtained reduced disclosure requirements applicable to “Emerging Growth Company” could make our common stock less attractive to investors.
We are an “emerging growth company,” as defined in the JOBS Act, and, for as long as we continue to be an “emerging growth company,” we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to “emerging growth companies,” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We could be an “emerging growth company” for up to five years, or until the earliest of (i) the last day of the first fiscal year in which our annual gross revenues exceed $1 billion, (ii) the datefinancial trends that we become a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three year period.
In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to opt in to the extended transition period for complying with the revised accounting standards.
Because we have elected to defer compliance with new or revised accounting standards, our financial statement disclosurebelieve may not be comparable to similar companies.
We have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. This allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of our election, our financial statements may not be comparable to companies that comply with public company effective dates.
Our status as an “Emerging Growth Company” under the JOBS Act of 2012 may make it more difficult to raise capital as and when we need it.
Because of the exemptions from various reporting requirements provided to us as an “emerging growth company” and because we will have an extended transition period for complying with new or revised financial accounting standards, we may be less attractive to investors and it may be difficult for us to raise additional capital as and when we need it. Investors may be unable to compare our business with other companies in our industry if they believe that our financial accounting is not as transparent as other companies in our industry. If we are unable to raise additional capital as and when we need it,affect our financial condition, and results of operations, business strategy and financial needs. These forward-looking statements are subject to several risks, uncertainties and assumptions described in “Risk Factors” and elsewhere in this prospectus.

Other sections of this prospectus may include additional factors that could adversely affect our business and financial performance. Moreover, we operate in a highly regulated, very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

We undertake no obligation to update publicly or revise any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events or performance. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be materiallyachieved or will occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We have an ongoing obligation to continually disclose material future changes in the Company and adversely affected.its operations.

11

USE OF PROCEEDS

We will not receive any of the proceeds from the sale of the common stock by the Selling Shareholders.

12

DETERMINATION OF OFFERING PRICE

The Selling Shareholders may sell their shares in the over-the-counter market or otherwise, at market prices prevailing at the time of sale, at prices related to the prevailing market price, or at negotiated prices. We will not receive any proceeds from the sale of shares by the Selling Shareholders.

13

THE SELLING SHAREHOLDERS

A portion of the Selling Shareholders for approximately ten (10) years, with them currently restricted under the Securities Act of 1933, as amended. A certain Selling Shareholder was issued his shares in 2014 with a Rule 144 legend on it. Certain shareholders were issued an aggregate of 675,000 shares upon the conversion of preferred shares. The remaining Selling Shareholders were issued their shares of common stock byon or about December 9, 2022, pursuant to the selling security holders. AllMerger Agreement, whereby Ameriguard became a wholly owned subsidiary of AGSS, and AGSS its only shareholder. The Selling Shareholders relinquished all of their Ameriguard common shares, in exchange for the net proceeds from the resaleshares of our common stock will go to the selling security holders as described belowbeing registered in the sections entitled “Selling Security Holders” and “Plan of Distribution.” We have agreed to bear thethis registration statement on Form S-1.

All expenses relatingincurred with respect to the registration of the common stock for the selling security holders.


The prices at which the shares or common stock covered by this prospectus may actually be sold will be determinedborne by the prevailing public market price for sharesCompany, but we will not be obligated to pay any underwriting fees, discounts, commission or other expenses incurred by Selling Shareholders in connection with the sale of common stock, by negotiations betweensuch shares. 

None of the selling security holders and buyersSelling Shareholders nor any of our common stocktheir associates or affiliates has held any position, office, or other material relationship with us in private transactions or as otherwise described in “Plan of Distribution.”

The common stock to be sold by the selling shareholders is common stock that is currently issued and outstanding. Accordingly, there will be no dilution to our existing shareholders. 
The common shares being offered for resale by the selling stockholders consist of 5,125,000 shares of common stock consisting of shares issued as compensation to employees and consultants.
past three years.

The following table sets forth the namesname of the selling stockholders,Selling Shareholders, the number of shares of common stock beneficially owned by eachthe Selling Shareholders as of the selling stockholders as of January 31, 2014date hereof and the number of shares of common stock being offered by the selling stockholders.Selling Shareholders. The offer and sale of the shares being offered hereby are being registered to permit public secondary trading, and the selling stockholders may offer all or part of the shares for resale from time to time. However, the selling stockholdersherein. The Selling Shareholders are under no obligation to sell all or any portion of such shares nor are the selling stockholders obligated to sell any shares immediately upon effectiveness of this prospectus.shares. All information with respect to share ownership has been furnished by the selling stockholders.Selling Shareholders, respectively. The “Amount Beneficially Owned After the Offering” column assumes the sale of all shares offered herein.

Name Shares of
Common Stock
Beneficially
Owned prior to
Offering
  Maximum
Number of
Shares of
Common Stock
to be Offered
  Number of
Shares of
Common
Stock
Beneficially
Owned after
Offering
  Percent
Ownership
after Offering
 
STEPHANIE POPE(1)  140,625   140,625   0   0%
STACEY VARGAS(1)  140,625   140,625   0   0%
MICHAEL ROMERO(1)  140,625   140,625   0   0%
MARTHA GARCIA(1)  140,625   140,625   0   0%
LEO REIJNDERS(1)  140,625   140,625   0   0%
LAWRENCE GARCIA JR.(1)  140,625   140,625   0   0%
LAURA GARCIA(1)  140,625   140,625   0   0%
HARLAN HARTMAN(1)  140,625   140,625   0   0%
GCT EQUITY HOLDINGS, LLC(1)  1,125,000   1,125,000   0   0%
ALI MUSLEH(1)  140,625   140,625   0   0%
                 
ALMORLI ADVISORS, INC.(2)  5,000   5,000   0   0%
WALD BLOISE(2)  2,500   2,500   0   0%
INTERED, INC(2)  2,500   2,500   0   0%
JOSEPH BROPHY(2)  16,983   16,983   0   0%
CARL ABBONIZIO(2)  2,500   2,500   0   0%
DANNY FEDER(2)  6,250   6,250   0   0%
ROBERT FREEDMAN(2)  7,500   7,500   0   0%
SERGE MILMAN(2)  1,250   1,250   0   0%
ROY LANTZ(2)  517   517   0   0%
ALAN DRUCKER(2)  1,429   1,429   0   0%
JIA LI(2)  179   179   0   0%
SUSAN HUDDLESTON(2)  715   715   0   0%
RONNIE EBANKS(2)  1,250   1,250   0   0%
VALERIE A. RINKLE(2)  1,000   1,000   0   0%
GREGORY S. DAHL(2)  90   90   0   0%

JAMES MCCORMACK(2)  36,667   36,667   0   0%
JOSEPH E. TOENISKOETER(2)  100   100   0   0%
KEITH LUNEBURG(2)  36,667   36,667   0   0%
ROBERTA A. ANDERSON(2)  1,000   1,000   0   0%
DEAN BOYER(2)  32,250   32,250   0   0%
BRUCE A OSBORN(2)  554   554   0   0%
DANIEL J HAPNER(2)  893   893   0   0%
DENISE WILLIAMS(2)  1,647   1,647   0   0%
GARRY BACHER(2)  200   200   0   0%
MARILYN HAPNER(2)  179   179   0   0%
PEGGY M HAPNER(2)  358   358   0   0%
SECURE INVESTIGATION CONSULTING(2)  900   900   0   0%
MARIO SCINICARIELLO(2)  10,078   10,078   0   0%
FINEST MANAGEMENT LLC(2)  2,500   2,500   0   0%
LOUIS J. ALIMENA(2)  5,000   5,000   0   0%
ANTHONY MANGANARO(2)  2,692   2,692   0   0%
DONNA RUDOLPH(2)  274   274   0   0%
ELEANOR EDELSTEIN(2)  138   138   0   0%
EMILY EDELSTEIN(2)  410   410   0   0%
GARRY CONNELL(2)  2,692   2,692   0   0%
JUGNA SHAH(2)  4,543   4,543   0   0%
KAREL GINSBERG(2)  1,363   1,363   0   0%
LINDA PRESTO(2)  410   410   0   0%
LINDA RUBINOWITZ(2)  1,363   1,363   0   0%
PEGGY HAPNER(2)  1,363   1,363   0   0%
S&S FISCHER HOLDINGS, LP(2)  6,814   6,814   0   0%
SAM CZYSZ(2)  274   274   0   0%
SAM WAKSMAN(2)  2,726   2,726   0   0%
CHRISTIE RAMPONE(2)  1,250   1,250   0   0%
FIDELIS HOLDINGS LLC(2)  4,499   4,499   0   0%
BRADLEY JAMES COHEN(2)  10,384   10,384   0   0%
EDWARD ROSENTHAL(2)  3,750   3,750   0   0%
MARTIN J. HASEY(2)  15,117   15,117   0   0%
RICHARD COHEN & WILLA COHEN TEN ENT(2)  10,385   10,385   0   0%
VINCENT BURKE AND TONI BURKE TEN ENT(2)  2,017   2,017   0   0%
DIRING HOLDING LLC(2)  341   341   0   0%
DON LUNEBURG(2)  70,697   70,697   0   0%
GLENN COTTON(2)  101,639   101,639   0   0%
WILLIAM E. SCHIFFER(2)  59,024   59,024   0   0%
                 
HERBERT C POHLMANN, JR. TR(3)  37,500   37,500   0   0%
                 
BIOMEDICAL INSTITUTIONAL VALUE FUND, L.P.(4)  75,262   75,262   0   0%
BIOMEDICAL OFFSHORE VALUE FUND, LTS.(4)  166,137   166,137   0   0%
BIOMEDICAL VALUE FUND, L.P.(4)  293,132   293,132   0   0%
CLASS D SERIES GEF-PS, L.P.(4)  122,788   122,788   0   0%
WS INVESTMENTS II, LLC(4)  17,682   17,682   0   0%

 
8

Health Revenue Assurance Associates
Selling Shareholders Share List
Name of Selling Stockholder Shares Beneficially Owned Prior to Offering 
Shares to be 
Offered
 
Amount 
Beneficially 
Owned 
After 
Offering
  
Percent
Beneficially
Owned
After Offering (1)
 
           
Brett Borgersen   320,000 320,000  0   0%
John Paul O'Connor **   1,830,100 1,830,000  100   0%
Maurizio Corrao **  445,000 225,000  220,000   0.40%
Michael Ciprianni **  2,800,000 2,550,000  250,000   0.46%
Robert Freedman **   1,231,533 150,000  1,081,533   1.97%
Wald Bloise   70,000 50,000  20,000   0.04%
Total  6,696,633 5,125,000  1,571,633   2.87%
(1) Based on 54,752,294 shares outstanding as of January 31, 2014.
** Based on the combined total of the transfer agent Stock Report dated December 31, 2013 and Non Objective Beneficial Ownership report dated January 6, 2014.
These 5,125,000 shares of common stock being registered consist of shares issued as compensation to consultants for services performed for the company.
To our knowledge  (with the exception of  Mr. Michael Ciprianni a 5% beneficial owner, that entered into a material definitive consulting agreement as further disclosed in the footnote below) none of the selling stockholders or their beneficial owners:
-has had(1)These Selling Shareholders were issued their 2,390,625 shares of common stock on or about December 9, 2022, pursuant to the Merger Agreement, whereby Ameriguard became a material relationship with us other than as a shareholder at any time within the past three years; or
-has ever been onewholly owned subsidiary of our officers or directors or an officer or director of our predecessors or affiliates 
-are broker-dealers or affiliated with broker-dealers. AGSS, and AGSS its only shareholder.
(2)These Selling Shareholders were issued an aggregate of 482,821 restricted shares between February 15, 2012 and October 9, 2013, by the prior management of the Company.
(3)This Selling Shareholder was issued the 37,500 shares on April 23, 2014 by the prior management of the Company.
(4)These Selling Shareholders were issued the aggregate of 675,000 shares in March of 2023, upon the conversion of their preferred stock.

15

Footnote

On September 9, 2013, the Company entered into a one year Material Consulting Agreement with Mr. Michael Ciprianni to provide certain consulting services related to the Company’s business in exchange for four million one hundred twenty five thousand (4,125,000) shares of Common Stock in consideration of the services to be rendered.

This prospectus relates to the resale of up to 5,125,0003,585,946 shares of common stock issued as compensation to employees and consultants.


Each selling stockholder of our common stock by the Selling Shareholders, issued pursuant to the Merger Agreement.

The Selling Shareholders, and any of their pledgees, donees, assignees and other successors-in-interest may, from time to time sell any or all of their shares of common stock covered hereby on the principal trading market or any other stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. A selling stockholderThe Selling Shareholders may use any one or more of the following methods when selling shares:

ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;the purchaser;

block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to principal;
facilitate the transaction;
purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
an exchange distribution in accordance with the rules of the applicable exchange;
privately negotiated transactions;
settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part;
in transactions through broker-dealers thatmay agree with the Selling StockholdersShareholders to sell a specified number of such shares at a stipulated price per share;
through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;on the shares
a combination of any such methods of sale; orand
any other method permitted pursuant to applicable law.

The selling stockholdersSelling Shareholders, as applicable, shall have the sole and absolute discretion not to accept any purchase offer or make any sale of shares if it deems the purchase price to be unsatisfactory at any time.

The Selling Shareholders may also sell the shares under Rule 144 under the Securities Act, if available, rather than under this prospectus.

Broker-dealers engaged by the selling stockholders may arrangedirectly to market makers acting as principals and/or broker-dealers acting as agents for other brokers-dealers to participate in sales.  Broker-dealersthemselves or their customers. Such broker-dealers may receive commissionscompensation in the form of discounts, concessions or discountscommissions from the selling stockholders (or, if any broker-dealer acts as agent forSelling Shareholders and/or the purchaserpurchasers of shares fromfor whom such broker-dealers may act as agents or to whom they sell as principal or both, which compensation as to a particular broker-dealer might be more than customary commissions. Market makers and block purchasers purchasing the purchaser) in amountsshares will do so for their own account and at their own risk. It is possible that the Selling Shareholders will attempt to be negotiated, but, except as set forth in a supplement to this Prospectus, in the casesell shares of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2440.
In connection with the sale of the common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in block transactions to market makers or other purchasers at a price per share which may be below the course of hedging the positions they assume.  The selling stockholders may also sell sharesthen existing market price. We cannot assure that all or any of the common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities.  The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered byin this prospectus which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
will be sold by the Selling Shareholders. The selling stockholdersSelling Shareholders, and any broker-dealers or agents, that are involvedupon completing the sale of any of the shares offered in selling the sharesthis prospectus, may be deemed to be “underwriters” within the meaning ofas that term is defined under the Securities Act, in connection withthe Exchange Act and the rules and regulations of such sales.acts. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.  Each selling stockholder has informed the Company that it does not have

The Selling Shareholders, alternatively, may sell all or any written or oral agreement or understanding, directly or indirectly, with any person to distribute the common stock. In no event shall any broker-dealer receive fees, commissions and markups which, in the aggregate, would exceed eight percent (8%).  


Because selling stockholders may be deemed to be “underwriters” within the meaningpart of the Securities Act, they will be subject to theshares offered in this prospectus delivery requirements of the Securities Act including Rule 172 thereunder.through an underwriter. The selling stockholdersSelling Shareholders have advised us thatnot entered into any agreement with a prospective underwriter and there is no underwriter or coordinating broker acting in connection withassurance that any such agreement will be entered.

16

The Selling Shareholders may pledge its shares to its brokers under the proposed salemargin provisions of customer agreements. If any of the resale shares bySelling Shareholders default on a margin loan, the selling stockholders.

Under applicable rulesbroker may, from time to time, offer and regulations undersell the Exchange Act,pledged shares. The Selling Shareholders, and any person engagedother persons participating in the sale or distribution of the resale shares may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution.  In addition, the selling stockholders will be subject to applicable provisions of the Exchange Act, and the rules and regulations thereunder,under such act, including, without limitation, Regulation M, whichM. These provisions may restrict certain activities of and limit the timing of purchases and sales of any of the shares by any of the Selling Shareholders, or any other such person. Under Regulation M, persons engaged in a distribution of securities are prohibited from simultaneously engaging in market making and certain other activities with respect to such securities for a specified period prior to the commencement of such distributions, subject to specified exceptions or exemptions. All these limitations may affect the marketability of the shares.

The Selling Shareholders will be offering such shares for its own account. We do not know for certain how or when the Selling Shareholders will choose to sell its shares of common stock. However, it can sell such shares at any time or through any manner set forth in this plan of distribution.

To permit the Selling Shareholders to resell the shares of common stock issued to it, we agreed to file a registration statement, of which this prospectus is a part, and all necessary amendments and supplements with the SEC for the purpose of registering and maintaining the registration of the shares. We will bear all costs relating to the registration of the common stock offered by this prospectus, other than the selling stockholders or any other person.costs of our independent legal review. We will make copieskeep the registration statement effective until the earlier of this prospectus available to(i) the selling stockholders and have informed themdate after which all of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).

Authorized Capital and Preferred Stock
Our authorized capital stock consists of 500,000,000 shares of common stock par value $0.001 per share and 25,000,000 shares of preferred stock, par value $0.001 per share. As of January 31, 2014, there were 54,752,294 shares of common stock and 13,500,000 of Series A 8% Convertible Preferred Stock outstanding.
Common Stock
The following is a summary of the material rights and restrictions associated with our common stock.
The holders of our common stock currently have: (i) equal ratable rights to dividends from funds legally available therefore, when, as and if declaredheld by the Board of Directors of the Company; (ii)Selling Shareholders that are entitled to share ratably in all of the assets of the Company available for distribution to holders of common stock upon liquidation, dissolution or winding up of the affairs of the Company; (iii) do not have preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions or rights applicable thereto; and (iv) are entitled to one non-cumulative vote per share on all matters on which stock holders may vote. Please refer to the Company’s Articles of Incorporation, Bylaws and the applicable statutes of the State of Nevada for a more complete description of the rights and liabilities of holders of the Company’s securities.
Preferred Stock
On October 17, 2013, the Company amended its articles of incorporation to create a new class of stockcovered by the authorization of 25,000,000 preferred shares of stock. Please refer to the Company’s Articles of Incorporation, Bylaws and the applicable statutes of the State of Nevada for a more complete description of the rights and liabilities of holders of the Company’s securities.
Series A 8% Convertible Preferred Stock
On November 12, 2013, the Company filed a certificate of Certificate Of Designation Of Preferences, Rights and Limitations of Series A 8% Convertible Preferred Stock (the “Certificate of Designation”). A total of 13,500,000 shares of Series A Preferred Stock have been authorized for issuance under the Certificate Of Designation. The shares of Series A Preferred Stock have a stated value of $0.40 per share and are initially convertible into 27,000,000 shares of Common Stock at a price of $0.20 per share (subject to adjustment as provided in the Certificate of Designation).
Under the Certificate of Designation, the holders of the Series A Preferred Stock have the following rights, preferences and privileges:
The Series A Preferred Stock may, at the option of the holder, be converted at any time or from time to time into fully paid and non-assessable shares of Common Stock at the conversion price in effect at the time of conversion;  provided , that a holder of Series A Preferred Stock may at any given time convert only up to that number of shares of Series A Preferred Stock so that, upon conversion, the aggregate beneficial ownership of the Company’s Common Stock (calculated pursuant to Rule 13d-3 of the Securities Exchange Act) of such holder and all persons affiliated with such Purchaser, is not more than 9.985% of the Company’s Common Stock then outstanding. The number of shares into which one share of Series A Preferred Stock shall be convertible is determined by dividing the stated value of $0.40 per share plus the amount of any accrued and unpaid dividends thereon (the “ Stated Value ”), by the initial Conversion Price. The “Conversion Price” per share for the Series A Preferred Stock is initially equal to $0.20 (subject to appropriate adjustment for certain events, including stock splits, stock dividends, combinations, recapitalizations or other recapitalizations affecting the Series A Preferred Stock).
Shares of the Series A Preferred Stock shall receive dividends at an annual rate equal to 8% of the Stated Value per share for each of the then outstanding shares of Series A Preferred Stock. In the event of a liquidation, the Series A Preferred Stock is also entitled to a liquidation preference equal to the greater of: (i) the Stated Value in respect of such Series A Preferred Stock and (ii) an amount equal to the amount which the holder of Series A Preferred Stock would be entitled had the Series A Preferred Stock been converted to common stock immediately prior to such liquidation.
Except as otherwise required by law, the holders of shares of Series A Preferred Stock shall vote on an as-if-converted-to-Common-Stock basis with the Common Stock and shall not vote separately as a class. However, as long as any shares of Series A Preferred Stock are outstanding, the Company shall not, without the prior written consent of at least sixty-seven percent (67%) of the then outstanding Series A Preferred Stock: (a) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock or alter or amend the Certificate of Designation, (b) offer or sell following the date hereof any preferred stock of the Company or any security convertible into or exercisable for preferred stock of the Company, (c) permit any subsidiary of the Company to offer or sell following the date hereof any capital stock of such subsidiary, (d) create, incur, issue, assume, guaranty or suffer to exist, or permit any subsidiary of the Company to create, incur, issue, assume guaranty or suffer to exist, any indebtedness other than trade debt and capital lease obligation incurred in the ordinary course of business, (e) declare or pay dividends on, or make distributions with respect to, any capital stock of the Company, (f) effect a stock split or reverse stock split of the Series A Preferred Stock or any like event, (g) directly or indirectly redeem, purchase or acquire, or make a liquidation payment with respect to, or pay or make available monies for a sinking fund for the redemption of, any Common Stock or other Junior Securities, (h) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the Holders, (i) increase the number of authorized shares of Series A Preferred Stock, (j) enter into any Fundamental Transaction or (k) enter into any agreement with respect to any of the foregoing.
At any time following the forty-eighth (48th) month following the issuance of the Series A Preferred Stock, at the option of the holder, each share of Series A Preferred Stock shall be redeemable for an amount equal to the Stated Value.
Warrants
After September 30, 2013 but prior to the Securities Purchase Agreement (defined below) the Company had issued 2,415,000 Warrants. Of the 2,415,000 warrants, 1,890,000 have an exercise price of $0.30 and no expiration date. The remaining balance of 525,000 warrants were issued with an exercise price of $0.40; they have certain rights that include price protection and may be adjusted from time to time pursuant to the terms and conditions of the warrant agreement, and they have a five year expiration period.
On November 12, 2013, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain funds and accounts as to which Great Point Partners, LLC acts as an investment manager, in which the Company issued the following to the purchasers: (i) 13,500,000 shares of Series A Preferred Stock; and (ii) Warrants to purchase an aggregate of 27,000,000 shares of Common Stock for an exercise price of $0.30 per share.
Each Warrant entitles the Investor to purchase the number of shares into which such Purchaser’s Series A Preferred Stock is initially convertible. The Warrants are exercisable in whole or in part, at an initial exercise price per share of $0.30 (subject to adjustment) (the “Exercise Price”), and may be exercised in a cashless exercise. The exercise price and number of shares of Common Stock issuable under the Warrants are subject to adjustments for stock dividends, splits, combinations, subsequent rights offerings, pro rata distributions and similar events. Additionally, for the first two years following the issuance of the Warrant, at any time that the Company issues any common stock at a price less than the Exercise Price, the Exercise Price shall then be reduced to that lower issuance price. After the second anniversary of the Warrant, if the Company issues any common stock at a price less than the Exercise Price, the Exercise Price shall then be reduced on a weighted average calculation. Any adjustment to the Exercise Price shall similarly cause the number of warrant shares to be adjusted proportionately so that the total value of the Warrants shall remain the same. In the case of certain fundamental transactions affecting the Company, the holders of the Warrants will have the right to elect a cash payment in exchange for the then outstanding warrants in an amount equal to the Black-Scholes value of those warrants.
The number of outstanding warrants as of the date of this prospectus, of which this registration statement is a part, is 29,415,000.
Options
The Company employees, officers, and directors have outstanding stock options of 1,636,000 to purchase our securities as of January 31, 2014.
No expert or counsel named in this prospectus as having prepared or certified any part of this prospectus or having given an opinion upon the validity of the securities being registered or upon other legal matters in connection with the registration or offering of the common stock was employed on a contingency basis, or had, or is to receive, in connection with the offering, a substantial interest, direct or indirect, in the registrant or any of its parents or subsidiaries. Nor was any such person connected with the registrant or any of its parents or subsidiaries as a promoter, managing or principal underwriter, voting trustee, director, officer, or employee.
The financial statements as of December 31, 2012 included in this prospectus and the registration statement have been auditedsold by Salberg & Company, P.A.the Selling Shareholders pursuant to such registration statement and (ii) the extent and forfirst day of the periods set forth in their report appearing elsewhere herein and inmonth next following the 36-month anniversary of the date the registration statement, to which this prospectus is made a part, is declared effective by the SEC.

17

BUSINESS

Changes to the Business.

We intend to continue Ameriguard’s line of business. Ameriguard principally provides guard services to governmental, quasi-governmental and commercial property management. Guard services generated $22 million in revenues for the fiscal year ended December 31, 2021. Guard services include, providing armed and unarmed uniformed security personnel for access control, mobile patrols, traffic control, security console/system operators, fire safety directors, communication, reception, concierge and front desk/doorman operations.

Corporation Information

Our principal executive offices are included in reliance upon such report given upon the authority of said firm as experts in auditing and accounting.

The financial statements ascurrently located at 5470 W Spruce Ave Suite 102 Fresno CA 93722.

Our website; www.ameriguardsecurity.com.

Employees

As of December 31, 2011 included in this prospectus2022, we had 313 full-time employees, 237 of these employees are represented by collective bargaining agreements and the registration statement have been audited by Friedman LLPCompany considers it relations with its employees to the extent and for the periods set forth in their report appearing elsewhere herein and in the registration statement, and are included in reliance upon such report given upon the authority of said firm as experts in auditing and accounting.

The validity of the issuance of the common stock hereby will be passed upon for us by Szaferman Lakind Blumstein & Blader, PC., Lawrenceville, New Jersey.
very good.

Corporate History

The Company iswas incorporated in Nevada on December 13, 2010.

The Company intended to become a trusted source of timely, accurate and critical resources, technology and information that supports the performanceprovider of revenue integrity in assuring the existencecycle services to a broad range of healthcare organizations. The companyproviders. We offer our customers integrated solutions designed around their specific business needs, including revenue cycle data analysis, contract and its subsidiaries’ products and services include business intelligence technology solutions, contractoutsourced coding, billing, coding and compliance audits, coding education, revenue cyclecoding consulting, physician coding services and ICD-10 education and transition services. The Company provides customized solutions to its clients with the highest regard for ethical standards and responsibility.

Health Revenue Assurance Associates, Inc., a Maryland corporation and subsidiary of the Company (“HRAA”), was incorporated under the laws of the State of Maryland on February 21, 2001 as Healthcare Revenue Assurance Associates, Inc. Effective June 2001, HRAA changed its name to Health Revenue Assurance Associates, Inc.
Dream Reachers, LLC (“Dream Reachers”), owns the Company’s offices and is the borrower on a mortgage loan related to such offices. Dream Reachers does not engage in real estate rental business. Its offices are occupied by HRAA at no cost and HRAA pays the related mortgage’s principal and interest, taxes and maintenance. Dream Reachers was previously treated as a VIE, but became a wholly owned subsidiary in May 2011, and has been treated as such for accounting purposes in the Company’s consolidated financial statements.

On February 10, 2012, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Health Revenue Acquisition Corp.Assurance Holdings, Inc. (formerly known as Anvex International, Inc., “HRAH”), a Nevada corporationcompany, and its wholly-owned subsidiary Health Revenue Acquisition Corporation (“Acquisition Sub”), andwhich was treated for accounting purposes as a reverse recapitalization with HRAA, pursuant to which Acquisition Sub was merged with and into HRAA, and HRAA, asconsidered the surviving corporation, became a wholly-owned subsidiary of the Company (the “Merger”).accounting acquirer. Each share of HRAA'sHRAA’s common stock was exchanged for the right to receive approximately 1,271 shares of the Company’sHRAH’s common stock. Before their entry into the Merger Agreement, no material relationship existed between HRAH and Acquisition Sub or HRAA. On April 27, 2012, the Company or Acquisition Sub andcompleted a 12.98 to 1 forward stock split. On May 2, 2012, the Company changed its ticker symbol from ANVX to HRAA.

Prior to the closing

The Company then went dormant in August 2014.

On July 14, 2020, as a result of a custodianship in Clark County, Nevada, Case Number: A816259, Custodian Ventures LLC (“Custodian”) was appointed Custodian of the Merger, we transferred all of our operating assetsCompany.

On July 15, 2020 Custodian appointed David Lazar as the Company’s Chief Executive Officer, President, Secretary, Chief Financial Officer, Chief Executive Officer and liabilities to Anvex Split Corp., a Nevada corporation (the “Split-Off Subsidiary”), and contemporaneously with the closingChairman of the Merger, we split-offBoard of Directors.

On September 8, 2021, under the Split-Off Subsidiary through the saleterms of alla private stock purchase agreement, 10,000,000 shares of Series A-1 Preferred Stock, $0.001 par value per share (the “Shares”) of the outstanding capital stockCompany, were transferred from Custodian Ventures, LLC to Ameriguard Security Services, Inc. California corporation (Ameriguard). As a result, Ameriguard became holder of approximately 91% of the Split-Off Subsidiary (the “Split-Off”) to our former sole officervoting rights of the issued and director (the “Split-Off Shareholder”).outstanding share capital of the Company on a fully-diluted basis of the Company, and became the controlling shareholder. The consideration paid for the Shares was $450,000. In connection with the Split-Off, an aggregate of 3,500,000 shares of our common stock held bytransaction, David Lazar forgave the Split-Off Shareholder were surrenderedCompany from all debts owed to him and/or Custodian Ventures, LLC.

18

On September 8, 2021, the Company accepted the resignations from David Lazar as the Company’s Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and cancelled without further consideration.

Pursuant to the terms and conditionsas a Member of the Merger Agreement,Board of Directors. Effective on the same date to fill the vacancies created by Mr. Lazar’s resignations, the Company appointed Lawrence Garcia as the Company’s President, CEO, CFO, Treasurer, Secretary, and uponChairman of the Board of Directors. These resignations are in connection with the consummation of the Merger:

Each share of HRAA’s common stock issued and outstanding immediately prior to the closing of the Merger was converted into the right to receive 1,271,111 shares of the Company’s common stock.  An aggregate of 1,271,111 shares of the Company’s common stock were issued to the holders of HRAA’s common stock.  Immediately prior to the Merger, HRAA had no outstanding securities other than shares of its common stock. 
Anna Vechera resigned as the Company’s sole officer and director, and simultaneously with the Merger, a new board of directors and new officers were appointed. The Company’s new board of directors consisted of Robert Rubinowitz, Andrea Clark and Keith Siddel, previously the directors of HRAA. In addition, immediately following the Merger, Andrea Clark was appointed as the Company’s President and Chief Executive Officer, Robert Rubinowitz was appointed as the Company’s Chief Operating Officer, Secretary and Treasurer and Keith Siddel was appointed as the Company’s Chief Marketing Officer. Keith Siddel no longer holds this position.
Prior to the closing of the Merger and the closing on at least the Minimum Offering Amount (as defined below), the Company transferred all of its operating assets and liabilities to Anvex Split Corp., a Nevada corporation and its wholly-owned (the “Split-Off Subsidiary”), and contemporaneously with the closing of the Merger, the Company split-off the Split-Off Subsidiary through the sale of all of the outstanding capital stock of the Split-Off Subsidiary (the “Split-Off”) to its former sole officer and director (the “Split-Off Shareholder”).  In connection with the Split-Off, an aggregate of 3,500,000 shares of the Company’s common stock held by the Split-Off Shareholder were surrendered and cancelled without further consideration
On April 13, 2012, the Company’s board of directors (the “Board”) unanimously approved a change in the Company’s name from Anvex International, Inc. to Health Revenue Assurance Holdings, Inc.
On April 13, 2012, the Board authorized a 12.98-for-1 split of its common stock to stockholders of record as of April 13, 2012 (the “Stock Split”). The shares resulting from the Stock Split were issued on April 26, 2012. All share and per share amounts for all periods presented have been retroactively adjusted to reflect the Stock Split.
Private Placement Offering
Concurrentlyprivate stock purchase agreement and was not the result of any disagreement with the closing of the Merger and in contemplation of the Merger, we sold 2,676,255 shares of our Common Stock for gross proceeds of $663,908 at a purchase price of $0.25 per share in a private placement offering (the “Offering”). The Offering was being offered with a minimum amount of $470,000 and upCompany on any matter relating to a maximum of $1,500,000.
Company’s operations, policies or practices.

On April 12, 2012, we closed the Offering by selling an additional $349,000 at the purchase price of $0.25 and issuing 1,394,909 shares of Common Stock. The total raised in the Offering was $1,012,908.


The shares of Common Stock issued to the former stockholders of HRAA in connection with the Merger were not registered under the Securities Act, in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act and Regulation D promulgated thereunder, which exempts transactions by an issuer not involving any public offering. These securities may not be offered or sold absent registration or an applicable exemption from the registration requirements. We have not committed to registering these shares for resale. Certificates representing these shares contain a legend stating the restrictions applicable to such shares.
Overview
HRAA improves the healthcare delivery experience for doctors, nurses and patients while assuring the existence of healthcare organizations. Since 2001, we have been providing Revenue Integrity programs for healthcare organizations across the country and are committed to providing the most intuitive and effective solutions in the industry. HRAA’s products and services include business intelligence technology solutions, contract coding, billing, coding and compliance audits, education, revenue cycle consulting, physician services and ICD-10 transition services. Our collaborative approach provides the right solutions for our clients’ needs with the highest regard for ethical standards and responsibility.
We are subject to risks common to service providers and consulting companies, including competition and the ability to recruit, train, and put in place a sufficient quantity of proficient consultants and medical coders familiar with the requirements of IDC-10-CM/PCS, the uncertainty of future regulatory approvals and laws, the need for future capital and the retention of key employees. We cannot provide assurance that we will generate revenues sufficient to sustain profitability in the future.
Recent Developments
Certain significant items or events must be considered to better understand differences in our results of operations from period to period. We believe that the following items have had a material impact on our results of operations for the periods discussed below or may have a material impact on our results of operations in future periods.
ICD-10 Transition
In the short term, the main focus of our business will be with respect to the ICD-10 coding transition. In that regard, our potential clients are all hospitals and medical providers which currently maintain coding personnel in some form that are primarily responsible for seeking reimbursement for patients’ procedures. The current system in place that drives the appropriate medical codes from hospitals/medical facilities to insurance companies is called ICD-9, which was implemented over 30 years ago.
In January 2009, the United States Department of Health and Human Services published a final rule which mandated a change in medical coding in United States health care settings from the current system, International Classification of Diseases, 9th Edition, Clinical Modification (ICD-9-CM), to the International Classification of Diseases, 10th Edition, Clinical Modification/Procedure Coding System (ICD-10-CM/PCS). Compliance with this ruling was to be achieved by October 1, 2013. The new, mandated version expands the number of codes from 24,000 to 155,000, making it more precise and descriptive and more accurately describing the diagnoses and inpatient procedures of care delivered. The transition to ICD-10-CM/PS will require significant business and systems changes throughout the health care industry and will impact all processes and people from finance to compliance to doctors.
On April 9, 2012, as published in the Federal Register, citing concerns about the ability of provider groups to meet the looming compliance deadline to adopt ICD-10-CM/PCS, HHS announced a proposed rule which would delay the implementation date to October 1, 2014. Interested parties had the ability to comment during a period ending 30 days after the date of the announcement. On August 27, 2012, Health and Human Services Secretary Kathleen Sebelius announced the release of a rule that makes final a one-year proposed delay—from October 1, 2013, to October 1, 2014 — in the compliance date for the industry's transition to ICD-10 codes.
The Company anticipates implementation of ICD-10-CM/PCS to be completed by the newly proposed effective date of October 1, 2014.
We believe that we are capable of providing consulting and related services with respect to the ICD-10 coding transition and the potential issues that we believe medical providers will experience due to the transition. In that regard, we believe the following are some of the issues that will be experienced due to the changeover:
The new system will require time, money and commitment by over 6,000 hospitals, 600,000 physicians and every health insurance provider in the United States.
Re-education and training of every Health Information Management (“HIM”) department is required of every hospital and medical facility in the United States.

All claims submitted by hospitals and physicians for reimbursement without utilizing ICD-10 will result in immediate rejection and non-payment.
HRAA’s vision regarding ICD-10 Transition:
Hospitals and medical facilities will incur massive backlogs in their billing and coding departments.  Backlog in coding will lead to greater time between payments and crippling financial deficits.

There will likely be an increase in coding errors, resulting in incorrect payments that can lead to hefty fines.
Initial estimates based on other countries that have already converted to ICD-10 predict a 50% loss of productivity due to the complexity of the new system - a result of more time being allocated to the preparation of each individual patient case.
The sheer number of codes and time for each entry will dramatically impact the workload.  Currently there are not enough coders to meet this demand, resulting in an ongoing shortfall, with an accelerating shortfall anticipated after ICD-10 is implemented.
Every discipline in the hospital will be affected as they all revolve around the same coding system.

For each code in the ICD-9 format, there will be additional, more descriptive codes in the ICD-10 format. This will greatly increase the quality of patient care, but simultaneously put a burden on hospitals and their medical coders.
Currently under ICD-9, hundreds of millions of dollars of revenue are lost each year due to medical coding and billing errors.

The average age of a medical coder is 54. It is estimated that 20% of coders plan to retire or change activities because of this transition.
HRAH Chairman, CEO and Founder Andrea Clark, RHIA, CCS, CPC-H, continues to buildMarch 11, 2022, the Company, amended its articles of incorporation to meet the changing needs of the healthcare community and her accomplishments continuechange its name to be acknowledged. A few recent awards include:
“Female Executive of the Year” Gold Award Winner - Stevie Awards for Women in Business – December, 2012 
“Maverick of the Year” Bronze Award Winner - Stevie Awards for Women in Business – December, 2012

“Mentor of the Year" - 2012 AHIMA Triumph Awards – June, 2012 
“10 HIM Heroes, Professionals Who Have Made a Difference" - For The Record Magazine – October, 2011
“Broward County Ultimate CEO Award” – October, 2013
HRAA has also been recognized for tremendous growth and industry leadership. Recent acknowledgments include:
“Fastest Growing Company of the Year” Bronze Award Winner- Stevie Awards for Women in Business – December, 2012

“Top Ten Best Places To Work” - South Florida Business Journal – 2011
We believe we are able to provide hospitals and medical providers with the ability to effectively transition to ICD-10 and prevent massive backlogs that lead to crippling financial deficits. Our team of certified coders provides hospitals with the expertise needed to successfully input the proper data set into the Health Information Management (HIM) system which drives reimbursementAmeriguard Security Services, Inc. from insurance providers such as Medicare and Medicaid, as well as private insurance companies. We offer above industry standards ICD-9 and ICD-10 training to coders, equipping them with the knowledge to effectively assign the appropriate codes. We also conduct medical billing audits, identifying risks of lost revenue and ensuring the correct amounts have been paid. In doing so, we shorten the revenue cycle and prevent financial stress on healthcare providers.
The transition from ICD-9 to ICD-10 is and will drastically affect the entire healthcare industry, especially patients, hospitals, medical facilities, physicians, insurance providers and the coding workforce. Our goal is to optimize revenue integrity by providing expert contract coding and consulting services to hospitals and medical facilities throughout the United States. We will implement marketing tools in order to create our own brand identity and leverage this rapidly growing awareness of the upcoming switch to ICD-10 and the potential financial pressure a hospital will face if not properly prepared and trained.
We believe that the following tasks are essential to achieve ongoing success:
development of long lasting relationships with new clients and strengthen relationships with existing clients;
recruitment and proper training of qualified personnel;
appropriate fiscal planning and execution;
development of an extensive sales network;
effective and broad-reaching promotional programs;
connecting effectively with executive-level decision makers of hospitals and medical facilities;
accurately and efficiently audit the medical billing records to maximize revenue integrity;
ensure that we are supplying hospitals and medical facilities with top quality, certified medical coders;
developing and deploying dynamic and effective marketing strategies; and
informing healthcare professionals of the products, services and benefits of being an HRAA client.
In addition to the above, our ICD-10 coding transition services will also include the training of our client’s staff with respect to the ICD-10 coding system; providing coding resources while the client’s staff is undergoing training; coding resources to handle backlog as productivity levels drop off; and auditing resources to ensure retention and accuracy of the ICD-10 coding.
Products and Services
We provide our customers with customized, hands-on, strategy-focused and in-depth analysis of a hospital’s Revenue Cycle and their compliance, as well as APC and DRG coding and documentation audits. We also offer customized education and certification programs, charge master data integrity, reviews, and solutions yielding measurable results, increased productivity, reduced DNFB, improved APC accuracy and optimized Revenue Integrity. We are committed to providing the most intuitive Revenue Integrity solutions in the industry through various means including APC AuditPro™, our proprietary internal auditing technology for outpatient claims.
HRAA provides an in-depth analysis of a hospital’s revenue cycle and their compliance, and offers the only full suite of business intelligence products and consulting services required to keep up with the ever-changing healthcare industry. All of our products and services yield measurable results, increased productivity, reduced unbilled accounts, improved payment accuracy and provide optimized revenue integrity for hospitals and physicians.
Products
Healthcare is traversing a period of significant change with the dawning of Accountable Care Organizations (“ACOs”), the declaration of Meaningful Use, and probably the most important of these agents of change is the transition from ICD-9 to ICD-10. To understand the importance of these changes, healthcare’s decision makers need to recognize the impact these changes are having on their organizations. To do this they must visualize and analyze their available data to produce actionable results that improve the organization’s overall performance.
ICD-10 Education Curriculum
We provide our customers with an online internally developed education curriculum focused on ICD-10 CM Diagnosis and ICD-10-PCS Procedure course material.
Visualizer
Visualizer™ is an analytic platform that provides healthcare decision makers with an integrated view of financial, operational, and clinical data across multiple sources of data. Each  Visualizer  ™ building block is designed to meet a specific analytic need.
OMC Initiator
The Outsourced Medical Coding Initiator was created for processing healthcare claims within hospitals. This product captures data from the physician or the hospital’s financial systems and correlates the data in a manner that expedites the processing of a claim. To validate our new product, our team of Emergency Department Coders (ED Coders) is continuously evaluating the process of coding claims in order to enhance our product.
Verifier™ (Inpatient and Outpatient)
Healthcare organizations need executable tactics that can be implemented up and down the revenue cycle, with both inpatients and outpatients. These steps taken must be clear and simple to really improve the patient experience. Creating a successful revenue integrity program will have the most immediate impact in that initiative. However, there is a significant challenge in today’s environment of complex regulations, changing payer requirements, and RAC, CERT, HIPAA along with ICD-10 pressures and increasing financial and workforce resource constraints.
Under the Center for Medicare and Medicaid Services’ (“CMS’”) value-based purchasing rules, hospitals will be assessed on quality performance, with clinical measures weighted at 70% and patient experience measures weighted at 30%. Verifier™ Suite is the most comprehensive solution for healthcare organizations performing internal auditing that provides insight into both clinical quality and service quality. This proven technology has been stress tested by HRAA providing internal auditing services to our clients for over 10 years. Although, conducting regular audits and taking a high level view of the reimbursement landscape is required, it’s not until you roll up your sleeves and start digging into the claim details, that you will uncover hidden revenue integrity issues.
Services
Coding Services
The HRAA coding solution provides hospitals and physicians across the United States with an experienced team of backlog coders to assist facility coding departments or provide outsourcing services. Certified HRAA associates supply hospitals and physicians with medical coding and billing expertise, while reducing the risk of error and maximizing accuracy, efficiency and profitability. Medical coding is the process of taking information from a wide variety of patient medical records, charts and notes, and converting it into an alphanumeric data set. The data set then drives the payment for the services rendered when submitted to Medicare, Medicaid, commercial payers and other healthcare providers. Medical coders analyze the documentation maintained within medical records and assign codes that drive reimbursement. Additionally, the data set is utilized as a collection methodology for tracking diseases, quality of care and treatment.
Billing & Coding Audits
HRAA’s team motivates excellence and reimbursement proficiency through customized, hands-on, strategy-focused and in-depth approach to the issues facing hospitals today and preparing them for tomorrow. While increasing profits for healthcare professionals remains a moving target, it is paramount to focus attention on compliant reimbursement dollars.
Education
We offer various training and educational opportunities to our clients, including Education Sessions, Coding Boot Camps, Workshops, and Webinars.
Consulting
We have specialized in building reimbursement proficiency by focusing on the entire revenue cycle, not just coding, and by providing RAC oriented audits, education and consulting services. Because our approach is to focus on the client’s needs and develop the solution on an individual basis, our team possesses extensive experience in revenue cycle issues. We focus not merely on the revenue and codes, but on their operational uses. HRAA’s consulting services provide secure and effective solutions for complex regulatory challenges, internal inefficiencies and revenue cycle analysis.
ICD-10 Transition Services
The transition to ICD-10 codes is not just a coding conversion; it is a change that impacts virtually all areas of the revenue cycle. HRAA’s unique approach to this business transition is multidimensional, providing organizations with a smooth and sustainable transition. HRAA offers “turn-key ICD-10 services” to assist clients with all aspects of the transition, with great emphasis on streamlined comprehensive training while maintaining productivity.
HRAA's ICD-10 Transition Services Include ICD Visualizer™, Needs Assessment, ICD-9/ICD-10 Dual Audit, Education, Reserved Medical Coder Personnel, Auditing, Continuous Support.
Business Intelligence
HRAA offers Business Intelligence Services to help clients interpret data and make healthcare organizations more efficient and effective.
HRAA Business Intelligence team offers a number of solutions including: Implementation of Visualizer™ Suite products, Deployment of solution templates, Development of custom applications. HRAA solution template offers the flexibility to customize the solution to meet client's needs without having to start application development from scratch.
HRAA's implementation experience of templates include: Surgery Center Analytics, Revenue Cycle Management, Customer satisfaction surveys, Hospital Statistics, Quality measures.
Physician Services
Certified coders and auditors are fully trained and are required to maintain continuing education each year to uphold their certification. HRAA is proactive providing each coder and auditor with many opportunities for additional training to make certain we are always providing the highest quality standard you expect from HRAA. HRAA takes each encounter through a rigorous review in-line with the documentation guidelines used by CMS.
The education that follows an audit includes the basic fundamentals of appropriate documentation for the levels of service billed. Physician will be introduced to the specific issues noted within the documented service. Recommendations on how to improve upon the documentation will be discussed, including template usage, appropriate EHR revisions, form creation, and so forth.
Marketing
We will utilize the following sales and marketing methods to reach our target markets:
Direct Sales – In addition to our management building sales nationwide, we plan on hiring additional sales people who will target direct institutional healthcare facilities according to geographic area.
Local, Federal and State Industry Associations – We plan on actively developing relationships with the hundreds of medical associations throughout the United States.
Trade Shows and Conferences – We plan on highlighting our products and services at trade shows and industry conferences across the United States, which provide access to key healthcare decision makers and client leads.
Internet Marketing & E-commerce Strategy – We plan to utilize web-based tools and Internet marketing methods to increase the brand name by search engine optimization, mining and partner links.
Public Relations and Branding – Our reputation has been well established in the industry as a result of the success of our founder, Andrea Clark. We plan on expanding our presence in the public vision and in the healthcare industry by working hand in hand with a top public relations firm.
Subsidiaries
Following the Merger, HRAA became our wholly-owned subsidiary.
Dream Reachers, LLC, owns the Company’s offices and is the borrower on a mortgage loan related to such offices. Dream Reachers does not engage in real estate rental business. Its offices are occupied by HRAA at no cost and HRAA pays the related mortgage’s principal and interest, taxes and maintenance. Dream Reachers was previously treated as a VIE, but became a wholly owned subsidiary in May 2011, and has been treated as such for accounting purposes in the Company’s consolidated financial statements.
Competition
Our competition includes companies such as Advance Computer Software Group PLC, Nexus AG, Mediware Info, SHL Telemedicine Ltd., Pro Medicus Ltd., Noemalife SpA, MedAssets, Medical Columbus AG, Clinical Computing PLC, and Medquist Inc. However, while we exclusively dedicate our operations to providing coding and billing audits, consulting services, medical backlog coding and staffing, and ICD-10 educational and training services to hospitals and healthcare facilities, none of our competitors provide the full spectrum of these services, specifically backlog coding and staffing.
Regulatory Matters/Compliance
We are not aware of any need for any government approval of our principal products or services. We do not anticipate any governmental regulations on our business.
Intellectual Property
We have a patent pending on our computer software and technology relating to hospital claims auditing system and methods. We filed for this patent on October 13, 2006.
Employees
As of January 31, 2014, we had one hundred and seven (107) full-time and part-time employees. None of these employees are represented by collective bargaining agreements and the Company considers it relations with its employees to be good.
Corporation Information
Our principal executive offices are located at 8551 West Sunrise Blvd., Suite 304, Plantation, FL 33322. Our telephone number is (954) 472-2340 and our fax number is (954) 370-0157. Our website is www.healthrevenue.com.
Other Information
News and information about Health Revenue Assurance Holdings, Inc. The name was deemed effective by FINRA on March 17, 2022.

Pursuant to the Merger Agreement, we acquired the business of Ameriguard and will continue the existing business of Ameriguard as our wholly owned subsidiaries is availablesubsidiary.

Ameriguard was formed on and/or may be accessed through our website, www.healthrevenue.com. In addition to news and other information about our company, we have provided access through this site to our filingsNovember 14, 2002. The corporation was incorporated with the Securitiesissuance of 1,000 common shares formerly held by Lawrence Garcia, President and Exchange CommissionCEO with 550 shares and Lillian Flores, former VP of Operations with 450 shares. On July 12, 2022 under the terms of a Settlement Agreement, Flores exchanged her 450 shares for consideration of $3,384,950 and a promissory note in that amount secured by a stock pledge. Ameriguard provides armed guard services as soona federal contractor with licenses in 7 states and provides commercial guard services in California.

Our Industry

Security guard and related services in the US is a $43 billion industry comprising over 11,000 companies and 900,000 officers. Over 55%, ($24 billion) of this market is serviced by 40 companies, with the top 4 firms, with Allied Universal, Securitas, G4S and Prosegur Security controlling 74% ($31.8 billion), an average revenue of $7.9 billion; the next 21 firms control 8.4% ($3.6billion), an average of 172 million and the next 10 firms control 1% ($550 million) with a range of $20 to $100 million with average of $50 million. Ameriguard’s approximately $22 million in annual revenue places is within the top 25 firms in the country. The rest of the market comprises over 7,900 firms with $19 billion or an average of $2.5 million in revenue. This consolidation of market share has not been gradual but rather a rapid shift over the last five years in an industry which once was highly fragmented and widely dispersed, from smaller regional and local companies to the largest companies.

We believe that the top 40 companies have the resources to harness technology, to expand their business into related services other than guard services. Companies with over $50 million in revenue have, over the last 10 years, experienced steady growth while those guard companies under $20 million, the remaining 9,900 firms, have experienced declining revenues. We believe that the principal reason for this is the steady diversification of security services away from the traditional guard services to areas of utilization of technology requiring capital. Along with this, we believe that the profitability challenges below $20 million annual sales are much more difficult that above $50 million is sales, largely due to the significant economies of scale achieve at the higher revenue levels.

The proliferation of technology while increasing efficacy in performance and inevitably lower costs in the future, the impact on the contract security industry will likely have mixed results – positive for companies who harness technology into their service delivery strategies – and negative for those companies who fail to invest in or adopt these service-enhancing capabilities. Despite the advances in the U.S. contract guarding business over recent years, there remains a question as reasonably practicable after we fileto the industry’s viability in view of the increasing trend for integrating manned services with security systems (i.e. security video, access control and monitoring) along with the emergence of other new smart technology options and solutions (i.e. robotics, drones, cybersecurity and crowd sharing alert notification).

The recent merger and acquisition trend, primarily by the major national and international security organizations and fueled by investment and funding from private equity firms, is continuing. The underlying reason for this shift is less obvious and suggests an increasing number of sellers who concluded that their better option was to exit and sell rather than remain in the marketplace and try to compete and organically grow their market share.

Despite its low barriers of entry and nominal capital requirements, the security guard business has become more challenging for the smaller owner/operator. The traditionally historic advantage of the smaller operator’s ability to offer relationship-driven customized services is no longer totally sufficient for sustainable growth – especially with the increasing regulatory challenges of the Affordable Care Act, federal and state minimum wage laws, Family Medical Leave Act and state laws (i.e. meal and rest break reporting and now, predictive scheduling).

19

Even stronger local and smaller regional companies are finding it more difficult to protect their client base and grow revenues under increasing regulatory as well as competitive pressures. Larger regional and national organizations are dealing with the regulatory climate while growing market share by leveraging infrastructure, technology, economies of scale with more aggressive pricing and better service reliability. This approach appears to offer a more compelling value proposition from the client’s perspective, which seems evident by the higher client retention rates reported by the major security companies.

However, this consolidating trend may not be inevitable for the future as newer, more tech-savvy owner/operators enter the business and recognize how to adopt best practices with a variety of sophisticated third-party software platforms and applications to help level the playing field. These include talent management and on-boarding applications to attract, hire and maintain a more skilled and reliable workforce; integrated labor management platforms to control scheduling, compliance, operations, payroll, billing and financial reporting; and state-of-the-art social media marketing applications.

The contract security industry should now be able to more effectively capitalize on and penetrate opportunities in a $20 billion in-house market – especially for those companies who have invested and integrated technology into a more highly reliable ecosystem of protective services.

For the foreseeable future, the U.S. manned guarding business seems likely for continued sustainable growth. While the technology/manpower ratio may shift the revenue mix going forward, based on today’s currently expanding U.S. economy, the prospects for an aggregate growth rate of four percent or furnish them electronically. Information on our websitemore seem realistic and perhaps even conservative, especially for ownership who have prudently invested in technology enhancements to their core guarding operations.

Providing these strategies can yield an attractive ROI, increase operating profits (EBITDA ranges of four to six percent and higher) and enterprise valuations, this industry seems not only viable but also opportune for further investment consideration

(The above industry data taken from https://www.nasco.org/wp-content/uploads/2021/08/2021-Bob-Perry-Contract-Security-Industry-White-Paper-1.pdf)

Regulatory Matters/Compliance

Each State has specific licensing requirements companies must meet to perform guard services, especially armed guard services. To date, the Company holds firearm licenses in over twelve States and does not constitute part of andforesee any license or governmental requirements preventing us from continuing to operate in any State a contract is not incorporated by reference into this Annual Report on Form 10-K or any other reportawarded to us. As a company with over 300 employees, we file or furnish with the SEC. You may also read and copy any document that we file at the public reference facilitiesare subject to all of the SEC in Washington, D.C. You may callstandard federal and state labor laws and have consistently met those requirements to date, including ERISA.

Contracting officers have indicated that they believe the SEC at 1-800-SEC-0330 for further information on the public reference rooms. Our SEC filings are also availablegovernment has no concern relating to the public frommerger as long as the SEC’s website at http://www.sec.gov.

responsible person(s) remains.

Properties

The Company’s corporate headquarters is located in Plantation, Florida. The Company currently leases space located at 85515470 W. Sunrise Boulevard, Unit 305, Plantation, Florida 33322.Spruce Avenue, Suite 102, Fresno CA. The lease is currently month to month. Landlord has not indicated a desire for a term of one-year beginning on September 1, 2012 and ending August 31, 2013. We have elected to renew our current lease starting September 1, 2013 for an additional one-year term. As of September 1, 2013, our monthlynew lease. Our lease payments are approximately $5,500 for a total of approximately $66,000$55,767 for the totalentire term (or, $4,230 per month).

Legal Proceedings

While we have not been involved in any litigation related to the performance of our guard services, armed or otherwise, to date, as an armed guard Company with contracts with Governmental entities is a possibility of legal proceedings that could be more serious than the lease.

Dream Reachers, LLC, also owns property located at 8551 W. Sunrise Boulevard, Unit 304, Plantation, Florida 33322. This condominium is located adjacent to our corporate headquarters and we use it for employees and training. There was an original mortgage on the property in the amount of $192,500.
average business. From time to time, we may becomethe Company is involved in various lawsuits and legal proceedings, which arise, inmatters relating to claims arising from the ordinary course of business. However, litigation is subject to inherent uncertainties,business, but those claims have been labor and union related and have been settled on an adverse resultadministrative level not in thesecourt.

While the results of such claims and legal actions cannot be predicted with certainty, the Company’s management does not believe that there are claims or other matters may arise from time to time that may harm our business. We are currently not awareactions, pending or threatened against the Company, the ultimate disposition of any such legal proceedings or claims that we believe willwhich would have a material adverse effect on our business, results of operations, financial condition or operating results.cash flows.

20

Price Range of Common Stock
Our common stock is quoted on the OTCBB since July 2012 under the symbol “HRAA.” The OTCBB is a quotation service that displays real-time quotes, last-sale prices, and volume information in over-the-counter equity securities. An OTCBB equity security generally is any equity that is not listed or traded on a national securities exchange. The following table shows, for the periods indicated, the high and low bid prices per share of our common stock as reported by the OTCBB quotation service. These bid prices represent prices quoted by broker-dealers on the OTCBB quotation service. The quotations reflect inter-dealer prices, without retail mark-up, mark-down or commissions, and may not represent actual transactions.
  Fiscal 2012-2014 
  High  Low 
       
Third Quarter (July 1 - September 30) 2012 $0.29  $0.29 
Fourth Quarter (October 1 - December 31) 2012 $0.35  $0.10 
First Quarter (January 1 - March 31) 2013 $0.52  $0.25 
Second Quarter (April 1 - June 30) 2013 $0.62  $0.25 
Third Quarter (July 1 - September 30) 2013 $0.52  $0.20 
Fourth Quarter (October 1 - December 31) 2013 $0.30  $0.11 
First Quarter (January 1 – February 10) 2014 $0.29  $0.20 
As of January 31, 2014 we had approximately 400 record holders of our common stock, holding 54,752,294 shares of common stock.
Holders of our common stock are entitled to one vote for each share on all matters submitted to a stockholder vote. Holders of common stock do not have cumulative voting rights.
Therefore, holders of a majority of the shares of common stock voting for the election of directors can elect all of the directors. Holders of our common stock representing a majority of the voting power of our capital stock issued and outstanding and entitled to vote, represented in person or by proxy, are necessary to constitute a quorum at any meeting of our stockholders. A vote by the holders of a majority of our outstanding shares is required to effectuate certain fundamental corporate changes such as liquidation, merger or an amendment to our Articles of Incorporation.
Although there are no provisions in our charter or by-laws that may delay, defer or prevent a change in control, we are authorized, without shareholder approval, to issue shares of preferred stock that may contain rights or restrictions that could have this effect.
Holders of common stock are entitled to share in all dividends that the board of directors, in its discretion, declares from legally available funds. In the event of liquidation, dissolution or winding up, each outstanding share entitles its holder to participate pro rata in all assets that remain after payment of liabilities and after providing for each class of stock, if any, having preference over the common stock. Holders of our common stock have no pre-emptive rights, no conversion rights and there are no redemption provisions applicable to our common stock.
We have never declared or paid dividends on our common stock. We do not intend to declare dividends in the foreseeable future because we anticipate that we will reinvest any future earnings into the development and growth of our business. Any decision as to the future payment of dividends will depend on our results of operations and financial position and such other factors as our Board of Directors in its discretion deems relevant.
The transfer agent for our common stock is Vstock Transfer, LLC at 77 Spruce Street, Suite 201, Cedarhurst, NY 11516, and its telephone number is (212) 828-8436.
The following discussion

Management’s Discussion and analysisAnalysis and Results of Operations

This Item 7 contains forward-looking statements. Forward-looking statements in this Registration Statement on Form S-1 are subject to a number of risks and uncertainties, some of which are beyond our control. Our actual results, performance, prospects or opportunities could differ materially from those expressed in or implied by the forward-looking statements. Additional risks of which we are not currently aware or which we currently deem immaterial could also cause our actual results of operationsto differ, including those discussed in the sections entitled “Forward-Looking Statements” and financial condition of Health Revenue Assurance Holdings, Inc. for the fiscal years ended December 31, 2012“Risk Factors” included elsewhere in this Annual Report.

Management’s Discussion and 2011 and for the three and nine months ended September 30, 2013 and 2012,Analysis should be read in conjunction with the Selected Consolidated Financial Data, Health Revenue Assurance Holdings’ financial statements included in this Registration Statement on Form S-1 (the “Financial Statements”). The financial statements have been prepared in accordance with generally accepted accounting policies in the United States (“GAAP”). Except as otherwise disclosed, all dollar figures included therein and in the following management discussion and analysis are quoted in United States dollars.

The following discussion of the Company’s financial condition and the notes to those financial statements that are includedresults of operations should be read in conjunction with the Financial Statements and footnotes thereto appearing elsewhere in this filing. Our discussion includesReport.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. In order to comply with the terms of the safe harbor, the Company notes that in addition to the description of historical facts contained herein, this report contains certain forward-looking statements based upon current expectations that involve risks and uncertainties such as our plans, objectives,detailed herein and from time to time in the Company’s other filings with the Securities and Exchange Commission and elsewhere. Such statements are based on management’s current expectations and intentions. Actualare subject to a number of factors and uncertainties, which could cause actual results and the timing of events couldto differ materially from those, anticipateddescribed in thesethe forward-looking statementsstatements. These factors include, among others: (a) the Company’s fluctuations in sales and operating results; (b) regulatory, competitive and contractual risks; (c) development risks; (d) the ability to achieve strategic initiatives, including but not limited to the ability to achieve sales growth, and (e) unknown litigation.

Corporate Structure

As previously mentioned, on December 9, 2022, AGSS executed a reverse merger with AmeriGuard resulting in AGSS becoming the sole owner of AmeriGuard. This merger establishes AGSS as a company operating a viable guard company with annual sales of approximately $24,000,000. It also is in the position to access the capital market to generate the capital needed to begin its growth strategy of mergers and acquisitions within the security industry.

Prior to and after the merger AGSS has been working on developing the leadership team needed. We have in place a CEO with 20 years of experience in our industry and has been very successful in the government contracting market. Our CFO has over 35 years of business finance experience, the last 15 of which he has been focusing on organizational development consulting across multiple industries, and an Operations team on the east coast managing IT and our federal contracts. We have an exclusive contract with Think Equity a New York Investment Banking Firm, and we have engaged legal and SEC compliance professionals. We have a Board Directors with Wall Street and government security experience making us well positioned to aggressively grow the business.

21

Results of Operations for the fiscal year ending December 31, 2022

Revenues and Cost of Goods Sold

2022 experienced a 10% increase of $2.2 million in security services revenue. The majority of which was from federal contracts in the amount of approximately $1.5 million and the remaining $700,000 from commercial guard services. The contract services revenue increase was the result of monthly fee increases within the four existing contract operated for during 2022 and 2021. As the costs of labor increases within the unionized contract so does the revenue. For the Commercial operations we saw a numbersignificant increase in demand for services, specifically our patrol services. Patrol services solve the problem of factors, including those set forth underdelayed police response. Our patrol officers respond to all alarms regardless of cause within 15 minutes of activation. This is a cost effect way for businesses to have protection without the Cautionary Notice Regarding Forward-Looking Statementshigh expense of a posted guard. This is an area of service we are continuing to expand.

We also had a significant increase of over $280,000 in this filing. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “on going,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressionsother related income. This increase was due to identify forward-looking statements.

Overview
On February 10, 2012, the Company entered into an Agreement and Plan of Merger and Reorganization with Health Revenue Acquisition Corp., a Maryland corporation and our wholly-owned subsidiary, and Health Revenue Assurance Associates, Inc., a Maryland corporation, pursuant to which Acquisition Sub was merged with and into HRAA, and HRAA, as the surviving corporation, became our wholly-owned subsidiary.
HRAA improves the healthcare delivery experience for doctors, nurses and patients while assuring the existence of healthcare organizations.  Since 2001, we have been providing Revenue Integrity programs for healthcare organizations across the country and are committed to providing the most intuitive and effective solutions in the industry. HRAA’s products and services include business intelligence technology solutions, contract coding, billing, coding and compliance audits, education, revenue cycle consulting, physician services and ICD-10 transition services.  Our collaborative approach provides the right solutions for our clients’ needs with the highest regard for ethical standards and responsibility.
On April 13, 2012, the Board unanimously approved a change in accounting practices. Prior to 2022, overhead expenses included management salaries were allocated to between AmeriGuard and three other related companies. Has part of our transition to prepare for the Company’s name from Anvex International, Inc.reverse merger we shifted to Health Revenue Assurance Holdings, Inc. to be consistentmanagement agreements between AmeriGuard and the other related entities. As a result, we saw both an increase in other revenues along with our current business followingan increase in administrative expenses.

As with all professional service industries the Merger.

vast majority of expense in with direct labor and expenses associated with that labor. We are subjectnot an exception. Our direct expenses average around 89% of revenues. Total cost of services increased approximately $1.3 million in 2022, and that increase is expected in relation to risks commonthe revenue increase in 2022 as previously discussed.

Operating Expenses and Other Expense

Operation expenses, overhead expenses, increased in 2022 over 2021 by approximately $1.3 million. Slightly more than half of that increase was in administrative salaries and related payroll expenses, of approximately $796,000. As mentioned earlier in 2021 overhead expenses included administrative salaries were allocated between related companies. In 2022, all the salaries were expensed to service providersAmeriGuard. Also, during 2022 as part of the reverse merger preparations, we added to our administrative team a full-time CFO, an HR Manager and consulting companies, including competitionan Operations Management team along with the necessary support positions in payroll and accounting. This was done in the preparations for the merger and the ability to recruit, train, and put in place a sufficient quantityfollowing expansion.

Other areas of proficient consultants and medical coders familiar with the requirements of IDC-10-CM/PCS, the uncertainty of future regulatory approvals and laws, the need for future capital and the retention of key employees. We cannot provide assurance that we will generate revenues or achieve and sustain profitabilityexpense increase were in the future.


Recent Developments

Certain significant items or events must be considered to better understand differences in our resultscost of vehicle operations from period to period. We believe that the following items have had a material impact on our results of operations for the periods discussed below or may have a material impact on our results of operations in future periods.

ICD-10 Transition

In the short term, the main focus of our business will be with respect to the ICD-10 coding transition. In that regard, our potential clients are all hospitals and medical providers which currently maintain coding personnel in some form that are primarily responsible for seeking reimbursement for patients’ procedures. The current system in place that drives the appropriate medical codes from hospitals/medical facilities to insurance companies is called ICD-9, which was implemented over 30 years ago.
In January 2009, the United States Department of Health and Human Services published a final rule which mandated a change in medical coding in United States health care settings from the current system, International Classification of Diseases, 9th Edition, Clinical Modification (ICD-9-CM), to the International Classification of Diseases, 10th Edition, Clinical Modification/Procedure Coding System (ICD-10-CM/PCS). Compliance with this ruling was to be achieved by October 1, 2013.  The new, mandated version expands the number of codes from 24,000 to 155,000, making it more precise and descriptive and more accurately describing the diagnoses and inpatient procedures of care delivered.  The transition to ICD-10-CM/PS will require significant business and systems changes throughout the health care industry and will impact all processes and people from finance to compliance to doctors. 
On April 9, 2012, as published in the Federal Register, citing concerns about the ability of provider groups to meet the looming compliance deadline to adopt ICD-10-CM/PCS, HHS announced a proposed rule which would delay the implementation date to October 1, 2014.  Interested parties had the ability to comment during a period ending 30 days after the date of the announcement. On August 27, 2012, HHS Secretary Kathleen Sebelius announced the release of a rule that makes final a one-year proposed delay—from October 1, 2013, to October 1, 2014 — in the compliance date for the industry's transition to ICD-10 codes.
The Company anticipates implementation of ICD-10-CM/PCS to be completed by the newly proposed effective date of October 1, 2014.
We believe that we are capable of providing consulting and related services with respect to the ICD-10 coding transition and the potential issues that we believe medical providers will experienceapproximately $138,000 due to the transition. In that regard, we believe the following are someleasing of four additional vehicles for patrols along with an increase in fuel costs. The category of General administrative expenses increased approximately $350,000. Approximately $100,000 of the issuesincrease related to expenses no longer allocated to the related companies as we did in 2021. Then the merger related expenses new to 2022 such as office rent in New York, marketing expenses, travel, shareholder buyout loan expense and Board of Director expenses totalling approximately $200,000. The remainder of the increase were minor changes in other operational expenses.

Other expenses in the amount of $344,105 that occurred in 2022, but not in 2021 are non-operational expenses related specifically to the preparations for and after the reverse merger. These expenses are legal, compliance, accounting and merger related expenses that are treated as non-operational expense to prevent distortions of operational net income or loss. It is anticipated that there will be experienced duecontinued non-operational expenses from ongoing capital raise activities moving forward.

At this time, our operating structure and current level of expense can handle twice the revenue stream with minor increases to our operating overhead expenses. This allows the entire gross profit of any new contract or company acquisition to go straight to the changeover:


The new system will require time, money and commitment by over 6,000 hospitals, 600,000 physicians and every health insurance provider in the United States.
Re-education and training of every Health Information Management (“HIM”) department is required of every hospital and medical facility in the United States.
All claims submitted by hospitals and physicians for reimbursement without utilizing ICD-10 will result in immediate rejection and non-payment.
HRAA’s vision regarding ICD-10 Transition:
Hospitals and medical facilities will incur massive backlogs in their billing and coding departments.  Backlog in coding will lead to greater time between payments and crippling financial deficits.
There will likely be an increase in coding errors, resulting in incorrect payments that can lead to hefty fines.
Initial estimates based on other countries that have already converted to ICD-10 predict a 50% loss of productivity due to the complexity of the new system - a result of more time being allocated to the preparation of each individual patient case.
The sheer number of codes and time for each entry will dramatically impact the workload.  Currently there are not enough coders to meet this demand, resulting in an on-going shortfall, with an accelerating shortfall anticipated after ICD-10 is implemented.
Every discipline in the hospital will be affected as they all revolve around the same coding system.
For each code in the ICD-9 format, there will be additional, more descriptive codes in the ICD-10 format. This will greatly increase the quality of patient care, but simultaneously put a burden on hospitals and their medical coders.
Currently under ICD-9, hundreds of millions of dollars of revenue are lost each year due to medical coding and billing errors.
The average age of a medical coder is 54. It is estimated that 20% of coders plan to retire or change activities because of this transition.
HRAH Chairman, CEO and Founder Andrea Clark, RHIA, CCS, CPC-H, continues to build the Company to meet the changing needs of the healthcare community and her accomplishments continue to be acknowledged. A few recent awards include:
“Female Executive of the Year” Gold Award Winner - Stevie Awards for Women in Business – December, 2012
"Maverick of the Year” Bronze Award Winner - Stevie Awards for Women in Business – December, 2012
“Mentor of the Year" - 2012 AHIMA Triumph Awards – June, 2012
“10 HIM Heroes, Professionals Who Have Made a Difference" - For The Record Magazine – October, 2011
“Broward County Ultimate CEO Award” – October, 2013
HRAA has also been recognized for tremendous growth and industry leadership. Recent acknowledgments include:
“Fastest Growing Company of the Year”  Bronze Award Winner- Stevie Awards for Women in Business – December, 2012
“Top Ten Best Places To Work” - South Florida Business Journal – 2011  

We believe we are able to provide hospitals and medical providers with the ability to effectively transition to ICD-10 and prevent massive backlogs that lead to crippling financial deficits.  Our team of certified coders provides hospitals with the expertise needed to successfully input the proper data set into the Health Information Management (HIM) system which drives reimbursementbottom line, providing a consistent return on investment.

Net Income/(Loss) from insurance providers such as Medicare and Medicaid, as well as private insurance companies.  We offer above industry standards ICD-9 and ICD-10 training to coders, equipping them with the knowledge to effectively assign the appropriate codes. We also conduct medical billing audits, identifying risks of lost revenue and ensuring the correct amounts have been paid. In doing so, we shorten the revenue cycle and prevent financial stress on healthcare providers.

The transition from ICD-9 to ICD-10 is and will drastically affect the entire healthcare industry, especially patients, hospitals, medical facilities, physicians, insurance providers and the coding workforce. Our goal is to optimize revenue integrity by providing expert contract coding and consulting services to hospitals and medical facilities throughout the United States.  We will implement marketing tools in order to create our own brand identity and leverage this rapidly growing awareness of the upcoming switch to ICD-10 and the potential financial pressure a hospital will face if not properly prepared and trained.
We believe that the following tasks are essential to achieve on-going success:
development of long lasting relationships with new clients and strengthen relationships with existing clients;
recruitment and proper training of qualified personnel;
appropriate fiscal planning and execution;
development of an extensive sales network;
effective and broad-reaching promotional programs;
connecting effectively with executive-level decision makers of hospitals and medical facilities;
accurately and efficiently audit the medical billing records to maximize revenue integrity;
ensure that we are supplying hospitals and medical facilities with top quality, certified medical coders;
developing and deploying dynamic and effective marketing strategies; and
informing healthcare professionals of the products, services and benefits of being an HRAA client.

In addition to the above, our ICD-10 coding transition services will also include the training of our client’s staff with respect to the ICD-10 coding system; providing coding resources while the client’s staff is undergoing training; coding resources to handle backlog as productivity levels drop off; and auditing resources to ensure retention and accuracy of the ICD-10 coding.

Products and Services

We provide our customers with customized, hands-on, strategy-focused and in-depth analysis of a hospital’s Revenue Cycle and their compliance, as well as APC and DRG coding and documentation audits. We also offer customized education and certification programs, charge master data integrity, reviews, and solutions yielding measurable results, increased productivity, reduced DNFB, improved APC accuracy and optimized Revenue Integrity. We are committed to providing the most intuitive Revenue Integrity solutions in the industry through various means including APC AuditPro™, our proprietary internal auditing technology for outpatient claims.
HRAA provides an in-depth analysis of a hospital’s revenue cycle and their compliance, and offers the only full suite of business intelligence products and consulting services required to keep up with the ever-changing healthcare industry. All of our products and services yield measurable results, increased productivity, reduced unbilled accounts, improved payment accuracy and provide optimized revenue integrity for hospitals and physicians.
Products
Healthcare is traversing a period of significant change with the dawning of ACOs, the declaration of Meaningful Use, and probably the most important of these agents of change is the transition from ICD-9 to ICD-10. To understand the importance of these changes, healthcare’s decision makers need to recognize the impact these changes are having on their organizations. To do this they must visualize and analyze their available data to produce actionable results that improve the organization’s overall performance.
ICD-10 Education Curriculum

We provide our customers with an online internally developed education curriculum focused on ICD-10 CM Diagnosis and ICD-10-PCS Procedure course material.

Visualizer

Visualizer™ is an analytic platform that provides healthcare decision makers with an integrated view of financial, operational, and clinical data across multiple sources of data. Each   Visualizer ™   building block is designed to meet a specific analytic need.
OMC Initiator
The Outsourced Medical Coding Initiator was created for processing healthcare claims within hospitals. This product captures data from the physician or the hospital’s financial systems and correlates the data in a manner that expedites the processing of a claim. To validate our new product, our team of Emergency Department Coders (ED Coders) is continuously evaluating the process of coding claims in order to enhance our product.
Verifier™ (Inpatient and Outpatient)
Healthcare organizations need executable tactics that can be implemented up and down the revenue cycle, with both inpatients and outpatients. These steps taken must be clear and simple to really improve the patient experience. Creating a successful revenue integrity program will have the most immediate impact in that initiative. However, there is a significant challenge in today’s environment of complex regulations, changing payer requirements, and RAC, CERT, HIPAA along with ICD-10 pressures and increasing financial and workforce resource constraints.

Under the CMS’ value-based purchasing rules, hospitals will be assessed on quality performance, with clinical measures weighted at 70% and patient experience measures weighted at 30%. Verifier™ Suite is the most comprehensive solution for healthcare organizations performing internal auditing that provides insight into both clinical quality and service quality. This proven technology has been stress tested by HRAA providing internal auditing services to our clients for over 10 years. Although, conducting regular audits and taking a high level view of the reimbursement landscape is required, it’s not until you roll up your sleeves and start digging into the claim details, that you will uncover hidden revenue integrity issues.
Services
Coding Services

The HRAA coding solution provides hospitals and physicians across the United States with an experienced team of backlog coders to assist facility coding departments or provide outsourcing services. Certified HRAA associates supply hospitals and physicians with medical coding and billing expertise, while reducing the risk of error and maximizing accuracy, efficiency and profitability. Medical coding is the process of taking information from a wide variety of patient medical records, charts and notes, and converting it into an alphanumeric data set. The data set then drives the payment for the services rendered when submitted to Medicare, Medicaid, commercial payers and other healthcare providers. Medical coders analyze the documentation maintained within medical records and assign codes that drive reimbursement. Additionally, the data set is utilized as a collection methodology for tracking diseases, quality of care and treatment.
Billing & Coding Audits
HRAA’s team motivates excellence and reimbursement proficiency through customized, hands-on, strategy-focused and in-depth approach to the issues facing hospitals today and preparing them for tomorrow. While increasing profits for healthcare professionals remains a moving target, it is paramount to focus attention on compliant reimbursement dollars.

Education

We offer various training and educational opportunities to our clients, including Education Sessions, Coding Boot Camps, Workshops, and Webinars.
Consulting

We have specialized in building reimbursement proficiency by focusing on the entire revenue cycle, not just coding, and by providing RAC oriented audits, education and consulting services. Because our approach is to focus on the client’s needs and develop the solution on an individual basis, our team possesses extensive experience in revenue cycle issues. We focus not merely on the revenue and codes, but on their operational uses. HRAA’s consulting services provide secure and effective solutions for complex regulatory challenges, internal inefficiencies and revenue cycle analysis.
ICD-10 Transition Services
The transition to ICD-10 codes is not just a coding conversion; it is a change that impacts virtually all areas of the revenue cycle. HRAA’s unique approach to this business transition is multidimensional, providing organizations with a smooth and sustainable transition. HRAA offers “turn-key ICD-10 services” to assist clients with all aspects of the transition, with great emphasis on streamlined comprehensive training while maintaining productivity.

HRAA's ICD-10 Transition Services Include ICDVisualizer™, Needs Assessment, ICD-9/ICD-10 Dual Audit, Education, Reserved Medical Coder Personnel, Auditing, Continuous Support.

Business Intelligence

HRAA offers Business Intelligence Services to help clients interpret data and make healthcare organizations more efficient and effective.

HRAA Business Intelligence team offers a number of solutions including: Implementation of Visualizer™ Suite products, Deployment of solution templates, Development of custom applications. HRAA solution template offers the flexibility to customize the solution to meet client's needs without having to start application development from scratch.

HRAA's implementation experience of templates include: Surgery Center Analytics, Revenue Cycle Management, Customer satisfaction surveys, Hospital Statistics, Quality measures.

Physician Services

Certified coders and auditors are fully trained and are required to maintain continuing education each year to uphold their certification. HRAA is proactive providing each coder and auditor with many opportunities for additional training to make certain we are always providing the highest quality standard you expect from HRAA. HRAA takes each encounter through a rigorous review in-line with the documentation guidelines used by CMS.

The education that follows an audit includes the basic fundamentals of appropriate documentation for the levels of service billed. Physician will be introduced to the specific issues noted within the documented service. Recommendations on how to improve upon the documentation will be discussed, including template usage, appropriate EHR revisions, form creation, and so forth.
Three months ended September 30, 2013 compared to September 30, 2012
Results of Operations
The following table presents a summary of operating information for the three months ended September 30, 2013 and 2012:
  For the three months ended       
  
September 30,
2013
  
September 30,
2012
  
Increase/
(Decrease) $
  
Increase/
(Decrease) %
 
Revenue $1,790,825  $1,985,516  $(194,691)  (9.81)%
Revenue – Related Party  60,552   -   60,552   100.00%
Total Revenue  1,851,377   1,985,516   (134,139)  (6.76)%
Costs of Revenues  1,088,442   758,267   330,175   43.54%
Gross profit  762,935   1,227,249   (464,314)  (37.83)%
                 
Selling and administrative expenses  1,898,595   1,069,870   828,725   77.46%
Research and development expenses  -   926   (926)   (100.00)%
Asset impairment  946,931   -   946,931   100.00%
Depreciation and amortization  19,616   14,007   5,609   40.04%
Total operating expenses  2,865,142   1,084,803   1,780,339   164.11%
Operating income (loss)  (2,102,207)  142,446   (2,244,653)  (1,575.79)%
Other expense, net  (459,268)  (372,595)  (86,673)  23.26%
Net loss $(2,561,475) $(230,149) $(2,331,326)  1,012.96%
Revenue:

Revenue decreased by $134,139 or approximately 7%, from $1,985,516 for the three months ended September 30, 2012 to $1,851,377 for the three months ended September 30, 2013.  The decrease was due primarily to reduction in education revenue as a result of the shift in the Company’s focus to technology and research development of our business intelligence  Visualizer  business software products.
Cost of Revenues:
Cost of revenues increased by $330,175 or approximately 44%, from $758,267 for the three months ended September 30, 2012 to $1,088,442 for the three months ended September 30, 2013. The increase was due primarily to additional personnel and related training costs associated with the build-up of the Company’s audit and coding service provider personnel required to service the anticipated increase in service contracts in future periods.
Gross Profit:
Gross profit decreased by $464,314, or approximately 38%, from $1,227,249 for the three months ended September 30, 2012 to $762,935 for the three months ended September 30, 2013.  The decrease in gross profit is primarily attributable to higher payroll cost, lower utilization rates, and a general decline in education revenue.
Selling and Administrative Expenses:
Selling and administrative expenses were $1,898,595 for the three months ended September 30, 2013, an increase of $828,725 or 77%, from $1,069,870 for the three months ended September 30, 2012.  The change in the 2013 period compared to the 2012 period was primarily due to:
Personnel costs have increased by $389,264 or approximately 63%, from approximately $615,000 for the three months ended September 30, 2012 to $1,005,075 for the three months ended September 30, 2013.  The increase is due primarily to increased compensation and related expenses associated with the build-up of the Company’s management, sales and administrative staff in anticipation of growth in business volume.
Professional fees have increased from $132,091 for the three months ended September 30, 2012 to $297,354 for the three months ended September 30, 2013, an increase of $165,242, or approximately 125%.This increase is attributable to legal, audit, consulting, investor and public relations, and accounting services provided in connection with expenses associated with financial reporting matters.
The remainder of the increase in Selling and administrative expenses is related to costs associated to the company’s business development such as marketing, communications, trade shows and seminars.
Research and Development Expenses:
We had no research and development expenses for the three months ended September 30, 2013, a decrease of $926, or 100%, for the three months ended September 30, 2012. The decrease is due to a significant reduction in the technology department personnel and Information Technology research projects. The Company lacked the available financial resources to invest in research and development.
Asset Impairment
At the end of September, 2013, the Company re-evaluated the capitalized research and development costs for the Visualizer  software suite of multiple offerings and the OMC Initiator after an evaluation based in part on the lack of cash flow and customer demand in ICD  Visualizer  after the general acceptance release date of July 15, 2013. In addition, the Company also considered its going concern opinion and cash liquidity concerns that restrain the ability to make capital investments in research and development to complete existing products in the pipeline as the available cash is needed to fund normal operating expenses. As a result of this evaluation, the Company recorded a loss of $946,931 that is presented as a line item entitled “asset impairment” on the consolidated statement of operations.
Depreciation and Amortization Expenses:
Depreciation and amortization expenses were approximately $84,000 for the three months ended September 30, 2013, an increase of approximately $70,000, or 500%, from approximately $14,000 for the three months ended September 30, 2012. The increase was primarily due to the amortization of the  Visualizer  software product that had a general release date of July 15, 2013.
Interest Expense (included in other expenses, net):
Interest Expense was approximately $357,000 for the three months ended September 30, 2013, a decrease of approximately $21,000, from approximately $378,000 for the three months ended September 30, 2012. The decrease in interest expense is primarily due to reduced finance charges related to the amortization of debt.
Net Income (loss):
As a result of the above factors, a

Combining 2022 net loss of approximately $2,561,000 was recognized for the three months ended September 30, 2013 as compared to net loss of approximately $230,000 for the three months ended September 30, 2012, an increase of approximately $2,331,000 or approximately 1013%.  The increase in net loss is outlined above.

Nine months ended September 30, 2013 compared to September 30, 2012
Results of Operations
The following table presents a summary of operating information for the nine months ended September 30, 2013 and 2012:
  For the nine months ended  Increase/  Increase/ 
  
September 30,
2013
  
September 30, 
2012
  
(Decrease)
$
  
(Decrease)
%
 
Revenue $5,787,811  $3,619,611  $2,168,200   59.90%
Revenue – Related Party  287,626   -   287,626   100.00
Total Revenue  6,075,437   3,619,611   2,455,826   67.85
Costs of Revenues  3,049,394   1,642,619   1,406,775   85.64%
Gross profit  3,026,043   1,976,992   1,049,054   53.06%
                 
Selling and administrative expenses  5,284,354   2,726,475   2,557,879   93.82%
Research and development expenses  289   54,059   (53,770)  (99.47)%
Asset impairment  946,931   -   946,931   100.00
Depreciation and amortization  64,214   36,758   27,456   74.69%
Total operating expenses  6,295,788   2,817,292   3,478,496   123.47%
Operating income (loss)  (3,269,745)  (840,300)  (2,429,445)  289.12%
Other expense, net  (823,619)  (383,437)  (440,182)  114.80%
Net loss $(4,093,364) $(1,223,737) $(2,869,627)  234.50%
Revenue:

Revenue increased by $2,455,826 or approximately 68%, from $3,619,611 for the nine months ended September 30, 2012 to $6,075,437 for the nine months ended September 30, 2013.  The increase was due primarily to increased revenue generated as a result of an increase in business development and marketing efforts put forth by HRAA.
Cost of Revenues:
Cost of revenues increased by $1,406,775 or approximately 86%, from $1,642,619 for the nine months ended September 30, 2012 to $3,049,394 for the nine months ended September 30, 2013. The increase was due primarily to additional  personnel and related training costs associated$74,003, with the build-up of the Company’s audit and coding service provider personnel required to service the anticipated increase in service contracts in future periods.
Gross Profit:
Gross profit increased by $1,049,054, or approximately 53%, from $1,976,992 for the nine months ended September 30, 2012 to $3,026,043 for the nine months ended September 30, 2013.  The increase in gross profit was due to the increase in business experienced during the year.
Selling and Administrative Expenses:
Selling and administrative expenses were $5,284,354 for the nine months ended September 30, 2013, an increase of $2,557,879 or 94%, from $2,726,475 for the nine months ended September 30, 2012.  The change in the 2013 period compared to the 2012 period was primarily due to:
Personnel costs have increased by approximately $1,604,308 or approximately 108%, from approximately $1,483,292 for the nine months ended September 30, 2012 to approximately $3,087,600 for the nine months ended September 30, 2013. The increase is due primarily to increased compensation and related expenses associated with the build-up of the Company’s management, sales and administrative staff in anticipation of growth in business volume.
Professional fees have increased from $234,703 for the nine months ended September 30, 2012 to $618,195 for the nine months ended September 30, 2013, an increase of $383,492, or approximately 163%.
This increase is attributable to legal, audit, consulting, investor and public relations, and accounting services provided in connection with expenses associated with financial reporting matters.
The remainder of the increase in Selling and administrative expenses is related to costs associated to the company’s business development such as marketing, communications, trade shows and seminars.
Research and Development Expenses:
Research and development expenses were $289 for the nine months ended September 30, 2013, a decrease of approximately $54,000, or 100%, for the nine months ended September 30, 2012. The decrease is due to a significant reduction in the technology department personnel and Information Technology research projects. The Company lacked the available financial resources to invest in research and development. 
Asset Impairment
At the end of September, 2013, the Company re-evaluated the capitalized research and development costs for the Visualizer  software suite of multiple offerings and the OMC Initiator after an evaluation based in part on the lack of cash flow and customer demand in ICD  Visualizer  after the general acceptance release date of July 15, 2013. In addition, the Company also considered its going concern opinion and cash liquidity concerns that restrain the ability to make capital investments in research and development to complete existing products in the pipeline as the available cash is needed to fund normal operating expenses. As a result of this evaluation, the Company recorded a loss of $946,931 that is presented as a line item entitled “asset impairment” on the consolidated statement of operations.

Depreciation and Amortization Expenses:
Depreciation and amortization expenses were approximately $128,300 (which includes $64,000 of amortization included in direct cost of sales) for the nine months ended September 30, 2013, an increase of approximately $91,500, or 249%, from approximately $36,800 for the nine months ended September 30, 2012. The increase was primarily due to the amortization of the  Visualizer  software product that had a general release date of July 15, 2013. There were also incremental depreciation costs associated with the Company’s purchases for computer equipment necessary to support the increase in personnel.

Interest Expense (included in other expenses, net):
Interest Expense was approximately $722,000 for the nine months ended September 30, 2013, an increase of approximately $329,000, or 84% from approximately $393,000 for the nine months ended September 30, 2012. The increase is due to the factoring fees experienced during the year along with interest on outstanding debt obligations and amortization of debt discounts.
Net Income (loss):
As a result of the above factors, a net loss of approximately $4,093,000 was recognized for the nine months ended September 30, 2013 as compared to net loss of approximately $1,224,000 for the nine months ended September 30, 2012, an increase of approximately $2,869,000 or approximately 234%.  The increase in net loss is outlined above.
Non-GAAP – Financial Measures

The following discussion and analysis includes both financial measures in accordance with GAAP, as well as a non-GAAP financial measure.  Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position or cash flows that either excludes or includes amounts that are not normally included or excluded in the most directly comparable measure calculated and presented in accordance with GAAP.   Non-GAAP financial measures should be viewed as supplemental to, and should not be considered as alternatives to2021 net income operatingof $128,038 we have a total operational income and cash flow from operating activities, liquidityof $54,035. Our operational structure that drives theses costs has excess capacity in anticipation of significant growth via new contracts or any other financial measures.  They may not be indicative of the historical operating results of the Company nor is it intendedmore specifically, company acquisitions. This allows additional revenue to be predictive of potential future results.  Investors should not consider non-GAAP financial measures in isolation or as substitutes for performance measures calculated in accordance with GAAP.go directly to our bottom line (see moving forward comments).

22


We believe that both management and shareholders benefit from referring to the following non-GAAP financial measure in planning, forecasting and analyzing future periods. Our management uses this non-GAAP financial measure in evaluating its financial and operational decision making and as a means to evaluate period-to-period comparison. Our management uses and relies on the following non-GAAP financial measure:

Adjusted EBITDA from continuing operations

Our management believes Adjusted EBITDA from continuing operations is an important measure of our operating performance because it allows management, investors and analysts to evaluate and assess our core operating results from period to period after removing the impact of items of a non-operational nature that affect comparability.  Our management recognizes that Adjusted EBITDA from continuing operations, like EBITDA from continuing operations, has inherent limitations because of the excluded items.
We have included a reconciliation of our non-GAAP financial measures to the most comparable financial measure calculated in accordance with GAAP.  We believe that providing the non-GAAP financial measure, together with the reconciliation to GAAP, helps investors make comparisons between the Company and other companies.  In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measure to evaluate their financial performance. Investors should pay close attention to the specific definition being used and to the reconciliation between such measure and the corresponding GAAP measure provided by each company under applicable SEC rules.
The Company defines Adjusted EBITDA from continuing operations as earnings (or loss) before interest expense, income taxes, depreciation and amortization asset impairment, loss on early extinguishment of debt, and non-cash stock-based compensation.  The Company excludes stock-based compensation because it is non-cash in nature.  The following table presents a reconciliation of Adjusted EBITDA from continuing operations to Net Income (loss) from continuing operations allocable to common shareholders, a GAAP financial measure:
  For the three months ended  For the nine months ended 
  September 30,  September 30,  September 30,  September 30, 
  2013  2012  2013  2012 
Net loss $(2,561,475) $(230,149) $(4,093,364) $(1,223,737)
  Interest expense  357,127   377,954   721,829   392,888 
  Asset Impairment  946,931   -   946,931   - 
  Loss on early extinguishment of debt  112,583   -   112,583   - 
  Depreciation and amortization  83,753   14,007   128,351   36,758 
  Stock based compensation expense  192,130   -   290,162   - 
Adjusted EBITDA (loss) from operations $(868,951) $161,812  $(1,893,508) $(794,091)

Liquidity and Capital Resources

The Company’s principal sources of liquidity include cash from operations and proceeds from long term debt and private placement of its shares. Overall, for the nine months ended September 30, 2013, the Company generated $2,503,000 from its financing activities primarily associated with the debt and equity financing. Such proceeds, coupled with its beginning cash balances, were utilized by the Company to fund its negative cash flow from operating activities in the amount of approximately $1,454,000 and investment in capitalized software, property and equipment of approximately $761,000.

As of September 30, 2013, the Company had cash balances of approximately $186,000 as compared to approximately $57,000 as of September 30, 2012, an increase of approximately $129,000.
Net cash used in operating activities was approximately $1,454,000 for the nine months ended September 30, 2013. This compared to net cash used by operating activities of approximately $872,000 for the nine months ended September 30, 2012. The increase of $582,000 was used to fund a net loss of $4,093,364 reduced by non-cash depreciation of $128,351, asset impairment of $946,931, loss on early extinguishment of debt of $112,583 stock compensation expense of $290,162, amortization of debt discount of $322,476, bad debt of $124,082, and changes in operating assets and liabilities totaling $715,099.
Net cash used in investing activities for the nine months ended September 30, 2013 was approximately $761,000 compared to approximately $102,000 for the nine months ended September 30, 2012. The increase is primarily attributable to the development of software.
Net cash provided by financing activities amounted to approximately $1,507,000 for the nine months ended September 30, 2013, compared to net cash provided in the nine months ended September 30, 2012 of approximately $833,000, representing an increase in net cash flow from financing activities of approximately $674,000. This was due to the receipt of net proceeds from the Company’s issuance of stock, net borrowings from new and existing debt obligations, offset by various debt repayments.
Financing:
The Company has the following financing arrangements:
1.The revolving line of credit for $150,000 with Bank of America for working capital needs was modified on September 19, 2013. The loan no longer has an expiration date of December 18, 2018, but instead a final maturity date of September 19, 2017. The interest rate per year is equal to the Bank’s Prime Rate plus 3.5 percentage points. The revolving line of credit was consolidated with an existing bank term loan  Bank’s prime rate of interest at September 30, 2013 was 3.25%. First payment of approximately $3,200 was paid October 19, 2013.
2.A term loan with Bank of America whose proceeds were used for general working capital. The term loan has been consolidated with an existing line of credit. The loan is personally guaranteed by one of the Company’s stockholders and is collateralized by the assets of HRAA. The balance due as of September 19, 2013 the date of the consolidation was approximately $20,697.
3.A mortgage made to HRAA’s subsidiary related to certain real estate which houses HRAA’s main offices in Plantation, Florida.  The loan originated in July 2010 in the amount of $192,500 and matures July 2020, when a balloon principal payment of approximately $129,000 becomes due.  The loan is collateralized by the real estate and is personally guaranteed by a stockholder of HRAA. Interest is fixed at 6.625% for the first five years of the loan, and converts to an adjustable rate for the second five years at the Federal Funds Rate plus 3.25%, as established by the United State Federal Reserve.  The balance under this mortgage loan as of September 30, 2013 was approximately $176,000. Monthly payments for principal and interest are approximately $1,500 until July 2015, when the total monthly payment may vary due to the adjustable interest rate provision in the note.
4.A factoring facility with a finance company whereby, under the terms of the agreement, the Company, at its discretion, assigns the collection rights of its receivables to the finance company in exchange for an advance rate of 85% of face value.  The assignments are transacted with recourse in the event of non-payment.   For the three months ended September 30, 2013, the Company had factored approximately $1,108,000 of receivables and had received cash advances of approximately $1,090,309. Outstanding receivables purchased by the factor as of September 30, 2013 were approximately $522,000 and included in accounts receivable in the accompanying unaudited condensed consolidated balance sheet, and the secured loan due to the lender was approximately $444,000. Factor fees in 2013 were approximately $104,000, and are included in interest expenses.
5.The Company leases certain office equipment under non-cancellable operating lease arrangements.  Monthly payments under the lease agreements are approximately $500 as of September 30, 2013.
6.During December 2012 and January 2013, the Company entered into a round of Loan Agreement and Promissory notes totaling $2,035,000. As of December 31, 2012, the Company had received $815,000.  The remainder of $1,220,000 was received in January and February 2013.
The Company’s Merger yielded cash from the sale of common stock that was approximately $600,000 short of the expected amount to be raised in order in order to execute its growth plan for the near future. Since the time of the Merger, the Company has transacted equity capital raises totaling approximately $1,685,000 of additional capital infusion. The Company has continued its build-up of the personnel and business development efforts and has incurred operating losses. As a result, the Company possesses a working capital of $26,892 at September 30, 2013 and continues to hold discussions with interested parties regarding additional investment in the Company’s common stock in amounts which approximate its current estimated working capital shortfall. Should efforts to raise additional capital prove to be unsuccessful; the Company will reduce its growth plans accordingly.
Year ended December 31, 2012 compared to the year ended December 31, 2011

Results of Operation

The following table presents a summary of operating information for the year ended December 31, 2012 and 2011:
  Year-ended  Year-ended  Increase/  Increase/ 
  December 31,  December 31,  (Decrease)  (Decrease) 
  2012  2011  ($)  (%) 
             
Revenues $5,806,848  $1,432,773  $4,374,075   305.3%
Cost of Revenues  2,830,008   473,719   2,356,289   497.4%
Gross profit  2,976,840   959,054   2,017,786   210.4%
                 
Selling and administrative expenses  3,853,820   1,976,655   1,877,165   95.0%
Research and development expenses  64,386   93,489   (29,103)  (31.1)%
Depreciation and amortization  50,765   31,362   19,403   61.9%
Other expenses, net  465,339   29,468   435,871   1,479.1%
Net income (loss) $(1,457,470) $(1,171,921) $(285,549)  24.4%
Revenue:

Revenue increased by approximately $4,374,000 or approximately 305%, from approximately $1,433,000 for the year ended December 31, 2011 to $5,807,000 for the year ended December 31, 2012.  The increase was due primarily to increased revenue2022, operations generated as a result of an increase in business development and marketing efforts put forth by HRAA.
Cost of Revenues:
Cost of revenues increased by approximately $2,356,000 or approximately 497%, from approximately $474,000 for the year ended December 31, 2011 to approximately $2,830,000 for the year ended December 31, 2012.  The increase was due primarily to greater personnel and related training costs associated with the buildup of the Company’s audit and coding service provider personnel required to service the anticipated increase in service contracts in future periods. Specifically, as of December 31, 2012, the Company employed 77 service providers, who have to go through a period of training, as compared to 5 service providers as of December 31, 2011.
Gross Profit:
Gross profit increased by approximately $2,018,000, or approximately 210%, from approximately $959,000 for the year ended December 31, 2011 to approximately $2,977,000 for the year ended December 31, 2012.  The increase in gross profit was due to the increase in business experienced in the year.
Selling and Administrative Expenses:
Selling and administrative expenses were approximately $3,854,000 for the year ended December 31, 2012, annet cash increase of approximately $1,877,000 or 95%,$258,000 while cash used from approximately $1,977,000 for year ended December 31, 2011.  The change infinancing activities during the 2012 period compared to the 2011same period was primarily due to:
Personnel costs have increased by approximately $1,735,000 or approximately 510%, from approximately $340,000 for the year ended December 31, 2011 to approximately $2,075,000 for the year ended December 31, 2012. The increase is due primarily to increased compensation and related expenses associated with the buildup of the Company’s management, sales and administrative staff in anticipation of growth in business volume.
Travel/Business Development has increased by approximately $295,000 or approximately 220%, from approximately $134,000 for the year ended December 31, 2011 to approximately $429,000 for the year ended December 31, 2012. The increase was due primarily to sales team efforts to develop new business growth.
Professional fees have increased from approximately $82,000 for the year ended December 31, 2011 to approximately $395,000 for the year ended December 31, 2012, an increase of approximately $313,000, or 382%.  This increase is attributable to legal and accounting services provided in connection with the merger and two subsequent capital rises, and expenses associated with audit and review services.
The remainder of the increase in Selling and administrative expenses is related to costs associated to the company’s business development such as marketing, trade shows and seminars. The increases were partially offset by decreased expenses of approximately $464,000.

Research and Development Expenses:
Research and development expenses were approximately $64,000 for the year ended December 31, 2012, a decrease of approximately $29,000, or 31%, from approximately $93,000 for the year ended December 31, 2011. The decrease is due to the capitalization of expenses related to the development of the  Visualizer ™ suite.
Depreciation and Amortization Expenses:
Depreciation and amortization expenses were approximately $51,000 for the year ended December 31, 2012, an increase of approximately $20,000, or 61%, from approximately $31,000 for the year ended December 30, 2011. The increase was primarily due to depreciation costs associated with the Company’s purchases for office furniture and computer necessary to support the increase in personnel.
Interest Expense (included in other expenses, net):
Interest Expense was approximately $465,000 for the year ended December 31, 2012, an increase of approximately $436,000, from approximately $29,000 for the year ended December 31, 2011. The increase is primarily due to the factoring fees in 2012 along with interest on outstanding debt obligations and a $300,000 non-cash expense related to the amortization of a $300,000 beneficial conversion feature which was expensed during the year ended December 31, 2012. Additionally, de minimums other income offset interest expense in the above captioned account "Other expense, net".
Net Loss:
As a result of the above factors, a net loss of approximately $1,457,000 was recognized for year ended December 31, 2012 as compared to net loss of approximately $1,172,000 for the year ended December 31, 2011, a decrease in income of approximately $285,000 or approximately 24%.  The increase in net loss is outlined above.
Non-GAAP – Financial Measures
The following discussion and analysis includes both financial measures in accordance with GAAP, as well as a non-GAAP financial measure.  Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position or cash flows that either excludes or includes amounts that are not normally included or excluded in the most directly comparable measure calculated and presented in accordance with GAAP.   Non-GAAP financial measures should be viewed as supplemental to, and should not be considered as alternatives to net income, operating income, and cash flow from operating activities, liquidity or any other financial measures.  They may not be indicative of the historical operating results of$1,160,000, the Company nor is it intended to be predictive of potential future results.  Investors shoulddid not consider non-GAAP financial measures in isolation or as substitutes for performance measures calculated in accordance with GAAP.
We believe that both managementreceive and shareholders benefit from referring to the following non-GAAP financial measure in planning, forecasting and analyzing future periods. Our management uses this non-GAAP financial measure in evaluating its financial and operational decision making and as a means to evaluate period-to-period comparison. Our management uses and relies on the following non-GAAP financial measure:
Adjusted EBITDA from continuing operations

Our management believes Adjusted EBITDA from continuing operations is an important measure of our operating performance because it allows management, investors and analysts to evaluate and assess our core operating results from period to period after removing the impact of items of a non-operational nature that affect comparability.  Our management recognizes that Adjusted EBITDA from continuing operations, like EBITDA from continuing operations, has inherent limitations because of the excluded items.
We have included a reconciliation of our non-GAAP financial measures to the most comparable financial measure calculated in accordance with GAAP.  We believe that providing the non-GAAP financial measure, together with the reconciliation to GAAP, helps investors make comparisons between the Company and other companies.  In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measure to evaluate their financial performance. Investors should pay close attention to the specific definition being used and to the reconciliation between such measure and the corresponding GAAP measure provided by each company under applicable SEC rules.
The Company defines Adjusted EBITDA from continuing operations as earnings (or loss) before interest expense, income taxes, depreciation and amortization, and non-cash stock-based compensation.  The Company excludes stock-based compensation because it is non-cash in nature.  The following table presents a reconciliation of Adjusted EBITDA   from continuing operations   to Net Income (loss) from continuing operations allocable to common shareholders, a GAAP financial measure:
  For the year ended 
  
December 31,
2012
  
December 31,
2011
 
Net loss $(1,457,470) $(1,171,921)
  Interest expense  465,349   29,468 
  Depreciation and amortization  50,765   31,362 
  Stock based compensation expense  -   818,595 
Adjusted EBITDA (loss) from operations $(941,356 $(292,496
Liquidity and Capital Resources
The Company’s principal sources of liquidity include proceeds from long term debt and private placementdebt. The net decrease in cash for 2022 was approximately $902,000.

The main use of its shares. Overall, forcash was the year ended December 31, 2012,first payment to shareholder from the Company generated approximately $2,803,000 from its financing activities primarily associated with the debt and equity financing.  Such proceeds, coupled with its beginning cash balances, were utilized by the Company to fund its negative cash flow from operating activitiesshareholder buyout agreement signed in July 2022 in the amount of approximately $1,699,000 and investment in property and equipment$686,990, as previously discussed. Other finance activities usage was building improvements of approximately $280,000.

As$224,000, loan payments $180,000 and owner distributions before merger in the amount of $63,000.

On December 31, 2012,2022, the Company had cash balanceson hand of approximately $894,000 as compared$1,226,600, with total current assets of $3,207,750.

Moving Forward

During the past eighteen months we have been working to approximately $199,000 asget to where we are today. It has been difficult and expensive, to get to this point of December 31, 2011, an increasebeing a public company with the corporate structure, systems and team that can expand our business with increasing profitability. Our current overhead expense structure has the capacity to manage two to three times the revenues from one of approximately $695,000.

Net cash usedtwo strategic sources.

Our first source is to continue down our historical path of seeking out contracts that meet our sweet spot and bidding with hope of successful award. However, this path is time consuming and isn’t a guarantee of the growth we desire and is outside of our control.

Our second source of growth is merger and acquisition. Now that we have the capital market available to us and our industry is positioned for long term growth, now is the time. The security industry continues to grow in operating activities was approximately $1,699,000 foropportunity, and at the year ended December 31, 2012.  This compared to net cash used by operating activitiessame there’s a lot of approximately $66,000 for the year ended December 31, 2011. The decrease of $1,633,000 was primarily due to higher personnel costs, greater travel and business development costs, and professional fees connected to the Company’s merger with HRAA which occurred in February 2012 along with non-cash charges of $355,573.

Net cash used in investing activities for the year ended December 31, 2012 was approximately $280,000 compared to approximately $47,000 for the year ended December 31, 2011.  The increase is primarily attributable to the development of software.
Net cash provided by financing activities amounted to approximately $2,674,000 for the year ended December 31, 2012, compared to net cash providedconsolidation occurring. As a top 25 company in the year ended December 31, 2011 of approximately $256,000, representing an increaseindustry, we can be the company acquiring others and quickly doubling our revenues with one or two key acquisitions. After which we could see all the gross profit from those companies going directly to our bottom line. The returns would be quick and significant.

There are also acquisition opportunities in net cash flow from financing activities of approximately $2,418,000.  This was dueseveral other industries that fits our business model. Those include transportation, cyber security, private security, ammunition manufacturing, and surveillance to the receipt of net proceeds from the Company’s issuance of stock, advances on convertible promissory notes, and net borrowings from new and existing debt obligations offset by various debt repayments.


Financing:
mention a few. The Company has already begun the following financing arrangements:
process of our first equity raise with Think Equity to recover our expended working capital and position the Company for its first acquisition. We anticipate the equity raise to be completed in the second quarter along with our first acquisition.

Management is very positive regarding profitable operations for the next twelve months based on the following:

1.AGSS operates in a growing industry.

The revolving linesecurity industry is recession proof.

There are over 10,000 security companies operating in our market, with 50% available for acquisition.

Our management team, Board of creditDirectors and supporting equity professionals can get the job done.

We have been and will continue to be a company that is very conservative with our resources and will use every possible dollar provide strength and good return to our investors.

We are in it for $150,000the long haul.

We make profits the old fashion way, hard work.

23

Management Discussion of Strategic Plans

On December 9, 2022, AGSS acquired AmeriGuard via a stock exchange. After which, AmeriGuard became the 100% subsidiary of AGSS resulting in the consolidated annual revenue of AGSS to exceed $22 million. We hope to achieve material growth following a very simple menu:

Aggressive bidding on new and current Federal Guard Contracts.

Meet the growing needs in the Commercial Guard services.

Acquisitions of Federal Contracting competitors, specifically those with Bankhigh level secret security clearance.

Acquisition of Americabusinesses operating in the governmental contracting market achieving greater margins such as the Transportation industry and technology, specifically cyber-security and related IT services.

Government Contracts

We intend to continue to take advantage of our federal contracting bidding category of a veteran owned, minority owned, small business (initially) narrowing the field of competition for each contract. The small business category is defined as average sales over 5 years at or below $25.5 million. We project that we will remain below that level for the next two calendar years. Another category that increases contracting opportunities is the much-coveted position of having high level secret clearance. We have held this clearance in the past and are actively seeking to gain such clearance again.

With over 20 years of experience with government contracts providing significant understanding of the bidding process along with a team of 5 individuals processing contract bids, we are confident of being awarded two or three new contracts in the next eighteen months.

As previously mentioned in the industry discussion, the industry is going through a merger and acquisition phase driven by the need to consolidate overhead and a significant percentage of owner retirements. One key reason for the creation of this public company is to gain the significant capital necessary to acquire two or three companies already in the governmental contract market.

Commercial Guard Services

With the increasing crime rates in most major cities across the country the gap between what the business owners expect from law enforcement and what law enforcement can deliver is widening. A specific concern is the amount of time it takes from the moment an alarm is triggered and the arrival of an officer. This can be multiple hours and sometimes not at all for local police departments. The time gap as described could mean the difference between a broken window to a multi thousand-dollar loss.

It is a part of our regular service to dispatch an armed officer to respond quickly to the alarm, secure the scene and await law enforcement or the business owner. We believe that this quick response ensures a higher level of security for our customers. We provide the complete package of alarms, video cameras to armed response. This complete vertical can be duplicated in any town USA. It is true that other guard companies do provide armed response, yet not many also have surveillance systems under their operational control and monitored with local dispatch as we do.

Our strategy is to acquire commercial guard companies in the states where we have federal contracts allowing us to establish a kind of farm system for guards who can start at a no experience entry position, receive experience and training to ultimately be employed at the high value level of unionized federal guard. Like many industries, it is extremely difficult to find and keep the employees needed for our federal contracts. This negatively impacts the bottom-line success of a contract due to extra overtime not anticipated. A program like this will allow individuals to start and build a career, not just a job.

24

Other Business Acquisitions

The last item on our menu is the acquisition of a related governmental contractor in the Transportation and/or Cyber Security business. These lines of business achieve high margins and play in the same contract market as our guard services. We can become successful players in this market very quickly.

AGSS will look to identify a few potential Cyber Security/IT companies that could be acquired. We see the acquisition of a quality Cyber Security company and an important aspect of our strategic plan. The Executive Team will identify potential acquisitions with great urgency.

Implementation and Timeline

For the acquisitions we will identify target companies that meets the specific strategic and financial criteria established by the board, and then seek the necessary capital. The acquisition offer will include both cash and AGSS stock.

The criteria that management is currently using to identify acquisition target are:

1.Currently holding governmental contracts in good standing and/or with solid commercial operations.

2.Companies in related industries provide significant value to our company’s bottom line.

3.A minimum of a 10% EBTIDA (non-guard companies), and guard companies with the majority of revenues from government contracts with an EBTIDA of 2.5+%.

4.Consolidation savings will bring EBTIDA to 15% (non-guard companies), and 8-10% for working capitalguard companies.

5.Monthly revenues exceeding $500,000.

6.Has a clear path for revenue growth.

7.If the company does not meet the criteria in 1-6. It needs was modified on December 18, 2012. The loan no longer hasto demonstrate an expiration date of December 18, 2012, but instead a final maturity date of December 18, 2018. The interest rateability to grow 10% per year is equalor more and bring positive cash flow to the Bank’s Prime Rate plus 6.5 percentage points. The Bank’s prime rate of interest at December 31, 2012 was 3.25%. First payment of $2,083 was due January 18, 2013.company.

For new government contracts, this approach is a bit more time-consuming and competitive. Preparing proposals for the contracts that become available is not the problem, the time aspect is the dates the contracts are awarded.

The capital required component of these contracts is twofold. First, the contract often requires new equipment and vehicles. Second, the bidding company must have enough working capital to cover the first three months of payroll. With payroll cost being 80% of the contract and various equipment requirements, the required capital on hand can be significant. For a contract that has $15 million per year in revenue the capital on hand requirement would exceed $3,000,000.

The following is a description of the assumptions made for each quarter of operation.

25

2.A term loan with Bank of America whose proceeds were used for general working capital. The loan is personally guaranteed by one of the Company’s stockholders and is collateralized by the assets of HRAA. Payments of principal and interest are approximately $2,700 per month. The loan matures in five years from September 2009, and incurs interest at the rate of 6.75% per annum. The balance due as of December, 2012 was approximately $39,000.
3.A mortgage made to HRAA’s subsidiary related to certain real estate which houses HRAA’s main offices in Plantation, Florida.  The loan originated in July 2010 in the amount of $192,500 and matures July 2020, when a balloon principal payment of approximately $129,000 becomes due.  The loan is collateralized by the real estate and is personally guaranteed by a stockholder of HRAA. Interest is fixed at 6.625% for the first five years of the loan, and converts to an adjustable rate for the second five years at the Federal Funds Rate plus 3.25%, as established by the United State Federal Reserve.  The balance under this mortgage loan as of December 31, 2012 was approximately $180,000. Monthly payments for principal and interest are approximately $1,500 until July 2015, when the total monthly payment may vary due to the adjustable interest rate provision in the note.
4.A factoring facility with a finance company whereby, under the terms of the agreement, the Company, at its discretion, assigns the collection rights of its receivables to the finance company in exchange for an advance rate of 85% of face value.  The assignments are transacted with recourse in the event of non-payment.  During 2012, the Company had factored approximately $3,850,000 of accounts receivable and had received cash advances of approximately $3,272,000 with a balance due to factor of approximately $827,000 at December 31, 2012.
5.The Company leases certain office equipment under non-cancelable operating lease arrangements.  Monthly payments under the lease agreements are approximately $500 as of December 31, 2012.
6.On May 14, 2012, the Company entered into a round of Convertible Promissory notes totaling $300,000.  These loans were to mature on May 14, 2013.  The loans converted to common stock on July 15, 2012.
7.During December 2012 and January 2013, the Company entered into a round of Loan Agreement and Promissory notes totaling $2,035,000. As of December 31, 2012, the Company had received $815,000.  
The Company’s recent merger yielded

Second quarter of operation, April – June 30, 2023

During this quarter our focus will be acquiring a guard company of a large enough size to have annual sales over $10 million, with the hopes of providing additional cash from operations at 6% of annual sales.

During this quarter we also look to acquire a transportation company, hopefully with federal contract(s). The capital required for this industry is heavy on the sale of common stockasset side in that was approximately $600,000 short of the expected amountvehicles need to be raised in orderready to execute its growth plan for the near future.  Sincego at the time of contract award. However, bottom line earnings can exceed 12%. Like the Merger, the Company has transacted equity capital raises totaling approximately $1,060,000 of additional capital infusion.  The Company has continued its buildup of the personnelguard industry, this industry is going through mergers and business development efforts and has incurred operating losses.  As a result, the Company possesses a working capital of approximately $157,000 at December 31, 2012 and continues to hold discussions with interested parties regarding additional investment in the Company’s common stock in amounts which approximate its current estimated working capital shortfall. Should efforts to raise additional capital prove to be unsuccessful; the Company will reduce its growth plans accordingly.

Going Concern

The Company’s future successacquisitions. Management is dependent upon its ability to achieve profitable operations and generate cash from operating activities, and upon additional financing, management believesconfident they can raise the appropriate funds needed to support their business plan and develop an operating company which is cash flow positive.

However, as of September 30, 2013, the Company has an accumulated deficit and for the three and nine months ended September 30, 2013, incurred net losses, and has used net cash in operations. The Company has not been able to generate sufficient cash from operating activities to fund its on-going operations. There is no guarantee that the Company will be able to generate enough revenue and/find a few companies that meet our acquisition requirements.

Third quarter of operation, July – September 30, 2023

The third quarter of operation anticipates the operations of an acquired transportation company with a net cash percentage of 12% or raise capitalmore. This quarter could see the blending in of the transportation company and the consolidation of overheads.

At this point AGSS should have a complete Executive Team, full Board of Directors, processes and procedures in place and will be aggressively working to support its operations. These factors raise substantial doubt aboutachieve our goal of $100 million in annual sales.

As previously indicated it is anticipated that AGSS will acquire additional Security Companies competing with AGSS in the government contracting market, along with companies that meet the acquisition criteria previously mentioned, from June 2023 through the end of the year. The previous comments and timeline reflect management’s expectations that are achievable and are at the minimum of management’s intentions. Based on market activities and investor readiness, the pace of acquisitions and contract awards could accelerate.

Potential Impact of COVID-19

The Company is concerned that the COVID-19 virus may impact the Company’s ability to raise additional equity capital due to the uncertainty of the virus’ effects on the economy and capital markets, which may make potential investors less likely to invest during the pandemic. This may affect the Company’s ability to raise equity capital to meet its financial obligations, implement its business plan and continue as a going concern.

On November 12, 2013, the Company entered into a Securities Purchase Agreement for the equity sale of $5.4 million in Series A Preferred Stock and warrants to purchase shares of the Company’s Common Stock. The net proceeds to the Company after commissions, professional fees, and payment of shareholder loans is $4,322,000. The net raise is sufficient to fund on-going operations for the next several months. However, the funding is not sufficient to alleviate the on-going concern issue.
2014 Outlook
Now that the deadline for the ICD-10 Transition is finalized for October 2014, many healthcare executives are asking, “How should we get back on track in order to mitigate our financial and compliance risk?”  In response to this question, HRAA developed the ICD Visualizer ™. Utilizing knowledge from healthcare industry subject matter experts combined with exceptional insight into what providers really need, the ICD Visualizer ™  assists healthcare leaders with their need to understand the exponential impact of the transition to ICD-10 and how it relates to reimbursement risks, clinical documentation quality, coding productivity and process changes.
By utilizing a business intelligence platform known for its ease of use and visualization capabilities, ICD Visualizer ™  is designed as a multidimensional environment that enables chief financial officers, vice presidents of payer relations, revenue cycle directors, HIM directors, coders and clinicians to explore the impact ICD-10 will have across the enterprise and within both inpatient and outpatient services.  ICD Visualizer ™  contains a set of baseline analytics that quantify the impact across hospitals, service lines, departments and physicians.  Because ICD Visualizer ™  has customizable analytics, analysts and executives are able to explore their own data and visualize a unique representation of their financial and operational needs well beyond the ICD-9 to ICD-10 transition phase.
Another outlook for 2013 and 2014 is the new Hospital Readmission Reduction Program, (HRRP), an Affordable Care Act provision, creates increasing financial penalties for hospitals with higher than expected adjusted readmissions within 30 days. The Centers for Medicare and Medicaid Services, (CMS) expect HRRP to help to control IPPS payment penalties to hospitals having higher than average readmissions within 30 days for 3 conditions: Acute Myocardial Infarction, (AMI), Heart Failure, (HF), and Pneumonia, (PN). The measures included in the policy represent high volume and high cost conditions and are endorsed by the National Quality Forum (NQF). The measures have some exclusion for readmissions that are unrelated to the prior discharge (such as planned admissions for scheduled procedures subsequent to AMI or transfers to another hospital).
In 2013, DRG payment rates will be reduced based on a hospital’s ratio of actual to expected readmissions. The reduction applies to the base DRG payment only and does not include IME, DSH or outlier payments. In FY 2013, the maximum payment reduction is 1 percent. In 2014, penalties double to 2% and cap at 3% in 2015. According to the CMS a total of 2,217 hospitals are expected to be penalized in the first year of the program. Of those hospitals, 307 will pay the maximum penalty at 1 percent of their regular Medicare reimbursements. The penalty cap will increase to two percent in 2014 and three percent in 2015 and new measures and metrics will be added.
Readmissions Visualizer ™  is a significant aspect of our value proposition for this factor. This business intelligence product is built on a premier business discovery platform that provides the ability to view current inpatient and historical readmission information through an intuitive Web interface for the purpose of decreasing readmissions within the healthcare system and to classify current census risk for readmission so care management can allocate appropriate resources.  Users can view current census including Reason for Admission, History of HF, AMI, PN, LACE Readmission Score, Emergency Room History, and more.
Readmissions Visualizer ™  also trends and analyses performance for predictive models to plan enterprise resource budgeting, partner planning, resource allocation and workflow interventions for care management at transitions to improve care quality and continuity.

The Company is poised to leverage these factors and more facing the healthcare industry through the sales of its products and solutions that allow healthcare organizations to view patient lifecycles horizontally as opposed to vertically thus reducing the cost of delivery and improving the delivery experience for Doctors, Nurses and Patients.

Off-Balance Sheet Arrangements


None.

We have no off-balance sheet arrangements.

Critical Accounting Policies

The preparation of unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires our management to make assumptions, estimates, and judgments that affect the amounts reported, including the notes thereto,Estimates

Our discussion and related disclosures of commitments and contingencies, if any. We have identified certain accounting policies that are significant to the preparation of our consolidated financial statements. These accounting policies are important for an understanding of our financial condition and results of operations. Critical accounting policies are those that are most important to the portrayalanalysis of our financial condition and results of operations and require management’s difficult, subjective, or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Certain accounting estimates are particularly sensitive because of their significance to financial statements and because of the possibility that future events affecting the estimate may differ significantly from management’s current judgments. We believe the following critical accounting policies involve the most significant estimates and judgments used in the preparation of our consolidated financial statements.

The Company is an emerging growth company; therefore we have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(2)(B) of the Jumpstart Our Business Startups Act. As a result of this election,based upon our consolidated financial statements, may not be comparable to companies that comply with public company effective dates.

Allowance for doubtful accounts

Accounts receivable balances are subject to credit risk. Management has reserved for expected credit losses, sales returns and allowances, and discounts based upon past experience, as well as knowledge of current customer information. The Company believes that its reserves are adequate. It is possible, however, that the accuracy of our estimation process could be impacted by unforeseen circumstances. The Company continuously reviews its reserve balance and refines the estimates to reflect any changes in circumstances.
Software
Costs incurred in connection with the development of software products are accounted forwhich have been prepared in accordance with the Financial Accounting Standards Board Accounting Standards Codification ("ASC") 985 Costs of Software to Be Sold, Leased or Marketed.” Costs incurred prior to the establishment of technological feasibility are charged to research and development expense. Software development costs are capitalized after a product is determined to be technologically feasible and is in the process of being developed for market and capitalization ceases after the general release of the software. Amortization of capitalized software development costs begins upon initial product shipment after general release. Capitalized software development costs are amortized over the estimated life of the related product (generally thirty-six months) using the straight-line method. The Company evaluates its software assets for impairment whenever events or change in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of software assets to be held and used is measured by a comparison of the carrying amount of the asset to the future net undiscounted cash flows expected to be generated by the asset.  If such software assets are considered to be impaired, the impairment to be recognized is the excess of the carrying amount over the fair value of the software asset. 
Software maintenance costs are charged to expense as incurred. Expenditures for enhanced functionality are capitalized. The cost of the software and the related accumulated amortization are removed from the accounts upon retirement of the software with any resulting loss being recorded in operations.
Asset Impairment
At the end of September, 2013, the Company re-evaluated the capitalized research and development costs for the Visualizer  software suite of multiple offerings and the OMC Initiator after an evaluation based in part on the lack of cash flow and customer demand in ICD Visualizer after the general acceptance release date of July 15, 2013. In addition, the Company also considered its going concern opinion and cash liquidity concerns that restrain the abilityU.S. generally accepted accounting principles. These principles require us to make capital investments in research and development to complete existing products in the pipeline as the available cash is needed to fund normal operating expenses. As a result of this evaluation, the Company recorded a loss of $946,931 that is presented as a line item entitled “asset impairment” on the consolidated statement of operations.
Use of Estimates

Management uses estimates and assumptions in preparing financial statements.  Those estimates and assumptionsjudgments that affect the reported amounts of assets, liabilities, revenue and liabilities, theexpenses, cash flow and related disclosure of contingent assets and liabilities,liabilities. Our estimates include those related to revenue recognition, accounts receivable reserves, income and other taxes, stock-based compensation and equipment and contingent obligations. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the reported revenues and expenses.circumstances. Actual results couldmay differ from these estimates. To the extent that there are material differences between these estimates and our actual results, our future financial statements will be affected.

We define our “critical accounting policies” as those estimates. SignificantU.S. generally accepted accounting principles that require us to make subjective estimates reflectedabout matters that are uncertain and are likely to have a material impact on our financial condition and results of operations as well as the specific way we apply those principles. Our estimates are based upon assumptions and judgments about matters that are highly uncertain at the time the accounting estimate is made and applied and require us to continually assess a range of potential outcomes. A detailed discussion of the critical accounting policies that most affect our company is in Footnote 2 of the notes to our financial statements.

26

DESCRIPTION OF PROPERTY

The Company’s corporate headquarters is located at 5470 W. Spruce Avenue, Suite 102, Fresno CA. The lease is currently month to month. Landlord has not indicated a desire for a new lease. Our lease payments are a total of $55,767 for the entire term (or, $4,230 per month).

27

LEGAL PROCEEDINGS

While we have not been involved in any litigation related to the performance of our guard services, armed or otherwise, to date, as an armed guard Company with contracts with Governmental entities is a possibility of legal proceedings that could be more serious than the average business. From time to time, the Company is involved in matters relating to claims arising from the ordinary course of business, but those claims have been labor and union related and have been settled on an administrative level not in court.

While the results of such claims and legal actions cannot be predicted with certainty, the Company’s consolidated financial statements include valuation of accounts receivable, valuation of property and equipment, valuation and amortization period of software, valuation of beneficial conversion features in convertible debt, valuation of equity based instruments issued for other than cash, revenue recognition, and the valuation allowance on deferred tax assets.


Revenue Recognition
The Company recognizes services revenue based on the proportional performance method of recognizing revenue.
A portion of the Company’s revenue is generated from medical coding audit services. Auditing revenue is invoiced in accordance with the contract, generally at three benchmark time periods which coincide with when specific, obligatory field work services have been rendered and completed, the value of this portion of the contract price has been predetermined and agreed upon, and the client has received benefitmanagement does not believe that there are claims or value in the form of the independent identification of system weaknesses and risk analysis. Further, collectability is reasonably assured due to the existence of a fixed fee contract and the size and financial health of the Company’s clients. Below is a description of the general benchmarks and work phases associated with the Company’s audit services:
Planning Phase - work commences prior to and as soon as the contract is signed and includes setting the audit scope, scheduling of the job, assignment of audit staff, understanding the client and their systems, determination of sample size and sampling methods to be employed, and other specific items as outlined in the contract. The planning phase includes the determination of deliverables as defined in the contract, generally consisting of a listing of errors, training and a final report. The Company generally invoices and recognizes 50% of the contract value at the completion of the Planning Phase. Although all of the contracts contain a clause making the first 50% of the engagement fee due and non-refundable at this point, the Company does not deem this initial fee to be recognized as deferred revenue under SAB 104 due to the extensive amount of work to be done prior to accepting the contract.
Field Work Phase – is performed at the client location and generally lasts one week and encompasses actual testing of sample claims preselected in the Planning Phase. The auditor generally preloads the selected claims into the Company’s proprietary software and audits the claim records by reviewing actual medical records. The software assists the auditor in determining proper classifications and allows the auditor to compare the proper classificationactions, pending or threatened against what was filed in the submission made by the client to Medicare. Notes and comments are recorded and audit reports are generated. The Company generally invoices and recognizes 40% of the contract value at the completion of the Field Work Phase.
Reporting Phase – includes a summary of audit findings, exit conference with clients, and any other specific deliverables as determined by the contract. The Company generally invoices and recognizes the remaining 10% of the contract value at the completion of the Report Phase.
A portion of the Company’s revenue is derived from consulting, training and coding services provided. Revenue from these revenue streams is recognized after services are performed based on the quoted and agreed upon fee contained in its contracts.
For our education products sold on a self-study standalone basis or in multiple element contracts which include training and the product and training are separable elements (see below) revenue is recognized for the product upon passing of title which occurs once the end user is granted access to our online curriculum courses.
The Company had a general release of its first software product in July 2013.  Software sales on a standalone basis will be recognized upon delivery of the software when evidence of the purchase arrangement exists and the price is determinable, and when collectability is reasonably assured.

Arrangements with customers may involve multiple elements including software products, education products, training, software product maintenance, coding services, coding audit services and other consulting services. Training on education products will occur after the education product sale. Education products are sold and may be used as a self-study product, although most of our customers elect to purchase our training services and therefore most of our contracts to date are multiple element contracts including one price for the education product and related training. We allocate the selling price to each element as discussed below. Training and maintenance on software products will generally occur after the software product sale. Other services may occur before or after the product sales and may not relate to the products.  Revenue recognition for multiple element arrangement is as follows:
Each element is accounted for separately when each element has value to the customer on a standalone basis and there is Company specific objective evidence of selling price of each deliverable. For revenue arrangements with multiple deliverables, the Company, allocates the total customer arrangement to the separate unitsultimate disposition of accounting basedwhich would have a material adverse effect on their relative selling prices as determined by the priceour business, results of the items when sold separately. Once the selling price is allocated, the revenue for each element is recognized using the general and specific criteria under GAAP as discussed above for elements sold in non-multiple element arrangements.    A delivered itemoperations, financial condition or items that do not qualify as a separate unit of accounting within the arrangement are combined with the other applicable undelivered items within the arrangement. The allocation of arrangement consideration and the recognition of revenue is then determined for those combined deliverables as a single unit of accounting.  The Company has historically sold its services with established rates which it believes is Company specific objective evidence of selling price. For the new software products, management has established selling prices which qualifies as Company specific objective evidence of selling price. Generally all elements in multiple element arrangements with Company customers qualify as separate units of account for revenue recognition purposes.cash flows.

28

Share Based Compensation

Compensation expense for all stock-based employee and director compensation awards granted is based on the grant date fair value estimated in accordance with the provisions of ASC Topic 718, Stock Compensation (“ASC Topic 718”). The Company recognizes these compensation costs on a straight-line basis over the requisite service period of the award, which is generally the option vesting term. Vesting terms vary based on the individual grant terms.
The Company estimates the fair value of stock-based compensation awards on the date of grant using the Black-Scholes-Merton (“BSM”) option pricing model, which was developed for use in estimating the value of traded options that have no vesting restrictions and are freely transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility. The BSM option pricing model considers, among other factors, the expected term of the award and the expected volatility of the Company’s stock price. Expected terms are calculated using the Simplified Method, volatility is determined based on the Company's historical stock price trends and the discount rate is based upon treasury rates with instruments of similar expected terms. Warrants granted to non-employees are accounted for in accordance with the measurement and recognition criteria of ASC Topic 505-50, Equity Based Payments to Non-Employees.

Directors, and Executive Officers

and Corporate Governance.

Set forth below are the names, ages and other biographicalis information ofregarding our directors and executive officers following the closing of the Merger. Pursuant to the terms of the Merger, our sole officer and director, Lawrence Garcia, was appointed as President and Chief Executive Officer, was appointed as our Chief Operating Officer, Secretary and Treasurer, Michael Goossen as our Chief Financial Officer. In addition, in connection with the Merger, Douglas Anderson was appointed to serve as a director on December 9, 2022

The following persons became our executive officers and directors upon effectiveness of January 31, 2014:

the Merger, and hold the positions set forth opposite their respective names.

NameAgePosition
Lawrence Garcia50Chairman of the Board, President and Chief Executive Officer
Chief Operating Officer, Secretary, Treasurer and Director
     
Andrea ClarkMichael Goossen, CPA5261

Chief ExecutiveMarketing Officer and Chairman of the BoardDirector

Chief Financial Officer

     
Robert RubinowitzDouglas Anderson*4760Chief Operating Officer, President, Secretary, Treasurer and Director
Evan McKeown55Chief Financial Officer
Peter Russo56Director
Michael Brainard43Director
Dean Boyer43Chief Technology Officer
David Kroin38Director
Mitchell D. Kaye J.D.45Director

 
*

Appointed December 9, 2022.

Directors serve until the next annual meeting and until their successors are elected and qualified. The following isdirectors of our company are elected by the vote of a descriptionmajority in interest of the business experienceholders of the voting stock of our company and hold office until the expiration of the term for which he or she was elected and until a successor has been elected and qualified.

Most of the authorized number of directors constitutes a quorum of the Board for the transaction of business. The directors must be present in person or telephonically at the meeting to constitute a quorum. However, any action required or permitted to be taken by the Board may be taken without a meeting if all members of the Board individually or collectively consent in writing to the action.

Directors may receive compensation for their services and reimbursement for their expenses as shall be determined from time to time by resolution of the Board. Our directors currently do not receive monetary compensation for their service on the Board of Directors.

Officers are appointed to serve until such time as their successors have been duly appointed by the Board of Directors.

The principal occupations for the past five years (and, in some instances, for prior years) of each of our executive officers and directors:

Andrea Clark, 52, Chief Executive Officerdirectors, followed by our key employees, are as follows:

Officers

Lawrence Garcia is the CEO and ChairmanPresident of Ameriguard Security Service, Inc incorporated in state of California in 2002. Lawrence is a disabled veteran of the Board

Andrea Clark serves as our ChairmanUnited States Navy and of Hispanic dissent. He has led the company from a small local guard company to a national company currently managing five Federal Government armed guard contracts with annual revenue of over $22 million. Mr. Garcia has twice been named, “Businessman of the Board and Chief Executive Officer. Ms. Clark is a prominent health information management expert, having working with hospitals, information systems, outpatient coding, operational and compliance training expertise, including hospital-based and free-standing day surgery sites, emergency room, hospital based clinics and ancillary diagnostic service areas forYear” in the last twenty-five years. In 2001, Ms. Clark founded HRAA and has been its chief executive officer since inception. Ms. Clark received her BS in Health Information Sciences from the UniversityState of Wisconsin. She California.

Michael Goossen, CPA is also certified by the American Health Information Management Association as a Registered Health Information Administrator (RHIA) and by the American Academy of Professional Coders as a Certified Coding Specialist (CCS) and as a Certified Procedural Coder-Hospital (CPCH).

Pursuant to the terms of the Securities Purchase Agreement entered into with certain funds and accounts as to which Great Point Partners, LLC acts as an investment manager, dated November 12, 2013, an executive search committee will be established comprising of three Board of Director members to search for a new Chief Executive Officer.
Robert Rubinowitz, 47, Chief Operating Officer, President, Secretary, Treasurer and Director
Robert Rubinowitz serves as our Chief Operating Officer, President, Secretary, Treasurer and Director, overseeing all of our business operations including client relations, sales, marketing, accounting and human resources. He has served in this capacity at HRAA since June 2001. Mr. Rubinowitz has more than twenty years of experience in operations, sales and marketing. Prior to joining HRAA, Mr. Rubinowitz was General Manager of e-Commerce for PRIMEDIA as well as having served as Vice President of Marketing and e-Business at Anchor Computer. Mr. Rubinowitz was also an adjunct professor for Florida International University where he taught direct marketing. Mr. Rubinowitz received a Bachelor’s degree in Economics from Rutgers University.
Evan McKeown, 55, Chief Financial Officer
Mr. Evan McKeown serves as the Chief Financial Officer of Ameriguard Security Services, Inc., a California Corporation. Michael has been a CPA since 1986, has worked in multiple industries as a CFO and CEO. During the Company,past 20 years he has been providing small business consulting, offering CFO services and executive leadership development. Michael began working with Ameriguard as a CFO consultant and business strategic services 3 years ago and became the full time CFO for Ameriguard in August 2022.

29

Board of Directors

Douglas Anderson, Board Director. Mr. Anderson is responsible for budgeting, financial reportingthe CEO of Wall Street Capital Partners and public disclosure, personnel management,has been involved in or exposed to most aspects of corporate finance with over 20 years on Wall Street. Prior to his work in corporate finance, he served in the U.S. Marine Corps, including the elite Marine Reconnaissance Battalion. He held a Top-Secret clearance while serving operationally in the U.S. State Department at American Embassies overseas, as well as helping to createat the U.N. in New York, where he participated in Security Enhancement programs. Mr. Anderson was formally trained on Wall Street as an Underwriter. He has been interviewed and overseebroadcast nationally and internationally, many times as an expert both on NASDAQ and at the financial goals of HRAA. Prior to joining the Company,NYSE. Mr. McKeown was formerly the Chief Financial Officer of Perry Baromedical, a regulated medical device manufacturer and world leader in the manufacture, installation and service of FDA approved Hyperbaric Oxygen Chambers. Mr. McKeown also served as the Chief Financial Officer and Controller of National Healing Corporation, a leader in providing comprehensive outpatient wound care centers and wound and disease management solutions for hospitals. DuringAnderson earned his tenure at National Healing Corporation, Mr. McKeown gained relevant experience with healthcare coding and hospital contract negotiations. Prior to that, Mr. McKeown was the Senior Vice President, Chief Financial Officer and Chief Accounting Officer for Applied Digital, a former public company that provides RFID identification and security technology for various consumer and commercial applications. Mr. McKeown also served as a Tax Manager for Ernst and Young and was a senior accountant with Coopers & Lybrand. Mr. McKeown received his B.S. in Business Administrationundergraduate degree from the University of MaineWashington and is licensed as a Certified Public Accountantpostgraduate graduate education includes executive education from Harvard in the state of Maine.

Peter Russo, 56, Director
Finance and Texas A&M in Agriculture Science. Mr. RussoAnderson has served as the Chief Financial Officeran Advisor, Director, public company CEO and Treasurerpublic company Board Director over his career.

Family Relationships

There are no family relationships among our executive officers and directors.

Board Leadership Structure and Role in Risk Oversight

Our Board of magicJack VocalTec Ltd. from July 2010 to May 2013 and also served as its Principal Accounting Officer. Mr. Russo servesDirectors focuses on the Advisory Board of Ocho Gaming, LLC. Ocho Gaming is a premiere operatormost significant risks facing our company and provider of online gaming inour company’s general risk management strategy, and ensure that risks undertaken by our Company are consistent with the Latin American market. Mr. Russo, along with his wife, is a co-founder of bracelet retailer FriendlyBands LLC. Mr. Russo also serves as a consultant to ResumeBear, a leading online job search technology company. Prior to his appointment as CFO of magicJack VocalTec Ltd., Mr. Russo served as CFO of YMax since 2005. Prior to joining YMax, from 1996-1999, he was a consultant and served as CFO of Group Long Distance, Inc. (GLD), a publicly traded reseller of local and long distance services. Prior to joining GLD, Mr. Russo was the Executive Vice President of the State Bank of South Australia. He holds a B.B.A. degree from Pace University in New York.

Michael Brainard, 43, Director
Mr. Brainard brings over 15 years of experience toBoard’s appetite for risk. While the Board as aoversees our company’s risk management, consultant, senior executive, executive coach, manager, entrepreneur, and researcher. As a management consultant, Michael has designed and conducted process re-engineering and re-structuring, organizational assessments, leadership development initiatives, performance management systems, change management processes, and a variety of strategic planning initiatives. Additionally Michael has worked as a post-acquisition internal and external integration leader. Mr. Brainard has provided strategy and consulting services to companies such as Scripps, AMN Healthcare, AccentCare, Memorialcare, and Patient Safe Solutions. He holds a B.A. in Psychology from the University of Delaware, an M.S. in Industrial Psychology from Alliant International University and a Ph.D. in Industrial Psychology from Alliant International University.
Dean Boyer, 43, Chief Technical Officer
Mr. Boyer has over 30 years IT experience specializing in software engineering, business intelligence, performance management, data integration, healthcare and banking. As Chief Technology Officer (CTO), Mr. Boyer manages the resources and technologies required to deliver HRAA’s services and solutions. His innovative team is responsible for developingday-to-day risk management processes. We believe this division of responsibilities is the Visualizer™most effective approach for addressing the risks facing our company and Verifier™ product suites. These suitesthat our Board leadership structure supports this approach.

Limitation of products are basedLiability and Indemnification of Officers and Directors

Under Nevada General Corporation Law and our articles of incorporation, our directors will have no personal liability to us or our stockholders for monetary damages incurred as the result of the breach or alleged breach by a director of his “duty of care.” This provision does not apply to the directors’ (i) acts or omissions that involve intentional misconduct or a knowing and culpable violation of law, (ii) acts or omissions that a director believes to be contrary to the best interests of the corporation or our shareholders or that involve the absence of good faith on QlikView’s business intelligence platformthe part of the director, (iii) approval of any transaction from which a director derives an improper personal benefit, (iv) acts or omissions that provides an easy to use access to operational, financial and clinical healthcare information. In addition, HRAA’s IT department is developingshow a national remote medical coding environment that will enable HRAA to outsource medical coding operations for a variety of healthcare organizations. Over the past 25 years, he has built several IT organizations from scratch including a startup that Mr. Boyer founded in 1997 for which he raised over $42 million in venture capital. He has successfully built software products that generated over $300 million in revenue for their respective software firms and continues to develop innovative solutionsreckless disregard for the healthcare industry. Priordirector’s duty to joining HRAA; Mr. Boyerthe corporation or our shareholders in circumstances in which the director was aware, or should have been aware, in the Directorordinary course of performing a director’s duties, of a risk of serious injury to the corporation or our shareholders, (v) acts or omissions that constituted an unexcused pattern of inattention that amounts to an abdication of the Healthcare IT Practicedirector’s duty to the corporation or our shareholders, or (vi) approval of an unlawful dividend, distribution, stock repurchase or redemption. This provision would generally absolve directors of personal liability for McGladrey, where he managed an IT team that specializednegligence in business intelligence for hospitals, clinics, and healthcare organizations. Priorthe performance of duties, including gross negligence.

The effect of this provision in our articles of incorporation is to McGladrey, Mr. Boyer waseliminate the Director of Worldwide Healthcare for Sybase, Inc. where he managed the healthcare and federal program offices consisting of over 200 consultants and architects that delivered product and technology solutions. Mr. Boyer is an accomplished presenter and has presented on topics such as the value of Business Intelligence in Healthcare, Building Actionable and Predictive Analytics for Physicians, and Adoption the Critical Factor in Business Intelligence for HIMSS, HFMA, and other healthcare audiences. Mr. Boyer holds a patient for point of care technology that he developed to bring the patient, payer and provider together at the point of care to settle a claim. Mr. Boyer holds a B.S. in Business Administration from Elizabethtown College.

David Kroin, 38, Director
Mr. Kroin has over fifteen years of investing experience and is a co-founder of Great Point Partners, LLC. Mr. Kroin is co-portfolio manager for the Biomedical Value Fund and an Investment Committee Member for GPP I and GPP II. Mr. Kroin is currently on the Boards of Connecture Inc., Cytovance Biologics and ProfesionalPT. He was previously a Board Member of US BioServices Corp. (acquired by AmerisourceBergen), Caprion Proteomics (acquired by CGP), Mediatech Acquisition Corp (acquired by Corning Inc.), Biodel, Inc. (NASD: BIOD), Gentium Spa (NASD:GENT), and several other companies. While at Great Point, Mr. Kroin has also led structured investments in several leading public companies including AMAG Pharmaceuticals (NASD:AMAG), Dynavax Technologies (NASD:DVAX), Hyperion Therapeutics (NASD: HPTX), Streamline Health (NASD: STRM) and Amarin Corp. (NASD:AMRN). Prior to Great Point Partners, Mr. Kroin was a Partner in J.H. Whitney & Co. funds and a senior member of its health care group. While at J.H. Whitney & Co., Mr. Kroin completed investments in over 25 leading growth companies. He began his career as an investment banker at Merrill Lynch & Company in mergers and acquisitions. He graduated from the University of Michigan with a B.S. in actuarial mathematics and is a currently on the Leadership Councilrights of the University of Michigan’s Life Sciences Institute.
Mitchell D. Kaye J.D., 45, Director
Mitchell D. Kaye, J.D. is a Managing Director at BVF Partners, a biotechnology investment fund. Prior to that, from 2010-2013, he was the Chief Executive Officer of MedClaims Liaison, LLC, a consumer advocacy business that he foundedCompany and which worksour stockholders (through stockholder’s derivative suits on behalf of families in managing reimbursement disputes with medical providers and insurance companies. From 2008-2010, Mr. Kaye wasthe Company to recover monetary damages against a Managing Director with Navigant Capital Advisors, a financial and strategic advisory services firm, and Headdirector for breach of Navigant’s Financial Institutions Restructuring Solutions Team (FIRST). While at Navigant, Mr. Kaye led numerous high profile engagements on behalfhis fiduciary duty of investment funds and investors. Previously,care as a successful entrepreneurdirector (including breaches resulting from negligent or grossly negligent behavior) except in the asset management industry, Mr. Kaye launched two highly profitable asset management companies. Mr. Kaye wassituations described in clauses (i) through (vi) above. This provision does not limit nor eliminate the founding member of Xmark Opportunity Partners, LLC, an investment fund exclusively focused on investments in publicly traded life sciences companies. In 1996, Mr. Kaye began his career as a founding member of Brown Simpson Asset Management, LLC (Brown Simpson), an investment fund that was at the foreground of private placement investing in the public markets. During his career, Mr. Kaye has consummated over 100 transactions as a lead investor, structured over a billion dollars in debt and equity-linked transactions, and taken an active role in the management of numerous portfolio companies. Mr. Kaye has served on the boards of several private and public companies, and also served on the boardrights of the New York Alzheimer’s Association. From September 2007 until the company’s unwinding in June 2009, Mr. Kaye served on the board of directors of Genaera Corporation, a biopharmaceutical company that was listed on the Nasdaq Capital Market. Mr. Kaye received his BA from Wesleyan University, and his Juris Doctorate from Northwestern University School of Law.
Family Relationships
Our Chairman and Chief Executive Officer, Andrea Clark, is married to our Chief Operating Officer, President, Secretary and Treasurer, and Director, Robert Rubinowitz.
Involvement in Certain Legal Proceedings
To our knowledge, during the past ten (10) years, none of our directors, executive officers, promoters, control persons,Company or nominees has been:
the subject of any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;
convicted in a criminal proceeding or is subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);
subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities; or
found by a court of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law.
Section 16(a) Beneficial Ownership Compliance
As of the date of this report, we are not subject to Section 16(a) of the Exchange Act.
Corporate Governance
The Board has not adopted Corporate Governance Principles. Currently, the Company’s Chief Executive Officer also holds the position of Chairman of the Board of Directors. In the future, however, the Board may reconsider whether its Chief Executive Officer should also serve as Board Chairman.
Audit Committee and Financial Expert
We do not have a standing audit committee of the Board of Directors. Management has determined not to establish an audit committee at present because of our limited resources and limited operating activities do not warrant the formation of an audit committee or the expense of doing so. We do not have a financial expert serving on the Board of Directors.
Compensation Committee and Nominating Committee
We currently do not have a compensation committee or a nominating committee. Determining compensation for our officers and directors is done by our board of directors. Nominations for election to our board of directors may be made by the board of directors or by any stockholder entitled to vote for the election of directors in accordance with our bylaws and Nevada law.
Code of Conduct and Corporate Ethics Policy
Our Board has approved, and we have adopted, a Code of Conduct and Corporate Ethics Policy,seek non-monetary relief such as an injunction or the Code of Conduct, which applies to all of our directors, officers and employees. Our Board has also approved, and we have adopted, a Code of Ethics for Senior Financial Officers, or the Code of Ethics for SFO, which applies to our Directors, Senior Financial Officers and management team in contact with key financial data. The Code of Conduct and the Code of Ethics for SFO are available free of charge upon written request to Health Revenue Assurance Associates, 8551 W. Sunrise Blvd. Suite 304, Plantation, Florida 33322, Attention: Chief Financial Officer.
Summary Compensation Table
The following table presents information concerning compensation for each of our named executive officers for services in all capacities during the years indicated:
                Non-equity       
Name and         Stock  Option  Incentive Plan  All Other    
Principal   Salary  Bonus  Awards  Awards  Compensation  Compensation  Total 
Position Year ($)  ($)  ($)  ($)  ($)  ($)  ($) 
                        
Andrea Clark – 2012  175,000               19,000(1)  194,000 
Chief Executive Officer 2011  175,000                  175,000 
                               
Robert Rubinowitz – 2012  175,000               19,000(1)  194,000 
Chief Operating Officer, President and Secretary 2011  175,000                  175,000 
                               
Evan McKeown, 2012  
               
   
 
CFO (2) 2011  
                  
 
                               
Dean Boyer 2012 $135,115                 $135,115 
Chief Technical Officer 2011  
                  
 
                               
Peter Russo, 2012  
               
   
 
Director (3) 2011  
                  
 
                               
Michael Brainard, 2012  
                  
 
Director (3) 2011  
                  
 
                               
David Kroin 2012  
                  
 
Director (4) 2011  
                  
 
                               
Mitchell D. Kaye J.D. 2012  
                  
 
Director (4) 2011  
                  
 
(1)This amount includes $12,000 for a car allowance and $7,000 for health insurance related costs.
(2)Evan McKeown was appointed as Chief Financial Officer of the Company on April 22, 2013.
(3)Messrs. Russo and Brainard were appointed as members of the Board on August 7, 2013.
(4)Messrs. Kroin and Kaye were appointed as members of the Board on November 12, 2013.
Employment Agreements
We have entered into employment agreements with our officers and directors.
Employment Agreement with Andrea Clark
On October 2, 2013, the Company entered into an employment agreement with Andrea Clark and amended such agreement on November 12, 2013 (the “Clark Agreement”). Pursuant to the Clark Agreement, Ms. Clark will receive annual base compensation of $175,000, which may be increased but not decreased from time to time as determined by the Board of Directors of the Company. The Clark Agreement also provides for incentive awards, as well as a benefit package, including medical, disability, insurance, 401(k) and other equity programs. The term of the Clark Agreement is three (3) years and shall automatically be renewed for successive three (3) year terms thereafter, unless otherwise notified in writing ninety (90) days prior to the termination of the agreement. The Clark Agreement may be terminated by the Company for cause. Should the Company terminate the agreement without cause, Ms. Clark is entitled to receive two times her base salary at the time of termination; a pro-rata bonus payment on any bonus or incentive plan; any earned but unpaid base salary, and accrued but unpaid vacation time. Should the Clark Agreement be terminated by Ms. Clark two years after the effective date, Ms. Clark shall be entitled to receive: any earned but unpaid base salary and bonus compensation; any earned but unpaid vacation time; a pro-rata bonus or incentive plan award; and, at Ms. Clark’s election, either (i) registered shares of the Company’s common stock equal to 100% of her base salary at the time of resignation, or (ii) fully vested and cashless exercisable discounted stock options. In the event there is: (1) a change of control of the Company; and (2) Ms. Clark is terminated within six months following such change of control, Ms. Clark shall be entitled to receive any earned but unpaid base salary, any earned but unpaid bonus compensation, two times her base salary as of the date of the change of control, two times the average bonus paid to Ms. Clark over the three previous calendar years, and accrued but unpaid vacation time.. Should the Clark Agreement be terminatedrescission in the event of deatha breach of a director’s duty of care. In addition, our Articles of Incorporation provide that if Nevada law is amended to authorize the future elimination or disabilitylimitation of Ms. Clark, Ms. Clarkthe liability of a director, then the liability of the directors will be eliminated or her estate, shall be entitledlimited to receive two times her base salary immediately priorthe fullest extent permitted by the law, as amended. Nevada General Corporation Law grants corporations the right to termination, a pro-rata bonus payment onindemnify their directors, officers, employees and agents in accordance with applicable law. Our bylaws provide for indemnification of such persons to the full extent allowable under applicable law. These provisions will not alter the liability of the directors under federal securities laws.

30

We intend to enter into agreements to indemnify our directors and officers, in addition to the indemnification provided for in our bylaws. These agreements, among other things, indemnify our directors and officers for certain expenses (including attorneys’ fees), judgments, fines, and settlement amounts incurred by any bonussuch person in any action or incentive plan; earned but unpaid base salary and earned but unpaid bonus compensation, and accrued but unpaid vacation time.

The Clark Agreement supersedes previously entered into betweenproceeding, including any action by or in the right of the Company, and Ms. Clark dated July 15, 2011.
Employment Agreement with Robert Rubinowitz
On October 2, 2013,arising out of such person’s services as a director or officer of the Company, entered into an employment agreement with Robert Rubinowitz and amended such agreement on November 12, 2013 (the “Rubinowitz Agreement”).
Pursuantany subsidiary of the Company or any other company or enterprise to which the Rubinowitz Agreement, Mr. Rubinowitz will receive annual base compensation of $175,000, which may be increased but not decreased from time to time as determined byperson provides services at the Board of Directorsrequest of the Company. The Rubinowitz Agreement also providesWe believe that these provisions and agreements are necessary to attract and retain qualified directors and officers.

Insofar as indemnification for incentive awards, as well as a benefit package, including medical, disability, insurance, 401(k) and other equity programs. The termliabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Company pursuant to the foregoing provisions, the Company has been informed that in the opinion of the Rubinowitz AgreementSecurities and Exchange Commission, such indemnification is three (3) years and shall automatically be renewed for successive three (3) year terms thereafter, unless otherwise notified in writing ninety (90) days prior to the termination of the agreement. The Rubinowitz Agreement may be terminated by the Company for cause. Should the Company terminate the agreement without cause, Mr. Rubinowitz is entitled to receive two times his base salary at the time of termination; a pro-rata bonus payment on any bonus or incentive plan; any earned but unpaid base salary, and accrued but unpaid vacation time. Should the Rubinowitz Agreement be terminated by Mr. Rubinowitz two years after the effective date, Mr. Rubinowitz shall be entitled to receive: any earned but unpaid base salary and bonus compensation; any earned but unpaid vacation time; a pro-rata bonus or incentive plan award; and, at Mr. Rubinowitz ’s election, either (i) registered shares of the Company’s common stock equal to 100% of his base salary at the time of resignation, or (ii) fully vested and cashless exercisable discounted stock options. In the event there is: (1) a change of control of the Company; and (2) Mr. Rubinowitz is terminated within six months following such change of control, Mr. Rubinowitz shall be entitled to receive any earned but unpaid base salary, any earned but unpaid bonus compensation, two times his base salaryagainst public policy as of the date of the change of control, two times the average bonus paid to Mr. Rubinowitz over the three previous calendar years, and accrued but unpaid vacation time. Should the Rubinowitz Agreement be terminatedexpressed in the event of death or disability of Mr. Rubinowitz, Mr. Rubinowitz or his estate, shall be entitled to receive two times his base salary immediately prior to termination, a pro-rata bonus payment on any bonus or incentive plan; earned but unpaid base salarySecurities Act and earned but unpaid bonus compensation, and accrued but unpaid vacation time.

The Rubinowitz Agreement supersedes previously entered into between the Company and Mr. Rubinowitz dated July 15, 2011.
Employment Agreement with Evan McKeown
On October 2, 2013, the Company entered into employment agreement with Evan McKeown and amended such agreement on November 12, 2013 (the “McKeown Agreement”).
Pursuant to the McKeown Agreement, Mr. McKeown will receive annual base compensation of $180,000, which may be increased but not decreased from time to time as determined by the Board of Directors of the Company. The McKeown Agreement also provides for incentive awards, as well as a benefit package, including medical, disability, insurance, 401(k) and other equity programs. The term of the McKeown Agreement is two (2) years and shall automatically be renewed for successive two (2) year terms thereafter, unless otherwise notified in writing ninety (90) days prior to the termination of the agreement. The McKeown Agreement may be terminated by the Company for cause. Should the Company terminate the agreement without cause, Mr. McKeown is entitled to receive: (1) two times his base salary at the time of termination if terminated within six months of execution of the McKeown Addendum, and one time base salary if terminated after six months of execution of the McKeown Addendum; (2) a pro-rata bonus payment on any bonus or incentive plan; and (3) any earned but unpaid base salary, and accrued but unpaid vacation time. In the event there is: (1) a change of control of the Company; and (2) Mr. McKeown is terminated within six months following such change of control, Mr. McKeown shall be entitled to receive any earned but unpaid base salary, any earned but unpaid bonus compensation, two times his base salary as of the date of the change of control, two times the average bonus paid to Mr. McKeown over the three previous calendar years, and accrued but unpaid vacation time. Should the McKeown Agreement be terminated in the event of death or disability of Mr. McKeown, Mr. McKeown or his estate, shall be entitled to receive the greater of the base salary owed immediately prior to termination or one year’s base salary, a pro-rata bonus payment on any bonus or incentive plan; earned but unpaid base salary and earned but unpaid bonus compensation, and accrued but unpaid vacation time.
Additionally, Mr. McKeown was granted options to purchase 1,000,000 shares of the Company’s common stock (the “ Options ”) at a per share exercise price of the fair market value per share of the Company’s common stock at the time of execution. The Options shall vest after two years or upon termination of Mr. McKeown for any reason, whichever happens sooner.
Employment Agreement with Dean Boyer
On October 2, 2013, the Company entered into employment agreement with Dean Boyer and amended such agreement on November 12, 2013 (the “Boyer Agreement”).
Pursuant to the Boyer Agreement, Mr. Boyer will receive annual base compensation of $200,000, which may be increased but not decreased from time to time as determined by the Board of Directors of the Company. The Boyer Agreement also provides for incentive awards, as well as a benefit package, including medical, disability, insurance, 401(k) and other equity programs. The term of the Boyer Agreement is two (2) years and shall automatically be renewed for successive two (2) year terms thereafter, unless otherwise notified in writing ninety (90) days prior to the termination of the agreement. The Boyer Agreement may be terminated by the Company for cause. Should the Company terminate the agreement without cause, Mr. Boyer is entitled to receive one times his base salary at the time of termination; a pro-rata bonus payment on any bonus or incentive plan; any earned but unpaid base salary, and accrued but unpaid vacation time. In the event there is: (1) a change of control of the Company; and (2) Mr. Boyer is terminated within six months following such change of control, Mr. Boyer shall be entitled to receive any earned but unpaid base salary, any earned but unpaid bonus compensation, two times his base salary as of the date of the change of control, two times the average bonus paid to Mr. Boyer over the two previous calendar years, and accrued but unpaid vacation time. Should the Boyer Agreement be terminated in the event of death or disability of Mr. Boyer, Mr. Boyer or his estate, shall be entitled to receive the greater of the base salary owed immediately prior to termination or one year’s base salary, a pro-rata bonus payment on any bonus or incentive plan; earned but unpaid base salary and earned but unpaid bonus compensation, and accrued but unpaid vacation time.
Outstanding Equity Awards at Fiscal Year-End
There were no outstanding equity awards held by our officers as of December 31, 2012. As of January 31, 2014, Mr. McKeown was granted options to purchase 1,000,000 shares of the Company’s common stock (the “ Options ”) at a per share exercise price of the fair market value per share of the Company’s common stock at the time of execution of the amended employment agreement.
Board of Directors
The number of directors of the Company is such number as determined by the Board. All directors hold office until the next annual meeting of shareholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal. Officers are elected by and serve at the discretion of the board.
Our directors are reimbursed for expenses incurred by them in connection with attending board meetings, but they do not receive any other compensation for serving on the Board.
therefore unenforceable.

Related Party Transactions

\Mr. Michael Brainard and Mr. Peter Russo were elected to

On July 7, 2022 the Board of directors of Health Revenue Assurance Holdings, Inc. on August 8, 2013. Mr. Brainard is a Director of ResumeBear, Inc., a company with which HRAA has a sales contract worth approximately $300,000, pursuant to which HRAA provides website development services to ResumeBear, Inc. Mr. Russo is the Chief Executive Officer and director for ResumeBear, Inc. In January 2014, the Company wrote off approximately $100,000 of the receivables with ResumeBear.

On September 9, 2013, the CompanyAmeriguard entered into a one year Material Consulting Agreementbuyout agreement with Mr. Michael Ciprianni to provide certain consulting services related to the Company’s business in exchange for four million one hundred twenty five thousand (4,125,000) sharesits minority shareholder Lillian Flores. The value of Common Stock in consideration of the servicesAmeriguard to be rendered.
The Company owed its CEO $75,000 as stated inused for the February 2012 merger agreement. The balancebuyout agreement was calculated using an independent evaluation service which determined the December 31, 2020 value to be approximately $6,400,000. As a 45% owner, Mrs. Flores’ share was approximately $2,885,000. After negotiation of some additional funds due toMrs. Flores, the CEOfinal buyout amount was formalized in aapproximately $3,385,000. A 5-year promissory note dated November 1, 2013. The Company also owed its President $40,000 forwas executed and the note is secured by a promissory note dated November 1, 2013 for funds advanced in September 2013. On November 12, 2013 the promissory notes for thestock pledge.

Director Independence

Lawrence Garcia, CEO and the President were paid in full from the net proceeds of the Securities Purchase Agreement, dated November 12, 2013.

Other than those listed above, there are no related party transactions reportable under Item 404(a) of Regulation S-K.
Director Compensation
On August 7, 2013, the Company entered into an agreement with each of Messrs. Russo and Brainard,majority Shareholder is our directors, to provided compensation in the form of 100,000 non-qualified stock options of the Company’s common stock, with a one year vesting period, once the Company has completed a non-qualified stock option plan.
Indemnification Agreements
In connection with the appointments of David Kroin and Mitchell Kaye, the Company and each of the new appointments to the Board entered into indemnification agreements (the “ Indemnification Agreements ”) with its officers and directors, providing for the indemnification of the officers and directors of the Company from the increased risk of litigation against such directors and officers.
Director Independence
Our Board of Directors consists of six (6) members, we have four (4) independent directors and two (2)only non-independent directors. director.

Because our common stock is not currently listed on a national securities exchange, we have used the definition of “independence” of The NASDAQ Stock Market to make this determination. NASDAQ Listing Rule 5605(a)(2) provides that an “independent director” is a person other than an officer or employee of the company or any other individual having a relationship which, in the opinion of the company’s board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The NASDAQ listing rules provide that a director cannot be considered independent if:

the director is, or at any time during the past three years was, an employee of the Company;
the director or a family member of the director accepted any compensation from the Company in excess of $120,000 during any period of 12 consecutive months within the three years preceding the independence determination (subject to certain exclusions, including, among other things, compensation for board or board committee service);
a family member of the director is, or at any time during the past three years was, an executive officer of the Company;
the director or a family member of the director is a partner in, controlling stockholder of, or an executive officer of an entity to which the Company made, or from which the Company received, payments in the current or any of the past three fiscal years that exceed 5% of the recipient’s consolidated gross revenue for that year or $200,000, whichever is greater (subject to certain exclusions);
the director or a family member of the director is employed as an executive officer of an entity where, at any time during the past three years, any of the executive officers of the Company served on the compensation committee of such other entity; or
the director or a family member of the director is a current partner of the Company’s outside auditor, or at any time during the past three years was a partner or employee of the Company’s outside auditor, and who worked on the company’s audit.

Involvement in Certain Legal Proceedings


To our knowledge, during the past ten years, none of our directors, executive officers, promoters, control persons, or nominees has:

been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);

had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time;
been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity;

been found by a court of competent jurisdiction in a civil action or by the Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;

been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or
been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

Code of Ethics

We have not adopted a code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer, or persons performing similar functions, because of the small number of persons involved in the management of the Company.

Director and Executive Compensation

No compensation has been paid and no stock options granted to any of our officers or directors in the last three fiscal years.

Employment Agreements

Prior to merger date no employment agreements were in place. It is the intention of ownership to rely on the recommendation of the compensation committee to be appointed by the Board of Directors 

2023 Equity Incentive Plan

Our Board of Directors and stockholders owning a majority of our outstanding shares plan to adopt an Equity Incentive Plan. Details of the plan will be developed with the input of the Board of Directors along with the then established compensation committee.

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the Exchange Act). Accordingly, we concluded that our disclosure controls and procedures were effective as of December 31, 2021.

32


Management’s Annual Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Securities Exchange Act, as amended. Internal control over financial reporting is a process designed by, or under the supervision of, the Chief Executive Officer and Principal Accounting Officer and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

The framework our management uses to evaluate the effectiveness of our internal control over financial reporting is based on the guidance provided by the Committee of Sponsoring Organizations (COSO) of the Treadway Commission in its 1992 report: INTERNAL CONTROL - INTEGRATED FRAMEWORK. Based on our evaluation under the framework described above, our management has concluded that our internal control over financial reporting was ineffective as of December 31, 2021 due to the same material weaknesses that rendered our disclosure controls and procedures ineffective. The Company’s internal control over financial reporting is not effective due to a lack of sufficient resources to hire a support staff in order to separate duties between different individuals. The Company lacks the appropriate personnel to handle all the varying recording and reporting tasks on a timely basis. The Company plans to address these material weaknesses as resources become available by hiring additional professional staff, such as a Chief Financial Officer, as funding becomes available, outsourcing certain aspects of the recording and reporting functions, and separating responsibilities. We have identified the following material weaknesses.

1.As of December 31, 2021, we did not maintain effective controls over the control environment. Specifically, we have not developed and effectively communicated to our employees the accounting policies and procedures. This has resulted in inconsistent practices. Further, the Board of Directors does not currently have any independent members and no director qualifies as an audit committee financial expert as defined in Item 407(d)(5)(ii) of Regulation S-K. Since these entity level programs have a pervasive effect across the organization, management has determined that these circumstances constitute a material weakness.

2.As of December 31, 2021, we did not maintain effective controls over financial statement disclosure. Specifically, controls were not designed and in place to ensure that all disclosures required were originally addressed in our financial statements. Accordingly, management has determined that this control deficiency constitutes a material weakness.

Because of these material weaknesses, management has concluded that the Company did not maintain effective internal control over financial reporting as of December 31, 2021, based on the criteria established in “INTERNAL CONTROL-INTEGRATED FRAMEWORK” issued by the COSO.

Change In Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during our last fiscal year that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Attestation Report of the Registered Public Accounting Firm

This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the SEC that permit us to provide only management’s report in this annual report.

33

EXECUTIVE COMPENSATION

During the years ended December 31, 2022, and December 31, 2021 no compensation was paid to Lawrence Garcia, our president, treasurer, secretary and director paid by AGSS.

Employment Agreements

Prior to merger date no employment agreements were in place. It is the intention of ownership to rely on the recommendation of the compensation committee appointed by the Board of Directors.

Outstanding Equity Awards at Fiscal Year-End

There were no outstanding equity awards held by our officers as of December 31, 2022.

Board of Directors

All directors hold office until the next annual meeting of shareholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal. Officers are elected by and serve at the discretion of the board.

Our directors are reimbursed for expenses incurred by them in connection with attending board meetings and receive a monthly honorarium for serving on the board.

Compensation committee

The board of directors plans to establish a compensation committee as required by Sarbanes-Oxley Act. The committee will make compensation recommendation to the board

2023 Equity Incentive Plan

Our Board of Directors and stockholders owning a majority of our outstanding shares plans to adopt an Equity Incentive Plan following the merger. Details of the plan will be developed with the input of the Board of Directors along with the then established compensation committee.

Executive Officer Compensation

The following table sets forth the annual compensation for years ended December 31, 2022, and 2021 to our Officers.

Executive positions and salaries:

Name and Position Year Salary
($)
  Bonus
($)
  Other
Compensation
($)
  Total
($)
 
Lawrence Garcia - CEO 2022  146,551   -   21,279   167,830 
  2021  129,190   -   19,789   148,979 
                   
Michael Goossen, CPA - CFO(1) 2022  134,250   -   650   134,900 
  2021  98,423   -   -   98,423 

(1)Mr. Goossen was an independent consultant until August 1, 2022.

Director Compensation

Our directors are reimbursed for expenses incurred by them in connection with attending board meetings and receive a monthly honorarium for serving on the board.

34

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT


Securities Authorized For Issuance Under Equity Compensation Plans

There are no securities authorized for issuance under an Equity Compensation Plan, other than 1,636,000 of stock options to employees, officers and directors.
Security Ownership Of Certain Beneficial Owners And Management
The following table sets forth information regarding the beneficial ownership of shares of our capital stock as of January 31, 2014 by:
Each of our directors;
Each of our named executive officers;
All of our directors and executive officers as a group; and
Each person known by us to beneficially own more than 5% of our outstanding common stock.
AND
RELATED STOCKHOLDER MATTERS.

The following table sets forth certain information regarding beneficial ownership of our shares of common stock beneficially owned as of JanuaryDecember 31, 2014, for2022 by (i) each stockholderperson (or group of affiliated persons) who is known by us to beown more than five percent of the beneficial owner of 5% or more of our outstanding shares of common stock, (ii) each named executive officer and director, and (iii) all executive officers and directors as a group. A person is considered to beneficially own any shares: (i) over which such person, directly or indirectly, exercises sole or shared voting or investment power, or (ii) of which such person has the right to acquire beneficial ownership at any time within 60 days through an exercise of stock options or warrants. Unless otherwise indicated, voting and investment power relating to the shares shown in the table for our directors and executive officers is exercised solely by the beneficial owner or shared by the owner and the owner’s spouse or children.

Under SEC rules, beneficial ownership includes any shares of common stock which a person has sole or shared voting power or investment power and any shares of common stock which the person has the right to acquire within 60 days through the exercise of any option, warrant or right, through conversion of any security or pursuant to the automatic termination of a power of attorney or revocation of a trust, discretionary account or similar arrangement. Percentage of beneficial ownership is calculated based on shares of our common stock, outstanding(ii) each director, executive officer and director nominee, and (iii) all of our directors, executive officers and director nominees as of January 31, 2014. In calculatinga group. Immediately following the number of shares beneficially owned and the percentage ownership,Merger, we have 93,417,302 shares of common stock subjectissued and outstanding.

Beneficial ownership is determined in accordance with SEC rules and generally includes voting or investment power with respect to Preferredsecurities. All share ownership figures include shares of our Common Stock conversion rights (including accrued dividends), options or warrants held by that person that are currently exercisable orissuable upon securities convertible or become exercisable or convertibleexchangeable into shares of our Common Stock within 60sixty (60) days after Januaryof December 31, 20142022 which are deemed outstanding even if they have not actually been exercisedand beneficially owned by such person for purposes of computing his or converted. The shares issuable under these securities are treated as outstanding for computing theher percentage ownership, of the person holding these securities but are not treated as outstanding for the purposepurposes of computing the percentage ownership of any other person. Unless otherwise indicated, we believe that all persons named in this table have sole voting power and investment power over all the shares beneficially owned by them.

Name and Address 

Beneficial

Ownership

  

Percentage
of Class(1)

 
Lawrence Garcia  80,578,125   86,26%
Michael Goossen, CPA  2,671,875   2.86%
Douglas Anderson*  3,515,625   3.76%
All officers/directors as a group (3 people)  86,765,625   92.88%

 
Title of ClassName Beneficial Owner 
Amount and
Nature
of Beneficial
Ownership
 
Percent
age of
Class (1)
 
Directors and Executive Officers         
Common StockAndrea Clark*†  6,599,604   12.07 %
Common StockRobert Rubinowitz*†  6,599,617   12.07%
Common StockEvan McKeown  0   0%
Common StockPeter Russo  0   0%
Common StockMichael Brainard  0   0%
Common StockDavid Kroin  0   0%
Common StockMitchell D. Kaye  0   0%
Common StockDirectors and executive officers as a group (7 people)  13,199,221   24.14%
5% Stockholders        
Common StockAndrea Clark*  6,599,604   12.07%
Common StockRobert Rubinowitz*  6,599,617   12.07
Common StockMichael Ciprianni**  2,800,000   5.11
Common StockDonald Luneburg**  3,213,900   5.87%
Common StockBiomedical Value Fund, L.P. (2)  23,057,648   21.22%
Common StockBiomedical Institutional Value Fund, L.P. (3)   6,020,924   5.54
Common StockBiomedical Offshore Value Fund, Ltd. (4)   13,290,920   12.23%
Common StockClass D Series Of Gef-Ps, L.P. (5)   9,823,064   9.04
*  Andrea Clark and Robert Rubinowitz are husband and wife.
†  On November 12, 2013, Andrea Clark and Robert Rubinowitz executed a Voting Agreement pursuant to the terms of the Securities Purchase Agreement whereby their “Owned Shares” shall be caused to vote in favor of electing and appointing Directors to the Board.

**Based on the combined total of the transfer agent Stock Report dated December 31, 2013 and Non Objective Beneficial Ownership report dated January 6, 2014.

(1)(1)Based on 54,752,29493,418,291 shares of common stock outstanding as of January 31, 2014.
(2)Based on shares of Common Stock underlying (i) 5,756,312 shares of Series A Preferred Stock and (ii) Warrants to purchase 11, 527,822 shares of Common stock presently exercisable by Biomedical Value Fund, L.P. The 5,756,312 shares of Series A Preferred Stock carry voting rights equivalent to 11,528,828 shares of Common Stock.
(3)Based on shares of Common Stock underlying (i) 1,505,231 shares of Series A Preferred Stock and (ii) Warrants to purchase 3,010,462 shares of Common Stock presently exercisable by Biomedical Institutional Value Fund, L.P. The 1,505,231 shares of Series A Preferred Stock carry voting rights equivalent to 3,010,462 shares of Common Stock.
(4)Based on shares of Common Stock underlying (i) 3,322,730 shares of Series A Preferred Stock and (ii) Warrants to purchase 6,645,460 shares of Common Stock presently exercisable by Biomedical Offshore Value Fund, Ltd. The 3,322,730 shares of Series A Preferred Stock carry voting rights equivalent to 6,645,460 shares of Common Stock.
(5)Based on shares of Common Stock underlying (i) 2,455,755 shares of Series A Preferred Stock and (ii) Warrants to purchase 4,911,532 shares of Common Stock presently exercisable by Class D Series of Gef-Ps, L.P. The 2,455,755 shares of Series A Preferred Stock carry voting rights equivalent to 4,911,532 shares of Common Stock.March 27, 2023.
*Appointed on December 9, 2022.

TRANSACTIONS

Certain Relationships and Related Transactions

Notes Payable – Related Party Transactions

Mr. Michael Brainard and Mr. Peter Russo were elected to the Board of directors of Health Revenue Assurance Holdings, Inc. on August 8, 2013. Mr. Brainard, a director of the Company, is also a Director of ResumeBear, Inc., a company with which we have a sales contract worth approximately $300,000 for HRAA to provide website development services to ResumeBear, Inc. Mr. Russo, a Director of the Company, is the Chief Executive Officer and director for ResumeBear, Inc. In January 2014, the Company wrote off approximately $100,000 of the receivables with ResumeBear.

On September 9, 2013, the CompanyJuly 7, 2022, Ameriguard entered into a one year Material Consulting Agreementbuyout agreement with Mr. Michael Ciprianniits minority shareholder Lillian Flores. The value of Ameriguard to provide certain consulting services relatedbe used for the buyout agreement was calculated using an independent evaluation service which determined the December 31, 2020 value to be approximately $6,400,000. As a 45% owner, Mrs. Flores’ share was approximately $2,885,000. After negotiation of some additional funds due Mrs. Flores, the Company’s businessfinal buyout amount was approximately $3,385,000. A 5-year promissory note was executed.

Director Independence

We currently have two independent directors as that term is defined in exchange for fourRule 4200 of Nasdaq’s listing standards.

36

DESCRIPTION OF SECURITIES

Authorized Capital Stock

Our authorized capital stock consists of five hundred million one hundred twenty five thousand (4,125,000)(500,000,000) shares of common stock, in considerationpar value $0.001 per share. Immediately after giving effect to the Merger and related transactions, there were 93,417,302 shares of our common stock issued and outstanding.

Common Stock

The following is a summary of the servicesmaterial rights and restrictions associated with our common stock.

The holders of our common stock currently have (i) equal ratable rights to be rendered. On September 12, 2013,dividends from funds legally available therefore, when, as and if declared by the Consulting Agreement was filed as an exhibitBoard of Directors of the Company; (ii) are entitled to share ratably in all of the assets of the Company available for distribution to holders of common stock upon liquidation, dissolution or winding up of the affairs of the Company (iii) do not have preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions or rights applicable thereto; and (iv) are entitled to one non-cumulative vote per share on all matters on which stock holders may vote. Please refer to the Company’s Current ReportArticles of Incorporation, Bylaws and the applicable statutes of the State of Nevada for a more complete description of the rights and liabilities of holders of the Company’s securities.

Preferred Stock

The holders of our Series A-1 Preferred Stock currently (i) have preferred equal ratable rights to dividends from funds legally available therefore, when, as and if declared by the Board of Directors of the Company; (ii) hold distribution preferences upon liquidation, dissolution or winding up of the affairs of the Company (iii) convert into seventy-two (72) shares, for each share of Series A-1 Preferred Stock, at the discretion of the holder; and (iv) are entitled to seventy-two (72) votes per share of Series A-1 Preferred Stock on Form 8-K.

The Company owed its CEO $75,000 as statedall matters on which stock holders may vote.

Following the merger there were and are no Preferred Stock outstanding. Any future issuance will be at the discretion of the Board of Directors.

Dividend Policy

We have never declared or paid any cash dividends on our common stock. We currently intend to retain future earnings, if any, to finance the expansion of our business. As a result, we do not anticipate paying any cash dividends in the February 2012 merger agreement. foreseeable future.

Transfer Agent

The balance due totransfer agent for our common stock is VStock Transfer, and its telephone number is (727) 289-0010.

Trading Information

Our common stock is currently approved for quotation on OTC Markets (otcmarkets.com) under the CEO was formalized insymbol “AGSS”.

37

MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

Market Information

AGSS’s common stock is quoted through the over-the-counter market on the OTC Market Pink under the symbol “AGSS.” There is a promissory note dated November 1, 2013.limited trading of AGSS’s common stock. The Company also owed its President $40,000following table sets forth high and low sales prices of AGSS common stock for a promissory note dated November 1, 2013 for funds advanced in September 2013. On November 12, 2013 the promissory notes for the CEO and the President were paid in full from the net proceeds of the Securities Purchase Agreement.

Other than those listed above, there have been no material transactions, series of similar transactions or currently proposed transactions in which we or our subsidiaries was or is to be a party, in which the amount involved exceeded the lesser of $120,000 or 1% of the average of our total assets at year endeach fiscal quarter for the last two completed fiscal years as reported by the OTC Markets., based on closing prices. The prices in the table reflect inter-dealer prices, without retail markup, markdown or commission and may not represent actual transactions.

  High  Low 
Third Quarter ended September 30, 2021 $4.39  $0.50 
Fourth Quarter ended December 31, 2021 $4.39  $0.50 
         
First Quarter ended March 31, 2022 $4.39  $0.50 
Second Quarter ended June 30, 2022 $5.34  $1.70 
Third Quarter ended September 30, 2022 $3.00  $1.25 
Fourth Quarter ended December 31, 2022 $3.38  $1.00 
         
First Quarter ended March 31, 2023 $3.35  $1.975 

As of March 27, 2023, there were approximately 91 record holders of AGSS common stock, not including shares held in which“street name” in brokerage accounts. As of March 27, 2023, there were approximately 93,418,291 shares of AGSS’s common stock issued and outstanding on record.

Dividends

AGSS has not declared or paid any director or executive officer or any security holder who is known to us to owncash dividends on its common stock.

Transfer Agent and Registrar

The transfer agent and registrar for AGSS’s common stock VStock Transfer LLC, 18 Lafayette Place, Woodmere, NY 11598, telephone number 212-828-8436.

Repurchases of record or beneficially more than 5%Our Securities

None of the shares of our common stock were repurchased by the Company during the fiscal year ended December 31, 2022.

Sales of Our Unregistered Securities during 2022 Not Previously Disclosed

None

Penny Stock Considerations

Our common stock will be deemed to be “penny stock” as that term is generally defined in the Securities Exchange Act of 1934 to mean equity securities with a price of less than $5.00. Our shares thus will be subject to rules that impose sales practice and disclosure requirements on broker-dealers who engage in certain transactions involving a penny stock.

Under the penny stock regulations, a broker-dealer selling a penny stock to anyone other than an established customer or any member ofaccredited investor must make a special suitability determination regarding the immediate family or sharingpurchaser and must receive the household (other thanpurchaser’s written consent to the transaction prior to the sale, unless the broker-dealer is otherwise exempt. Generally, an individual with a tenant or employee) of any of the foregoing persons, had a direct or indirect material interest.

Indebtedness Of Management
No officer, director or security holder known to us to own of record or beneficiallynet worth more than 5%$1,000,000 or annual income exceeding $100,000 individually or $300,000 together with his or her spouse is considered an accredited investor. In addition, under the penny stock regulations the broker-dealer is required to:

38

Deliver, prior to any transaction involving a penny stock, a disclosure schedule prepared by the SEC relating to the penny stock market, unless the broker-dealer or the transaction is otherwise exempt.

Disclose commissions payable to the broker-dealer and our registered representatives and current bid and offer quotations for the securities.

Send monthly statements disclosing recent price information pertaining to the penny stock held in a customer’s account, the account’s value and information regarding the limited market in penny stocks; and

Make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction, prior to conducting any penny stock transaction in the customer’s account.

Because of these regulations, broker-dealers may encounter difficulties in their attempt to buy or sell shares of our common stock, which may affect the ability of Belair or any memberother holders to sell their shares in the secondary market and have the effect of reducing the immediate family or sharinglevel of trading activity in the household (other thansecondary market. These additional sales practice and disclosure requirements could impede the sale of our common stock even if our common stock becomes publicly traded. In addition, the liquidity for our common stock may be decreased, with a tenant or employee)corresponding decrease in the price of any ofour common stock. Our shares are likely to be subject to such penny stock rules for the foregoing persons is indebtedforeseeable future.

Reports to us.

Transactions With Promoters
We did not expressly engage a promoter at the time of its formation. Stockholders

We have used selling agentsfiled all necessary periodic reports, and consultants from time to time. The terms of those arrangements have been disclosed in previous filingsother information with the Securities and Exchange Commission.SEC. We have provided annual reports to our stockholders containing audited financial statements.

39

Our directors and officers are indemnified as provided byBylaws, subject to the provisions of the Nevada corporate law and our Bylaws. We have agreedRevised Statutes, contain provisions which allow the Company to indemnify eachany person against liabilities and other expenses incurred as the result of our directorsdefending or administering any pending or anticipated legal issue in connection with service to us if it is determined that person acted in good faith and certain officers against certain liabilities, including liabilities underin a manner which he reasonably believed was in or not opposed to the Securities Act.best interest of the Company. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our directors, officers and controlling persons, pursuant to the provisions described above, or otherwise, we have been advised that in the opinion of the SECSecurities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In

EXPERTS

Financial Auditors

Our most current audited consolidated financial statements for the event that a claimyears ending December 31, 2021 and December 31, 2020, are included in this prospectus have been so included in reliance on the reports of BF Borgers CPA PC), Lakewood, CO, independent public accountants, given on this firm’s authority as experts in auditing and accounting.

Legal Counsel Providing Legal Opinion

The validity of the issuance of the shares of common stock will be passed upon for indemnification against such liabilities (other than our payment of expenses incurred or paidthe company by our director, officer or controlling personMcMurdo Lawa Group, LLC. Counsel has additionally consented to his opinion being included as an exhibit to this filing. Additionally, counsel has consented to being named in the successful defenseprospectus.

The legal counsel that passed their opinion on the legality of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with thethese securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

We have been advised that in the opinionis:

Matthew McMurdo, Esq.

McMurdo Law Group, LLC

1185 Avenue of the SEC indemnification for liabilities arising under the Securities Act is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities is asserted by one of our directors, officers, or controlling persons in connection with the securities being registered, we will, unless in the opinion of our legal counsel the matter has been settled by controlling precedent, submit the question of whether such indemnification is against public policy to a court of appropriate jurisdiction. We will then be governed by the court’s decision.Americas, 3rd Floor

New York, NY 10036

40

We have filed with the Securities and Exchange CommissionSEC a registration statement on Form S-1 (File Number _________) under the Securities Act of 1933 forregarding the shares of common stock in this offering.offered hereby. This prospectus does not contain all of the information found in the registration statement, portions of which are omitted as permitted under the rules and regulations of the exhibits and schedule that were filed with the registration statement.SEC. For further information with respect toregarding us and our common stock, wethe securities offered by this prospectus, please refer you to the registration statement, and theincluding its exhibits and schedule that were filed with the registration statement.schedules. Statements containedmade in this prospectus aboutconcerning the contents of any contract, or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and we refer you to the full text of the contractagreement or other document filed as an exhibit to the registration statement. A copystatement are summaries of the terms of those documents. The registration statement and theof which this prospectus forms a part, including its exhibits and schedules, that were filed with the registration statement may be inspected without chargeand copied at the Public Reference Roompublic reference room maintained by the Securities and Exchange CommissionSEC at 100 F.F Street, N.E., Washington, DC 20549-6010, and copies of all or any part of the registration statementD.C. 20549. You may be obtained from the Securities and Exchange Commission upon payment of the prescribed fee. Information regardingobtain information on the operation of the Public Reference Room may be obtainedpublic reference room by calling the Securities and Exchange CommissionSEC at 1-800-SEC-0330.

The Securities and Exchange CommissionSEC maintains a web site that contains reports, proxy and information statements,on the Internet at www.sec.gov. Our registration statement and other information regarding registrants that we file electronically with the SEC. The addressSEC are available at the SEC’s website.

We make available to our stockholders annual reports (on Form 10-K) containing our audited consolidated financial statements and make available quarterly reports (on Form 10-Q) containing our unaudited interim consolidated financial information for the first three fiscal quarters of the site is www.sec.gov.each of our fiscal years.

If you are a stockholder, you may request a copy of these filings at no cost by contacting us at:

Ameriguard Security Services, Inc.

5470 W. Spruce Avenue, Suite 102

Fresno, CA

Telephone number: (559) 271-5984

41

HEALTH REVENUE ASSURANCE HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2013

Financial Statements

Index to Financial Statements

 Page
Report of Independent Registered Public Accounting FirmF-2
Consolidated Balance Sheets at September 30, 2013 (Unaudited) andas of December 31, 20122022 and 2021 F-1F-3
F-2F-4
F-5
Statements of Cash Flows for the Nine MonthsYears Ended September 30, 2013December 31, 2022 and September 30, 2012 (Unaudited)2021 F-3F-6
 F-4 - F-14F-7

F-1

Report of Independent Registered Public Accounting Firm

To the shareholders and the board of directors of Ameriguard Security Services, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Ameriguard Security Services, Inc. as of December 31, 2022 and 2021, the related statements of operations, stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

Critical Audit Matter

Critical audit matters are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.

We determined that there are no critical audit matters.

/S/ BF Borgers CPA PC (PCAOB ID 5041)

We have served as the Company’s auditor since 2021

Lakewood, CO

March 30, 2023 

F-2

AmeriGuard Security Services, Inc.

CONSOLIDATED BALANCE SHEETS

         
  December 31,  December 31, 
  2022  2021 
Assets        
Current Assets        
Cash $1,227,654  $2,129,801 
Accounts receivable, net (note 1)  1,869,268   2,215,197 
Prepaid insurance  110,829   107,884 
Related Party Receivable (note 3)  -   - 
Total Current Assets  3,207,751   4,452,882 
         
Other Non-Current Assets        
Fixed assets, net depreciation (note 4)  298,806   132,802 
Operating Lease  302,695   - 
Total Non-Current Assets  601,501   132,802 
         
Total Assets $3,809,252  $4,585,684 
         
Liabilities        
Current Liabilities        
Accounts payable $761,516  $418,342 
Accrued Interest Due (note 6)  49,035   - 
Accrued Payroll  737,143   657,741 
Payroll liability - Pension (note 5)  453,965   616,579 
Current portion of notes payable (note 6)  719,563   127,615 
Total Current Liabilities  2,721,222   1,820,277 
         
Long Term Liabilities        
Long term portion of notes payable (note 6)  2,782,784   780,845 
Operating Lease  294,387   - 
Total Liabilities  5,798,393   2,601,122 
         
Stockholders’ equity        
Common stock, $.001 par value, 94,471,302 shares issued and outstanding at December 31, 2022 and 2021 (Note 7)  158,346   158,346 
Retained earnings/(defecit)  (2,147,486)  1,826,216 
Total Stockholders’ Equity  (1,989,140)  1,984,562 
Total Liabilities and Stockholders’ Equity $3,809,253  $4,585,684 

See accompanying notes to financial statements

F-3

AmeriGuard Security Services, Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS

         
  For the
Years Ended
 
  December 31,  December 31, 
  2022  2021 
Revenue        
Security Services $24,643,096  $22,418,328 
Other related income  304,305   24,185 
Total Revenue  24,947,401   22,442,513 
         
Cost of Services        
Salaries and related taxes  15,030,738   13,873,241 
Employee benefits  3,052,774   2,915,322 
Sub-Contractor payments  3,467,391   3,433,959 
Guard training  202,826   222,298 
Vehicles and equipment expenses  194,889   184,176 
Total Cost of Services  21,948,618   20,628,996 
Gross Margin  2,998,783   1,813,517 
         
Operating Expenses        
Salaries, payroll taxes and benefits  1,161,982   365,433 
Vehicle expense  433,424   295,054 
Professional services  361,314   318,442 
Cellular services  106,382   112,140 
General liability insurance  87,119   111,287 
Advertising and marketing  128,544   77,349 
General and administrative expenses  645,268   294,062 
Loan interest  105,826   59,439 
Depreciation expense  42,927   52,273 
Total Operating Expenses  3,072,786   1,685,479 
         
Net Income/(Loss) from Operations  (74,003)  128,038 
         
Other Income (Expenses)        
Other Income  -   - 
Other (Expense)  (344,105)  - 
Total Other Income  (344,105)  - 
         
Net Income/(loss) before Income Taxes  (418,108)  128,038 
         
Income tax expense  10,350   33,923 
         
Net Income/(loss) $(428,458) $94,115 
         
Net Income/(loss) per Common Share - Basic and Diluted $(0.0046) $0.0010 
         
Weighted Average Number of Common Shares Outstanding - Basic and Diluted  93,417,302   93,417,302 

See accompanying notes to financial statements

F-4

  September 30,  December 31, 
  2013  2012 
  (unaudited)    
Assets 
       
Cash $185,600  $893,458 
Accounts receivable  1,011,929   1,246,814 
Accounts receivable - Related Party, net of allowance $117,632 and $0, respectively  -   - 
Prepaid expenses  1,181,321   3,600 
Other current assets  70,020   688 
   Total Current Assets  2,448,870   2,144,560 
         
Property and Equipment, net  400,126   365,017 
         
Software, net  -   258,933 
Other assets  8,865   8,871 
Finance costs, net  2,232   2,477 
   Total Other Assets  11,097   270,281 
         
   Total Assets $2,860,093  $2,779,858 
         
Liabilities and Stockholders' Equity (Deficit) 
         
Accounts payable $520,054  $207,741 
Due to officers  115,000   75,000 
Accrued expenses  103,142   64,077 
Accrued payroll  693,826   412,186 
Loan payable to factor  443,648   827,075 
Accrued interest  -   4,524 
Line of credit, current portion  46,166   25,000 
Capital Leases, current portion  32,768   16,923 
Notes payable, current portion, net of discount  372,161   202,557 
Long term debt, current portion  43,956   37,513 
Settlement Payable  -   115,278 
Other current liabilities  51,257   - 
   Total Current Liabilities  2,421,978   1,987,874 
Capital Leases (net of current portion)  34,300   23,974 
Line of credit (net of current portion)  -   125,000 
Notes payable (net of current portion), net of discount  124,054   273,751 
Long term debt (net of current portion)  286,549   181,457 
   Total Liabilities $2,866,881  $2,592,056 
         
Commitments and Contingencies (see Note 8)        
         
Stockholders' Equity (Deficit):        
Preferred stock ($0.001 par value, 25,000,000 shares authorized, none issued or outstanding) $-  $- 
Common stock ($0.001 par value, 500,000,000 shares authorized, 54,577,294 shares and 39,054,867 issued and outstanding at September 30, 2013 and December 31, 2012, respectively)  54,577   39,055 
Additional paid-in capital  6,616,797   2,738,545 
Subscription receivable  -   (5,000)
Accumulated deficit  (6,678,162)  (2,584,798)
   Total Stockholders' Equity (Deficit)  (6,788)  187,802 
         
   Total Liabilities and Stockholders' Equity (Deficit) $2,860,093  $2,779,858 

AmeriGuard Security Services, Inc.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

FOR THE YEARS ENDED December 31, 2021 and 2022

                             
  Common Stock  Preferred Stock  Additional
Paid-In
  Stockholders’  Total
Stockholders’
 
  Shares  Amount  Shares  Amount  Capital  Equity  Equity 
Balance, December 31, 2020  2,743,302  $69,346   675,000  $10,000  $9,976,045  $(7,191,705) $2,863,685 
Owner draws (pre-merger)  -   -               (473,238) $(473,238)
Equity Merger  89,999,000   89,000       (10,000)  (579,000)     $(500,000)
Cancelation and conversion of preferred stock  675,000       (675,000)                
Net Income for year ended December 31, 2021                      94,115  $94,115 
Balance, December 31, 2021  93,417,302   158,346   -   -  $9,397,045  $(7,570,828) $1,984,562 
Owner draws (pre-merger)                     $(62,824) $(62,824)
Shareholder buyout                  (3,384,950)     (3,384,950)
Retained Deficit of merger with related entity                      (97,470) $(97,470)
Net (Loss) for year ended December 31, 2022      -        -        (428,458) (428,458)
Balance, December 31, 2022  93,417,302  $158,346   -  $-  $6,012,095  $(8,159,580) $(1,989,140)

See accompanying notes to financial statements

F-5

AmeriGuard Security Services, Inc.

STATEMENTS OF CASH FLOWS

         
  For the
Years Ended
 
  December 31,  December 31, 
  2022  2021 
Cash Flows from Operating Activities        
Net Income/(Loss) $(428,458) $94,115 
Adjustment to reconcile net loss from operations:        
Changes in Operating Assets and Liabilities        
Accounts receivable, net  345,929   (23,372)
Prepaid insurance  (2,945)  (32,949)
Depreciation  42,927   52,273 
Accounts payable  343,173   33,742 
Accrued Interest  49,035   - 
Accrued Payroll  79,402   75,693 
Payroll liability - Pension  (162,614)  77,237 
Net Cash (Used)/provided in Operating Activities  266,449   276,739 
         
Cash Flows Used from Investing Activities        
Purchase of fixed assets  (6,043)  (24,552)
Building improvements  (224,132)  - 
Operating lease liability  (79,358)  - 
Purchase of Shell Corporations - AGSS  -   (500,000)
Payment for Shareholder buyout  (686,990.00)  - 
Loan principle payments  (180,298)  (227,097)
Owner distributions  (62,824)  (473,238)
Net Cash Used by Investing Activities  (1,239,644)  (1,224,887)
         
Cash Provided from Financing Activities        
Secure Transportation vehicle loan  -   21,500 
Operating lease asset  71,049   - 
Net Cash Provided by Financing Activities  71,049   21,500 
         
Net Increase (Decrease) in Cash  (902,147)  (926,648)
Cash at Beginning of Period  2,129,801   3,056,449 
Cash at End of Period $1,227,654  $2,129,801 
         
Supplemental Cash Flow Information:        
Income Taxes Paid $10,350  $33,923 
Interest Paid $105,826  $59,439 
Supplemental disclosure of non-cash financing activities:        
Operating leases - right of use asset $302,695     
Operating leases - lease liability $294,387     

See accompanying notes to financial statements

F-6

The accompanying unaudited notes are an integral part of these unaudited consolidated financial statements.

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
             
  (For the three months ended)  (For the nine months ended) 
  September 30,  September 30,  September 30,  September 30, 
  2013  2012  2013  2012 
             
Revenue $1,790,825  1,985,516  $5,787,811  $3,619,611 
Revenue - Related Party  60,552   -   287,626   - 
Total Revenue  1,851,377   1,985,516   6,075,437   3,619,611 
                 
Cost of Revenues  1,088,442   758,267   3,049,394   1,642,619 
Gross Profit  762,935   1,227,249   3,026,043   1,976,992 
                 
Operating Expenses                
Selling and administrative expenses (includes stock compensation of $290,162 and $0 as of September 30, 2013 and 2012, respectively)  1,898,595   1,069,870   5,284,354   2,726,475 
Research and development  -   926   289   54,059 
Asset Impairment  946,931   -   946,931   - 
Depreciation and amortization  19,616   14,007   64,214   36,758 
Total Operating Expenses  2,865,142   1,084,803   6,295,788   2,817,292 
                 
Operating Income (Loss)  (2,102,207)  142,446   (3,269,745)  (840,300)
                 
Other Income (Expense)                
Other income  10,442   5,359   10,793   9,451 
Interest expense  (357,127)  (377,954)  (721,829)  (392,888)
Loss on extinguishment of debt  (112,583)  -   (112,583)   - 
Total Other Income (Expense), net  (459,268)  (372,595)  (823,619)  (383,437)
                 
(Loss) before provision for income taxes  (2,561,475)  (230,149)  (4,093,364)  (1,223,737)
                 
Net (Loss) $(2,561,475) $(230,149) $(4,093,364) $(1,223,737)
                 
Net Loss Per Share                
basic and diluted $(0.05) $(0.01) $(0.09) $(0.04)
Weighted Average Number of Shares Outstanding                
basic and diluted  49,438,329   32,843,413   46,239,643   31,468,471 
The accompanying unaudited notes are an integral part of these unaudited consolidated financial statements.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
 
  Nine Months Ended 
  September 30,  September 30, 
  2013  2012 
Cash flows from Operating Activities:      
Net loss $(4,093,364) $(1,223,737)
Adjustments to reconcile net loss to net cash used in operating activities:
        
Depreciation and amortization  128,351   36,758 
Stock issued for compensation  290,162   - 
Amortization of debt discount  322,476   300,000 
Asset Impairment  946,931   - 
Loss on early extinguishment of debt  112,583   - 
Bad debt expense  124,082   - 
Change in operating assets and liabilities:        
Accounts receivable, net  110,803   (332,604)
Prepaid expenses  51,444   17,997 
Other assets  (69,332)  (3,211)
Accounts payable  312,313   40,149 
Unearned revenue  -   (32,988)
Accrued liabilities  309,871   325,479 
Net Cash used in operating activities  (1,453,680)  (872,157)
         
Cash flows from Investing Activities:        
Capitalization of internally developed software  (752,135)  (92,727)
Purchases of property and equipment  (8,979)  (9,639)
Net Cash used in investing activities  (761,114)  (102,366)
         
Cash flows from Financing Activities:        
Shareholder Loan  40,000   - 
Borrowings (Repayments) on line of credit, net  (24,606)  51,500 
Payment for repurchase of common stock  -   (25,000)
Settlement payments  (115,278)  - 
Loan proceeds  1,220,000   443,908 
Loan proceeds from factor, net  (383,427)  - 
Repayments of debt obligations  (472,753)  (31,786)
Issuance of stock for cash net of offering cost  1,243,000   394,583 
Net Cash provided by financing activities  1,506,936   833,205 
         
Net decrease in cash  (707,858)  (141,318)
Cash at beginning of period  893,458   198,500 
Cash at ending of period $185,600  $57,182 
         
Supplemental schedule of cash paid during the period for:        
Interest $376,539  $25,827 
Income Taxes $-  $- 
Supplemental schedule of non-cash investing and financing activities:        
Issuance of stock to repay debt $514,667  $563,908 
Capital lease obligation incurred for use of equipment $90,099  $38,704 
Beneficial conversion feature on convertible debt charged to additional paid in capital $-  $300,000 
Conversion of $300,000 notes to common stock $-  $300,000 
Shares issued as a loan fee $679,353  $- 
Insurance premium finance contract recorded as prepaid asset $57,573  $- 
Prepaid common stock issued for services��$1,278,021  $- 
Reclassification of line of credit to note payable $133,333  - 
The accompanying unaudited notes are an integral part of these unaudited consolidated financial statements.
NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2013 (UNAUDITED)

NOTE 1 – NATUREORGANIZATION AND DESCRIPTION OF BUSINESS AND GOING CONCERN


Overview

AmeriGuard Security Services, Inc. (the Company), was incorporated on November 14, 2002, with an S-Corp tax election. The corporation was incorporated with the issuance of 1,000 shares of no-par value stock held by Lawrence Garcia, President and CEO with 550 shares and Lillian Flores, VP of Operations with 450 shares. The Company provides armed guard services as a federal contractor with licenses in 5 states and provides commercial guard services in California.

On July 7, 2021, the Company, entered into an agreement to gain 100% control of Health Revenue Assurance Holdings, Inc. (the “Company”) isInc (HRAA) a trusted sourcepublic corporation, incorporated in Nevada, by the purchase of timely, accurate and critical resources, technology and information that supports10,000,000 shares of Preferred A-1 Stock from the performanceseller, Custodian Ventures LLC. The purchase of revenue integrity in assuringHRAA allowed the existenceCompany to begin plans to consummate a reverse merger with HRAA becoming a wholly owned subsidiary of healthcare organizations. The Company and its subsidiaries’ products and services include business intelligence technology solutions, contract coding, billing, coding and compliance audits, education, revenue cycle consulting, physician services and ICD-10 transition services. The Company provides customized solutions to its clientsa public company. In March of 2022, a Certificate of Amendment was filed with the highest regard for ethical standardsNevada Secretary of State, changing the name of HRAA, to Ameriguard Security Services, Inc. (AGSS). Shortly thereafter, a stock name and responsibility.

Dream Reachers, LLC, ownsticker change report was filed with the Company’s officesSEC and is the borrower onstock ticker of HRAA was changed to AGSS.

On December 9, 2022, the Company executed the reverse merger agreement and became the subsidiary of AGSS. From that point forward, the financial statement filings will be the consolidation of Ameriguard Security Services, Inc, a mortgage loan related to such offices. Dream Reachers, LLC does not engage in real estate rental business. Its offices are occupied by Health Revenue Assurance Associates,Nevada company with Ameriguard Security Services, Inc. (“HRAA”) at no cost and HRAA pays the related mortgage’s principal and interest, taxes and maintenance. a California company.

The Company’s subsidiary HRAAaccounting year end is the sole member effective May 2011. Dream Reachers has been treated as a Subsidiary for accounting purposes in the Company’s unaudited condensed consolidated financial statements for all periods presented. (see Note 2)

Going Concern

The Company’s future success is dependent upon its ability to achieve profitable operations and generate cash from operating activities, and upon additional financing, Management believes they can raise the appropriate funds needed to support their business plan and develop an operating company which is cash flow positive.
However, as of September 30, 2013, the Company has an accumulated deficit and for the three and nine months ended September 30, 2013, incurred net losses, and has used net cash in operations. The Company has not been able to generate sufficient cash from operating activities to fund its on-going operations. There is no guarantee that the Company will be able to generate enough revenue and/or raise capital to support its operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability or classification of recorded assets and liabilities that might result should the Company be unable to continue as a going concern.
As of September 30, 2013, the Company has a cash balance of approximately $186,000. The Company is currently addressing the going concern and liquidity issues. The Company expects an increase in cash flow as the result of a growing customer demand for medical billing, IT consulting, training, education and services. In addition, the Company is evaluating financing opportunities through either equity or debt financing or a combination of both.
On November 12, 2013, the Company entered into a Securities Purchase Agreement for the equity sale of $5.4 million in Series A 8% convertible preferred stock (the “Series A Preferred Stock”) and warrants to purchase shares of the Company’s common stock. The net proceeds to the Company after commissions, professional fees, and payment of shareholder loans is $4,322,000. The net raise is sufficient to fund on-going operations for the next several months. However, the funding is not sufficient to alleviate the on-going concern issue. (see Note 11)
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

December 31.

Basis of Presentation


The accompanying unaudited condensed consolidated

These financial statements are presented in United States dollars and have been prepared in accordance with U.S.United States generally accepted accounting principles (“GAAP”) for interimprinciples.

Risks and Uncertainties

The risks and uncertainties described below may not be the only ones we are or may face in the future. If any of the following do occur, our business, financial information andcondition or results of operations could be materially adversely affected.

The company receives over 90% of its total revenue from four Federal contracts as described in Note 9 below. These contracts have specific terms, typically five years with the instructionsopportunity for extension, but there are no assurances they will be extended. Although we have had several extended in the past, there is no guarantee this will again happened in the future. However, there are significant direct expenses for each contract that also are removed from operations at the end of a contract. As a result, the revenue lost from a completed contract does not affect the bottom-line profits in an amount equal to Form 10-Q and Article 8 of Regulation S-X.


Accordingly, they do not include allthe revenue lost. The actual net income impact depends on the contract.

The process required to acquire a government contract takes several months to complete prior to delivery of the informationproposal to the contracting agency. Due to the time span required to prepare a proposal and footnotes required by U.S. GAAPwining the contract is not guaranteed, the company maintains a department of individuals who monitor and write proposals for complete financial statements. Inall government contracts that become open for bid on a continuing basis. It is important to the opinioncompany that new contracts are acquired consistently to maintain and grow annual revenue.

Other risks to operations consist of management, all adjustments (allState and Federal regulations, staffing shortages, the ongoing impact of which are of a normal recurring nature) considered necessary for a fair presentation have been included. Operating results for the three months ended September 30, 2013 are not indicative of the results that may be expected for the year ending December 31, 2013 or for any other future period. These unaudited condensed consolidated financial statementsCOVID, accelerating inflation, and the unaudited notes thereto should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2012 filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2013 (our “10-K”).overall business environment issues we cannot foresee.

F-7


Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Health Revenue Assurance Associates, Inc. and Dream Reachers, LLC. All significant inter-company transactions and balances are eliminated in consolidation.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates


The preparation of the consolidated

In preparing financial statements in conformity with GAAP requiresgenerally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts inof assets and liabilities and the consolidateddisclosure of contingent assets and liabilities at the date of the financial statements.statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant accounting estimates reflected in the Company’s consolidated financial statements include valuation of accounts receivable, valuationestimated useful lives and potential impairment of property and equipment, valuationalong with the collectability of some receivables from customers.

Cash and amortization period of software, valuation of beneficial conversion features in convertible debt, valuation of equity based instruments issued for other than cash, revenue recognition, and the valuation allowance on deferred tax assets.

HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2013 (UNAUDITED)
Cash

For purposes of the statement of cash flows, the Equivalents

The Company considers all highly liquid temporary cash investments with aan original maturity of three months or less when purchased to be cash equivalents. The Company’sOn December 31, 2022, and December 31, 2021, the Company had cash balances are maintainedand cash equivalents totaling $1,227,654 and $2,129,801 respectively.

Accounts Receivable

We record accounts receivable at various banks that are insured by the Federal Deposit Insurance Corporation subject to certain limitations.


Accounts Receivable and Factoring

Accounts receivable are stated at the amounts management expects to collect.  Annet realizable value. This value includes an appropriate allowance for doubtfulestimated uncollectible accounts to reflect any loss anticipated on the accounts receivable balances and is recorded using a specific identification methodcharged to other bad debt expense. We calculate this allowance based on a combinationour history of historical experience, aging analysis and information on specific accounts.  Account balances are written off againstwrite-offs, the allowance after all meanslevel of collection have been exhausted and the potential for recovery is considered remote.  Management has determined that an allowance in the amount of $117,632 is required as of September 30, 2013. The allowance arises from a website development project contracted with ResumeBear, a related party.  The Companypast-due accounts for its factoring arrangements as either a sale or a secured financing based on the criteria in ASC 860 "Transferscontractual terms of the receivables, and Servicing".  Estimatesour relationships with, and the economic status of, allowances for doubtful accounts are reflected as a recourse obligation, a liability, for factor arrangements treated as a sale with recourse or as a contra assetour customers. With over ninety percent of year end accounts receivable balance from Federal contracts that require payment, and the uncollectable amount historically has been less than 1%. As of December 31, 2022, and 2021, an allowance account for arrangements accounted for as a secured financing.
Software

Costs incurred in connection with the development of software products are accounted for in accordance with the Financial Accounting Standards Board Accounting Standards Codification ("ASC") 985   Costs of Software to Be Sold, Leased or Marketed.”     Costs incurred prior to the establishment of technological feasibility are charged to research and development expense. Software development costs are capitalized after a product isestimated uncollectible accounts was determined to be technologically feasibleunnecessary.

Property and is in the process of being developedEquipment

Property and equipment are recorded at cost. Expenditures for marketmajor additions and capitalization ceases after the general release of the software. Amortization ofimprovements are capitalized software development costs begins upon initial product shipment after general release. Capitalized software development costs are amortized over the estimated life of the related product (generally thirty-six months) using the straight-line method. The Company evaluates its software assets for impairment whenever events or change in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of software assets to be held and used is measured by a comparison of the carrying amount of the asset to the future net undiscounted cash flows expected to be generated by the asset.  If such software assets are considered to be impaired, the impairment to be recognized is the excess of the carrying amount over the fair value of the software asset. 


Softwareminor replacements, maintenance, costsand repairs are charged to expense as incurred. Expenditures for enhanced functionality are capitalized. The costWhen property and equipment is retired or otherwise disposed of, the softwarecost and the related accumulated amortizationdepreciation are removed from the accounts upon retirementand any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the softwarerelated assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful life for Machinery and Equipment, and Vehicles is 5 years, with any resultingLeasehold improvements useful life is 10 Years.

Operating Leases

In February 2016, FASB ASU No. 2016-02 established ASC Topic 842, Leases, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. Effective December 31, 2022, we have implemented ASU No. 2016-02 and booked the operating lease asset and the related liability.

Net Income/(Loss) per Share

Net income/(loss) per common share is computed by dividing net income or loss being recorded in operations. On July 15, 2013by the Companyweighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, “Earnings per Share”. Basic earnings/(loss) per common share (“EPS”) calculations are determined by dividing net income/(loss) by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.

F-8

Revenue Recognition

We recognize revenue when the Invoice for contracted services is issued a general release for oneas stipulated by the contract. Other services provided are recognized at the time the service is provided. Ninety eight percent of its products  Visualizer  ™. After the general release, the Company recorded approximately $64,000 in amortization expenserevenues are billed monthly and recognized in the accompanying unaudited consolidated financial statementsmonth the services were provided. Refunds and returns, which are minimal, are recorded as a reduction of September 30, 2013. At the end of September, 2013, therevenue. The Company has written off the capitalized research and development costsnot recorded a reserve for the visualizer software suite of multiple offerings and the OMC Initiater after an evaluation based in partreturns on the lack of cash flow and customer demand in ICD  Visualizer  after the general acceptance release date of July 15, 2013. In addition, the Company’s going concern opinion and cash liquidity concerns restrained the ability to make a capital investment in research and development to complete existing products in the pipeline as the available cash is needed to fund normal operating expenses. The resulting loss of $946,931 is presented as a line item entitled “asset impairment” on the consolidated statement of operations.

Share Based Compensation

Compensation expense for all stock-based employee and director compensation awards granted is based on the grant date fair value estimated in accordance with the provisions of ASC Topic 718, Stock Compensation (“ASC Topic 718”). The Company recognizes these compensation costs on a straight-line basis over the requisite service period of the award, which is generally the option vesting term. Vesting terms vary based on the individual grant terms.
The Company estimates the fair value of stock-based compensation awards on the date of grant using the Black-Scholes-Merton (“BSM”) option pricing model, which was developed for use in estimating the value of traded options that have December 31, 2022, or 2021 since it does no vesting restrictions and are freely transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility. The BSM option pricing model considers, among other factors, the expected term of the award and the expected volatility of the Company’s stock price. Expected terms are calculated using the Simplified Method, volatility is determined based on the Company's historical stock price trends and the discount rate is based upon treasury rates with instruments of similar expected terms. Warrants granted to non-employees are accounted for in accordance with the measurement and recognition criteria of ASC Topic 505-50, Equity Based Payments to Non-Employees.

Fair Value Measurements and t believe such returns will be material.

Fair Value of Financial Instruments


Fair

The Company applies the accounting guidance under Financial Accounting Standards Board (“FASB”) ASC 820-10, “Fair Value Measurements”, as well as certain related FASB staff positions. This guidance defines fair value isas the exchange price that would be received forfrom selling an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market forin which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, in an orderly transaction between market participants.  such as inherent risk, transfer restrictions, and risk of nonperformance.

The Company classifies assets and liabilities recorded at fair value under theguidance also establishes a fair value hierarchy based upon the observabilityfor measurements of inputs used in valuation techniques.  Observable inputs (highest level) reflect market data obtained from independent sources, while unobservable inputs (lowest level) reflect internally developed market assumptions. The fair value measurements are classified under the following hierarchy:

as follows:

Level 1—Observable inputs that reflect1 - quoted market prices (unadjusted)in active markets for identical assets and liabilities in active markets;or liabilities.
Level 2—Observable2 - inputs other than quoted market prices,Level 1 that are observable, either directly or indirectly, observablesuch as quoted prices in the marketplaceactive markets for similar assets or liabilities, quoted prices for identical or similar assets andor liabilities quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities; andor liabilities.

Level 3—Unobservable3 - unobservable inputs that are supported by little or no market activity that is significant to the fair value of assets or liabilities.

HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2013 (UNAUDITED)
The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

Revenue Recognition
The Company recognizes services revenue based on the proportional performance method of recognizing revenue.
A portion of the Company’s revenue is generated from medical coding audit services. Auditing revenue is invoiced in accordance with the contract, generally at three benchmark time periods which coincide with when specific, obligatory field work services have been rendered and completed, the value of this portion of the contract price has been predetermined and agreed upon, and the client has received benefit or value in the form of the independent identification of system weaknesses and risk analysis. Further, collectability is reasonably assured due to the existence of a fixed fee contract and the size and financial health of the Company’s clients. Below is a description of the general benchmarks and work phases associated with the Company’s audit services:
Planning Phase - work commences prior to and as soon as the contract is signed and includes setting the audit scope, scheduling of the job, assignment of audit staff, understanding the client and their systems, determination of sample size and sampling methods to be employed, and other specific items as outlined in the contract. The planning phase includes the determination of deliverables as defined in the contract, generally consisting of a listing of errors, training and a final report. The Company generally invoices and recognizes 50% of the contract value at the completion of the Planning Phase. Although all of the contracts contain a clause making the first 50% of the engagement fee due and non-refundable at this point, the Company does not deem this initial fee to be recognized as deferred revenue under SAB 104 due to the extensive amount of work to be done prior to accepting the contract.
Field Work Phase – is performed at the client location and generally lasts one week and encompasses actual testing of sample claims preselected in the Planning Phase. The auditor generally preloads the selected claims into the Company’s proprietary software and audits the claim records by reviewing actual medical records. The software assists the auditor in determining proper classifications and allows the auditor to compare the proper classification against what was filed in the submission made by the client to Medicare. Notes and comments are recorded and audit reports are generated. The Company generally invoices and recognizes 40% of the contract value at the completion of the Field Work Phase.
Reporting Phase – includes a summary of audit findings, exit conference with clients, and any other specific deliverables as determined by the contract. The Company generally invoices and recognizes the remaining 10% of the contract value at the completion of the Report Phase. 

A portion of the Company’s revenue is derived from consulting, training and coding services provided. Revenue from these revenue streams is recognized after services are performed based on the quoted and agreed upon fee contained in its contracts.
For our education products sold on a self-study standalone basis or in multiple element contracts which include training and the product and training are separable elements (see below) revenue is recognized for the product upon passing of title which occurs once the end user is granted access to our online curriculum courses.
On July 15, 2013 the Company issued a general release for one of its products Visualizer ™. Software sales on a standalone basis will be recognized upon delivery of the software when evidence of the purchase arrangement exists and the price is determinable, and when collectability is reasonably assured.

Arrangements with customers may involve multiple elements including software products, education products, training, software product maintenance, coding services, coding audit services and other consulting services. Training on education products will occur after the education product sale. Education products are sold and may be used as a self-study product, although most of our customers elect to purchase our training services and therefore most of our contracts to date are multiple element contracts including one price for the education product and related training. We allocate the selling price to each element as discussed below. Training and maintenance on software products will generally occur after the software product sale. Other services may occur before or after the product sales and may not relate to the products.  Revenue recognition for multiple element arrangement is as follows:

Each element is accounted for separately when each element has value to the customer on a standalone basis and there is Company specific objective evidence of selling price of each deliverable. For revenue arrangements with multiple deliverables, the Company allocates the total customer arrangement to the separate units of accounting based on their relative selling prices as determined by the price of the items when sold separately. Once the selling price is allocated, the revenue for each element is recognized using the general and specific criteria under GAAP as discussed above for elements sold in non-multiple element arrangements. A delivered item or items that do not qualify as a separate unit of accounting within the arrangement are combined with the other applicable undelivered items within the arrangement. The allocation of arrangement consideration and the recognition of revenue is then determined for those combined deliverables as a single unit of accounting.  The Company has historically sold its services with established rates which it believes is Company specific objective evidence of selling price. For the new software products, management has established selling prices which qualifies as Company specific objective evidence of selling price. Generally all elements in multiple element arrangements with Company customers qualify as separate units of account for revenue recognition purposes.
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2013 (UNAUDITED)
Cost of Revenues
Cost of revenues includes labor costs for services and education development costs. Amortization costs in 2013 of approximately $64,000 were allocable to cost of sales related to software amortization. In future periods, additional amortization of capitalized software costs may be included in costs of revenues.
Earnings Per Share
The Company computes and presents earnings or losses per share in accordance with FASB ASC Topic 260, Earnings per share . Basic earnings or losses per share are computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding. Diluted earnings or loss per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares and common stock equivalents outstanding, calculated on the treasury stock method for options and warrants using the average market prices during the period.
As the Company incurred a net loss in all periods presented, all potentially dilutive securities were excluded from the computation of diluted loss per share since the effect of including them is anti-dilutive. There were no dilutive securities outstanding at September 30, 2013 and 2012 respectively.
Recent Accounting Pronouncements

We have implemented all new accounting standards that are in effect and that may impact our unaudited condensed consolidated financial statements and do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our consolidated financial position or results of operations.

3 - ACCOUNTS RECEIVABLE

Accounts receivable at September 30, 2013 and December 31, 2012 was as follows:
  September 30,  December 31, 
  2013  2012 
Accounts receivable $1,011,929  $1,246,814 
Accounts receivable –Related party  117,632   - 
Allowance for doubtful accounts  (117,632  - 
 Total $1,011,929  $1,246,814 

We had $124,082 and $0 in bad debt expense on trade accounts receivable for nine months ended September 30, 2013 and 2012, respectively.
4 – RESEARCH AND DEVELOPMENT AND SOFTWARE
In Early 2012, the Company started developing the Visualizer™ suite. This intuitive and easy to use business intelligence product is designed to meet the emerging need for healthcare analytics. Customer data is infused into the suite, and the Company uses this to develop pre-defined analytics targeted to address healthcare’s emerging concerns and needs.

HRAA’s Visualizer™ suite encompasses multiple offerings. The first project is ICD Visualizer™, which assists healthcare leaders with their need to understand the exponential impact of the transition to ICD-10 including work flow, productivity, process changes and documentation and reimbursement risks. The application helps to visualize the reimbursement and operational effects of transitioning organizations to ICD-10 and identify where to focus education and documentation issues. It enables clients to develop a custom work plan to mitigate risks from the highest areas of exposure to the least.

The transition to ICD-10 is causing a paradigm shift in healthcare. In response, we have developed a new product called OMC Initiator (Outsourced Medical Coding) for processing healthcare claims within hospitals. This product captures data from the physician or the hospital’s financial systems and correlates the data in a manner that expedites the processing of a claim. To validate our new product, our team of Emergency Department Coders (ED Coders) is continuously evaluating the process of coding claims in order to enhance our product.

At September 30, 2013, the Company had accumulated a total of $1,011,068 in capitalized costs related to the development of the  Visualizer ™ suite and the OMC Initiater which was included as Software on the accompanying consolidated balance sheet. As of September 30, 2013 we amortized $64,137 of the capitalized software after the general release on July 15, 2013 for the Visualizer project.
At the end of September 2013, the Company re-evaluated the capitalized research and development costs for the Visualizer  software suite of multiple offerings and the OMC Initiater after an evaluation based in part on the lack of cash flow and customer demand in ICD  Visualizer  after the general acceptance release date of July 15, 2013. In addition, the Company also considered its going concern opinion and cash liquidity concerns that restrain the ability to make capital investments in research and development to complete existing products in the pipeline as the available cash is needed to fund normal operating expenses. As a result of this evaluation, the Company recorded a loss of $946,931 that is presented as a line item entitled “asset impairment” on the consolidated statement of operations.
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2013 (UNAUDITED)
Amortization expense for software, for the three months ended September 30, 2013 and 2012 was $64,137 and $0, respectively. Software consisted of the following at September 30, 2013 and December 31, 2012:

  
September 30,
2013
  
December 31,
2012
 
Software $1,011,068  $258,933 
Accumulated amortization  (64,137)  - 
Asset Impairment  (946,931  - 
Software, net $-  $258,933 
5 – LINES OF CREDIT

Bank
The Company had a $150,000 revolving line of credit with a bank, effective in December 2008, for its general working capital needs. The line of credit is secured by all business assets, collateral, and personal guarantees. The line of credit had a maturity date of December 18, 2018. On September 19, 2013 the Company converted the Line of Credit to a Term Note. The Company consolidated the line of credit and an existing bank term loan into a Consolidated Term Loan with a monthly payment in the amount of $3,209 with a new maturity date of September 17, 2017. At the time of the conversion the line of credit had an outstanding balance in the amount of $133,334. (see Note 6)
Dell

The Company maintains a Dell Business Credit line of up to $50,000.  Interest rates vary under the line based on difference types of payment plans.  The balance due under the line as of September 30, 2013 was $46,166, which is included in line of credit, current portion in the accompanying unaudited condensed consolidated financial statements.
6 – LONG TERM DEBT AND NOTES PAYABLE

Long Term debt:

Long Term debt consisted of the following at September 30, 2013:
  
September 30,
2013
  
December 31,
2012
 
Bank term loan $154,030  $38,897 
Mortgage loan  176,475   180,073 
   330,505   218,970 
Less current portion  (43,956  (37,513)
Total long term portion $286,549  $181,457 
On September 19, 2013, the Company consolidated the existing bank term loan with an existing line of credit. The outstanding balance for the bank term loan and the bank credit line prior to consolidation was $20,697 and $133,334, respectively. The original term loan was established in March 2009 as a result of a conversion of a revolving line of credit.  The new consolidated term loan is personally guaranteed by one of the Company’s stockholders and is collateralized by the assets of the Company.  Payments of principal and interest are approximately $3,200 per month. The new consolidated term loan matures in four years and incurs interest at a rate per year equal to the bank’s prime rate plus 3.5%. The balance due as of September 30, 2013 for the new consolidated Term loan was approximately $154,030.
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2013 (UNAUDITED)

The Company has a mortgage related to certain real estate, which houses the Company’s main offices in Plantation, Florida. The loan originated July, 2010 in the amount of $192,500 and matures July 2020, when a balloon principal payment of approximately $129,000 becomes due. The loan is collateralized by the real estate and is personally guaranteed by a principal stockholder of the Company. Interest is fixed at 6.625% for the first five years of the loan, and converts to an adjustable rate for the second five years at the Federal Funds Rate plus 3.25%, as established by the United State Federal Reserve. The balance under this mortgage loan as of September 30, 2013 was approximately $176,500 and is allocated to the current and long term debt line items in the accompanying unaudited condensed consolidated balance sheet. Monthly payments for principal and interest are approximately $1,500 until July 2015, when the total monthly payment may vary due to the adjustable interest rate provision in the note.
Notes payable:
In December 2012, the Company entered into loan agreements with various investors and issued promissory notes upon receipt of $815,000. The loan agreements have an interest rate of 12% per annum.  Principal and interest is payable over 26 months. Additionally, in connection with the financing, the Company issued 2,375,000 shares of common stock to the lenders as loan fees. The fair value per share of $0.28 (based on recent cash sales prices) was used to compute the relative fair value of the shares in accordance with ASC 470-20 which totaled $343,500 which was recorded as a debt discount with a credit to additional paid-in-capital and such discount is being amortized over the term of the loans. The unamortized discount was $141,484 as of September 30, 2013.
In January and February 2013, the Company entered into loan agreements with various investors and issued promissory notes upon receipt of $1,220,000. The loan agreements have an interest rate of 12% per annum.  Principal and interest is payable over 26 months. Additionally, in connection with the financing, the Company issued 5,575,000 shares of common stock to the lenders as loan fees (See note 9). The fair value per share of $0.28 (based on recent cash sales prices) was used to compute the relative fair value of the shares in accordance with ASC 470-20 which totaled approximately $679,500 which was recorded as a debt discount with a credit to additional paid-in-capital and such discount is being amortized over the term of the loans. The unamortized discount was $425,634 as of September 30, 2013.
The Company began paying principal and interest on the above mentioned notes in early 2013 in accordance with the payment terms. On August 2013, the Company converted $402,083 in unsecured investor promissory notes for five (5) individuals into one million six hundred eight thousand three hundred and thirty three (1,608,333) common shares at a conversion price of $0.25 per share. As a result of the conversion the Company expensed $128,452 of the unamortized discount as a finance expense.

Notes payable consisted of the following at September 30, 2013:
  
September 30,
2013
 
Principal amount of notes payable $1,063,333 
Unamortized discount  (567,118
Notes payable, net of discount  496,215 
Less current portion  (372,161
Total Long term portion $124,054 

7 – FACTORING AGREEMENT
In June 2012, the Company entered into a one-year factoring agreement with a finance company. The agreement automatically renews annually unless terminated by either party. Under the terms of the agreement, the Company, at its discretion, assigns the collection rights of its receivables to the finance company in exchange for an advance rate of 85% of face value. The assignments are transacted with recourse only at the option of the finance company in the event of non-payment. The Company's obligations under the factor agreement are secured by substantially all assets of the Company. In accordance with ASC 860 "Transfers and Servicing" regarding transfers of receivables with recourse, this factoring arrangement is accounted for as a secured financing. For the three months ended September 30, 2013, the Company had factored approximately $1,108,000 of receivables and had received cash advances of approximately $1,090,309. Outstanding receivables purchased by the factor as of September 30, 2013 were approximately $522,000 and are included in accounts receivable in the accompanying unaudited condensed consolidated balance sheet, and the secured loan due to the lender was approximately $444,000. Factor fees for the three and nine months ending September 30, 2013 were approximately $35,500 and $104,000, respectively and are included in interest expenses. (See Note 3)
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2013 (UNAUDITED)
8 – COMMITMENTS AND CONTINGENCIES
Commitments
Leases:
In September 2012, the Company started a non-cancellable operating lease for office equipment. The lease term is 5 years. Lease payments during the five years are approximately $500 per month.
On September 1, 2011, the Company entered into a commercial lease agreement for additional office space.  The lease term is one year with five successive one year renewal options. Starting September 1, 2012, the lease has been renewed for one year with a fixed payment of approximately $5,008 per month. For each year thereafter of the initial year, the rent will be subject to an increment of 4%.

Capital Leases:

The Company leases its property and equipment from Dell Financial Services L.L.C. under a capital lease. The economic substance of the lease is that the Company is financing the acquisition of the assets through the lease and accordingly, it is recorded in the Company’s assets and liabilities.
The following is an analysis of the leased assets included in Property and Equipment:
  
September 30,
2013
 
Equipment 79,210 
Less accumulated depreciation  (27,006)
Total $52,204 
The lease agreement contains a bargain purchase option at the end of the lease term. The total amount due at September 30, 2013 is $67,068 of which $32,768 is included in short term liabilities.
The following is a schedule by years of future minimum payments required under the lease together with their present value as of September 30, 2013:
Year Ending December 31:   
2013 $8,193 
2014  32,768 
2015  22,527 
2016  3,580 
Total minimum lease payments  67,068 
Less amount representing interest  (11,386)
Present value of minimum lease payments $55,672 
Amortization of assets held under capital leases is included with depreciation expense and is approximately $27,000 as of September 30, 2013.

Settlement Agreement:

On May 8, 2012, the Company terminated the employment of our Chief Marketing Officer (“CMO”) and subsequently amended its complaint to enforce certain non-competition clauses contained in the employment agreement. The Company sought a declaration of its obligations to pay severance under the terms of its then-existing employment agreement with the CMO.

On July 9, 2012, the Company and the former CMO entered into a Settlement Agreement to resolve two pending lawsuits arising out of the termination of his employment agreement. The lawsuit was initiated by the Company against the former CMO in the United States District Court for the Southern District of Florida.  In addition, the former CMO sued the Company in the United States District Court of the District of Colorado.
Pursuant to the Settlement Agreement, the former CMO agreed to abolish all claims and lawsuits against the Company and its CEO and COO and resigned any and all positions which he had or presently may have had with the Company. As part of the Settlement Agreement, the Company agreed to make eleven (11) payments totaling $232,500 pursuant to the terms of his prior employment agreement. Additionally, the CMO agreed to transfer his 3,299,802 shares to an officer of the Company in 2012. These payments commenced July 2012 and the final payment in the amount of $23,056 was disbursed on July 29, 2013. In addition, the Company has agreed to abolish all claims and lawsuits against the former CMO. The Settlement Agreement has a seven (7) day grace period for payments to the former CMO, after which time, he may seek court intervention to enforce the payments. The Company's Chief Executive Officer and Chief Operating Officer, respectively, have personally guaranteed the payments of the Settlement Agreement. As a result of the Settlement Agreement, both parties are dismissing their respective filings and have agreed to not enter any more lawsuits concerning the scope of this matter.
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2013 (UNAUDITED)
Employment Agreements:
On October 2, 2013 the Company entered into employment agreements with four (4) of our officers and directors. The Employment agreements provide for severance benefits, change in control provisions, accrued but unpaid wages and bonuses, accrued but unpaid vacation time, incentive awards, equity and stock options, and other benefits. These four (4) employment agreements were amended on November 12, 2013. As of September 30, 2013, no performance bonuses have been earned. The Company owes its CEO $75,000 as stated in the February 2012 merger agreement, which is accrued in the accompanying unaudited condensed consolidated Financial Statements as Due to officer. The balance due to the Company’s CEO was formalized in a promissory note in November 1, 2013. In Addition, the Company owes its President $40,000 for a promissory note dated November 1, 2013 for funds advanced in September 2013. On November 12, 2013, the promissory notes for the CEO and the president were paid in full with financing received in connection with the sale and issuance of Series A Preferred Stock and warrants to purchase shares of the Company’s common stock pursuant to the Securities Purchase Agreement dated and signed on November 12, 2013 with Great Point Partners, LLC. (see Note 11)
Contingencies
From time to time, the Company is involved in litigation matters relating to claims arising from the ordinary course of business. While the results of such claims and legal actions cannot be predicted with certainty, the Company’s management does not believe that there are claims or actions, pending or threatened against the Company, the ultimate disposition of which would have a material adverse effect on our business, results of operations, financial condition or cash flows.
9 – STOCKHOLDERS' EQUITY
Share Based Compensation

The Company is in the process of establishing a non-qualified stock option plan in advance of the actual establishment of the plan the Company has granted a total of six hundred thirty six thousand (636,000) stock options to several directors and officers. The grant date is that which an employer and its employee reach a mutual understanding of the key terms and conditions of a share-based payment arrangement. This is the date on which the employer becomes contingently obligated to issue equity instruments or transfer assets to the employee who renders the requisite service. The Company is obligated for these grants as adoption of a stock option plan and board approval is considered a mere formality.

Stock Options
During the three months ended September 30, 2013, the Company recorded pre-tax compensation expense of $24,935 related to the Company’s stock option shares. As of September 30, 2013, there was approximately $62,313 of unrecognized compensation expense related to stock options, which will be recognized over the weighted-average remaining requisite service period of 1.7 years. There were no exercises of stock options for the three months ended September 30, 2013.

The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model. The 636,000 options were valued at $87,249. The weighted-average estimated value of stock options granted during the three months ended September 30, 2013 was $0.42 per share, using the following weighted-average assumptions:
2013
Dividend yield (1)
0.0%
Expected volatility (2)
118%
5 Year Bond interest rate (3)
1.20%
Expected life (4)
1.5
(1) Represents cash dividends paid as a percentage of the share price on the date of grant.
(2) Based on historical volatility of the Company’s common stock over the expected life of the options.
(3) Represents the U.S. Treasury STRIP rates over maturity periods matching the expected term of the options at the time of grant.
(4) The period of time that options granted are expected to be outstanding based upon historical evidence.
The following table summarizes stock option activity for the three months ended September 30, 2013:
Options Shares  
Weighted-Average
Exercise Price
 
Weighted-Average
 Remaining
Contractual Term
 
Aggregate
Intrinsic Value
($000)
Outstanding at January 1, 2013  -   -    
Granted  636,000   - 1.7 yrs.  
Exercised  -   -    
Forfeited or expired  -   -    
Outstanding at September 30, 2013  636,000  $0.4225 1.7 yrs. -
Exercisable at September 30, 2013  -   - - -
The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the Company’s closing stock price on the last trading day of the third quarter of 2013 and the exercise price, multiplied by the number of in-the-money options).

HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2013 (UNAUDITED)
Non-Vested Equity Shares
The Company calculates compensation cost for restricted stock grants to employees and non-employee directors by using the fair market value of its Common Stock at the date of grant and the number of shares issued. This compensation cost is amortized over the applicable vesting period. During the three months ended September 30, 2013, the Company recorded pre-tax compensation expense of $24,935, related to the Company’s non-vested equity shares. As of September 30, 2013, there was approximately $62,313 of unrecognized compensation expense related to stock options, which will be recognized over the weighted-average remaining requisite service period of 1.7 years.
The following table details the status and changes in non-vested equity shares for the three months ended September 30, 2013:
Shares
Weighted-Average
Grant Date
Fair Value
Non-vested equity shares, January 1, 2013--
Granted636,000-
Vested--
Forfeited--
Non-vested equity shares, September 30, 2013636,000-
Common Stock
On January 15, 2013, the Company raised $13,000 through the issuance of 46,429 shares of common stock at a price per share of $0.28 per share.
On January 31, 2013, the Company issued 50,266 shares of common stock as compensation to an employee for services rendered through March 31, 2013. The shares were valued at $0.49 per share based on the quoted trading price per share or $24,630 which was expensed.
In February 2013, the Company issued 5,575,000 shares of common stock in connection with a financing transaction as more fully described in note 6.
In March 2013, the Company entered into a one-year agreement with a consultant for 230,000 vested shares and cash consideration.  The shares were valued on the agreement date which was the measurement date at $0.35, based on the quoted trading price and the $80,500 is being expensed over the term of the contract.  The shares were issued on April 4, 2013 to the consultant. During the three months ending June 30, 2013, the company expensed an additional $20,125 and recorded $57,021 as prepaid expense in connection with this transaction.
On April 1, 2013, the Company issued 54,847 shares of common stock as compensation to two employees for services rendered through March 31, 2013. The shares were valued at $0.40 per share based on recent cash sales by the Company or $21,939 which was expensed.
On May 19, 2013, the Company raised $250,000 through the issuance of 625,000 shares of common stock at a price per share of $0.40 per share.

On May 24, 2013 and June 21, 2013, the Company raised $50,000 and $300,000 through the issuance of 125,000 and 750,000 shares of common stock at a price of $0.40 per share.
On June 27, 2013, the Company entered into a financial advisor and agent placement agreement whereby the Company had the option to pay in cash or issue 100,000 shares of common stock. The shares were valued on the agreement date which was the measurement date at $0.51 per share based on the quoted trading price and the $51,000 is being expensed over the term of the contract. The Company issued the shares in September 2013.
On July 8, 2013 and August 7, 2013 pursuant to private placements, the Company issued 1,000,000 shares of common stock  in exchange for cash of $400,000 with a per share price of $0.40.
On August 21, 2013, August 27, and August 30, 2013, the Company raised $25,000, $100,000 and $100,000 through the issuance of 100,000, 400,000, and 400,000 shares of common stock at a price of $0.25 per share.
On August 22, 2013 and August 28, 2013, the Company converted $402,083 in unsecured investor promissory notes for five (5) individuals into one million six hundred eight thousand three hundred and thirty three (1,608,333) common shares at a conversion price of $0.25 per share. The shares were valued at $514,666 based on the quoted trading price of $0.32 and accordingly, the company recorded a loss on conversion of $112,583.

In September, 2013, the Company issued 95,052 shares of common stock as compensation to three (3) employees for services rendered through June 30, 2013. The shares were valued at $0.48 per share based on the quoted trading price per share or $45,625 which was expensed.
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2013 (UNAUDITED)
On September 6, 2013, the Company entered into a three year agreement with a company to provide consulting and recruiting services. Upon execution of the agreement, the Company issued 50,000 shares of common stock valued at $0.30 per share based on the quoted trading price, in consideration of their services to be rendered for the first year of the agreement. The $15,000 is being expensed over 12 months.
On September 9, 2013, the Company entered into a one year Material Consulting Agreement with Mr. Michael Ciprianni to provide certain consulting services related to the Company’s business in exchange for four million one hundred twenty five thousand (4,125,000) shares of common stock in consideration of the services to be rendered. The shares were valued on the agreement date which was the measurement date at $0.28 per share based on the quoted trading price and the $1,155,000 is being expensed over the term of the contract.
On September 30, 2013, the Company issued 187,500 shares of common stock as compensation to two (2) employees for services rendered through September 30, 2013. The shares were valued at $0.23 per share based on the quoted trading price per share or $43,125 which was expensed.
10 – CONCENTRATIONS

Sales to six hospitals represented approximately 52% of net sales for the three months ended September 30, 2013.
Four and three vendors represented approximately 42% and 68% of the outstanding accounts payable balance as of September 30, 2013 and December 31, 2012, respectively.
Four customers represented approximately 55% and 62% of the accounts receivable as of September 30, 2013 and December 31, 2012 respectively.
11 – SUBSEQUENT EVENTS

On October 2, 2013 the Company entered into employment agreements with four (4) of our officers and directors. The Employment agreements provide for severance benefits, change in control provisions, accrued but unpaid wages and bonuses, accrued but unpaid vacation time, incentive awards, equity and stock options, and other benefits. These four (4) employment agreements were amended on November 12, 2013.
On October 7, 2013, the Company entered into a one-year OID (Original Issue Discount) promissory note in the amount of $280,000 with a Utah corporation, (the “lender”). The purchase price for this note and the warrant is $250,000. The Company has the option to repay this note at any time on or before the date that is sixty (60) days from October 7, 2013 (the “effective date”).  The Company will record a debt discount for the OID of $30,000.  The debt will be treated as stock settled debt where a put premium of $120,000 will be recorded over the six month period to the first conversion date. The Lender has the right at any time after the date that is six (6) months from the effective date, at its election, to convert all or any part of the outstanding balance of the note into shares of fully paid and non-assessable common stock of the company based upon a formula that is seventy (70%) percent of the average of the two (2) lowest intra-day trade prices in the fifteen (15) trading days immediately preceding the conversion. The lender was granted the right to purchase at any time on or after October 7, 2013 (the “issue date”) until the date which is the last calendar day of the month in which the fifth anniversary of the “issue date” occurs (the “Expiration date”), 350,000 fully paid and non-assessable shares (the “warrant shares”) of the company’s common stock, par value $.001 per share (the “Common Stock”), as such number may be the adjusted from time to time pursuant to the price protection terms and conditions of this warrant to purchase shares of common stock. The initial “exercise price” is $0.40 per share of common stock, as the same may be adjusted from time to time pursuant to the terms and conditions of the warrant. On November 12, 2013, the OID promissory note was paid in full with financing received in connection with the sale and issuance of Preferred Stock and Series A Warrants pursuant to the Securities Purchase Agreement dated and signed on November 12, 2013 with certain funds and accounts as to which Great Point Partners, LLC Acts as an investment manager.  As mentioned above, the Company issued 350,000 free standing and detachable warrants related to the convertible promissory note. The Company will account for these warrants issued in accordance with the US GAAP accounting guidance under ASC 815 applicable to derivative instruments, which requires every derivative instrument within its scope to be recorded on the balance sheet as either an asset or liability measured at its fair value, with changes in fair value recognized in earnings. Based on this guidance, the Company determined that the Company's warrants do not meet the criteria for classification as equity. Accordingly, the Company classified the warrants as current liabilities. The warrants are subject to re-measurement at each balance sheet date, with any change in fair value recognized as a component of other income (expense), net in the statements of operations. We will estimate the fair value of these warrants at the respective balance sheet dates, based on the estimated market value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates and expected dividends on and expected volatility of the price of the underlying common stock.

On October 8, 2013, the Company amended its articles of incorporation by increasing the number of authorized shares of common stock from 75,000,000 to 500,000,000. This amendment has been retroactively disclosed on the Balance Sheet.
On October 9, 2013, the Company issued 100,000 shares of common stock as compensation to a consultant to provide services. The shares were valued at $0.24 per share based on the quoted trading price per share or $24,000, which was recorded as prepaid and will be expensed over the term of the agreement, which is six (6) months.

On October 17, 2013, the Company amended its articles of incorporation to create a new class of stock by the authorization of 25,000,000 preferred shares of stock. This amendment has been retroactively disclosed on the Balance Sheet.
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2013 (UNAUDITED)
On October 17, 2013, the Company entered into a one-year OID (Original Issue Discount) promissory note in the amount of $142,500 with a Utah corporation, (the “Lender”). The purchase price for this note and the warrant is $125,000. The Company has the option to repay this note at any time on or before the date that is sixty (60) days from October 17, 2013 (the “effective date”). The Company will record a debt discount for the OID of $17,500. The remaining debt will be treated as stock settled debt where a put premium of $61,071 will be recorded over the six month period to the first conversion date. The Lender has the right at any time after the date that is six (6) months from the effective date, at its election, to convert all or any part of the outstanding balance of the note into shares of fully paid and non-assessable common stock of the company based upon a formula that is seventy (70%) percent of the average of the two (2) lowest intra-day trade prices in the fifteen (15) trading days immediately preceding the conversion. The lender was granted the right to purchase at any time on or after October 17, 2013 (the “issue date”) until the date which is the last calendar day of the month in which the fifth anniversary of the “issue date” occurs (the “Expiration Date”), 175,000 fully paid and non-assessable shares (the “warrant shares”) of the Company’s common stock, par value $.001 per share (the “Common Stock”), as such number may be the adjusted from time to time pursuant to the price protection terms and conditions of this warrant to purchase shares of common stock. The initial “exercise price” is $0.40 per share of common stock, as the same may be adjusted from time to time pursuant to the terms and conditions of the warrant. On November 12, 2013, the OID promissory note was paid in full with financing received in connection with the sale and issuance of Series A Preferred Stock and warrants to purchase shares of the Company’s Common Stock pursuant to the Securities Purchase Agreement dated and signed on November 12, 2013 with certain funds and accounts as to which Great Point Partners, LLC acts as an investment manager. As mentioned above, the Company issued 175,000 free standing and detachable warrants related to the convertible promissory note. The Company will account for these warrants issued in accordance with the US GAAP accounting guidance under ASC 815 applicable to derivative instruments, which requires every derivative instrument within its scope to be recorded on the balance sheet as either an asset or liability measured at its fair value, with changes in fair value recognized in earnings. Based on this guidance, the Company determined that the Company's warrants do not meet the criteria for classification as equity. Accordingly, the Company classified the warrants as current liabilities. The warrants are subject to re-measurement at each balance sheet date, with any change in fair value recognized as a component of other income (expense), net in the statements of operations. We will estimate the fair value of these warrants at the respective balance sheet dates, based on the estimated market value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates and expected dividends on and expected volatility of the price of the underlying common stock.
On November 12, 2013, the Company entered into a Securities Purchase Agreement (SPA) for the equity sale of Series A Convertible Preferred Stock and warrants to purchase shares of the Company’s common stock. The Company sold 13,500,000 of Series A 8% Convertible Preferred stock and warrants to purchase 27,000,000 shares of the Company’s common stock for gross proceeds of $5,400,000. The net proceeds to the Company after debt offering costs are $4,885,000. The preferred stock is convertible into Common on a 2 for 1 basis. The Company recorded a beneficial conversion value for the preferred stock of approximately $2.6 million as an immediate charge to accumulated deficit as it is considered a constructive dividend to Series A preferred stockholders. The net raise is sufficient to fund on-going operations for the next several months. However, the funding is not sufficient to alleviate the going concern issue. As part of this equity financing transaction, the Company issued 27,000,000 warrants with immediate vesting rights to convert into common shares at an initial exercise price of $0.30 per share under price protection provisions. The warrants also contain cashless exercise provisions. The Company will account for these warrants issued in accordance with the US GAAP accounting guidance under ASC 815 applicable to derivative instruments, which requires every derivative instrument within its scope to be recorded on the balance sheet as either an asset or liability measured at its fair value, with changes in fair value recognized in earnings. Based on this guidance, the Company determined that the Company's warrants do not meet the criteria for classification as equity. Accordingly, the Company classified the warrants as current liabilities. The warrants are subject to re-measurement at each balance sheet date, with any change in fair value recognized as a component of other income (expense), net in the statements of operations. We estimated the fair value of these warrants at the issuance date at approximately $2,820,000 which will be reclassified from equity. The warrants will be revalued on the respective balance sheet dates, based on the estimated market value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates and expected dividends on and expected volatility of the price of the underlying common stock. The SPA contains registration rights requiring registration within 30 days of the funding date and effectiveness within 90 days of the filing date. The registration rights agreement contains a liquidated damage provision whereby the Company must pay 1% per month of the investment amount if not filed or effective within stipulated time frames.
The Company owes its CEO $75,000 as stated in the February 2012 merger agreement, which is accrued in the accompanying unaudited condensed consolidated Financial Statements as Due to officer. The balance due to the Company’s CEO was formalized in a promissory note in November 1, 2013. In Addition, the Company owes its President $40,000 for a promissory note dated November 1, 2013 for funds advanced in September 2013. On November 12, 2013, the promissory notes for the CEO and the president were paid in full from the net proceeds of the Securities Purchase Agreement; no interest was accrued for the notes, as it was immaterial.
HEALTH REVENUE ASSURANCE HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2012

INDEX TO FINANCIAL STATEMENTS

To the Board of Directors and Stockholders of:
Health Revenue Assurance Holdings, Inc.

We have audited the accompanying consolidated balance sheet of Health Revenue Assurance Holdings, Inc. and Subsidiaries as of December 31, 2012, and the related consolidated statements of operations, changes in stockholders’ equity (deficit) and cash flows for the year then ended.  These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement.  An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall consolidated financial statement presentation.  We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Health Revenue Assurance Holdings, Inc. and Subsidiaries as of December 31, 2012, and the consolidated results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.  As discussed in Note 1 to the consolidated financial statements, the Company has a net loss and net cash used in operating activities in 2012 of $1,457,470 and $1,699,466, respectively, and has an accumulated deficit of $2,584,798 at December 31, 2012. These matters raise substantial doubt about the Company's ability to continue as a going concern. Management’s Plan in regards to these matters is also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
/s/ Salberg & Company, P.A.
SALBERG & COMPANY, P.A.
Boca Raton, Florida
April 1, 2013
2295 NW Corporate Blvd., Suite 240 ● Boca Raton, FL 33431-7328
Phone: (561) 995-8270 ● Toll Free: (866) CPA-8500 ● Fax: (561) 995-1920
www.salbergco.com • info@salbergco.com
Member National Association of Certified Valuation Analysts ● Registered with the PCAOB
Member CPA Connect with Affiliated Offices Worldwide ● Member AICPA Center for Audit Quality

To the Board of Directors and Stockholders
Health Revenue Assurance Holdings, Inc. (f/k/a Anvex International, Inc.)

We have audited the accompanying consolidated balance sheet of Health Revenue Assurance Holdings, Inc. and Subsidiaries (f/k/a Anvex International, Inc.) (the “Company”) as of December 31, 2011, and the related consolidated statements of operations, stockholders’ equity, and cash flows for the year then ended. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.  The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.  Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting.  Accordingly, we express no such opinion.  An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.  We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2011, and the results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

/s/  Friedman LLP
Marlton, NJ
April 16, 2012
CONSOLIDATED BALANCE SHEETS
  December 31,  December 31, 
  2012  2011 
Assets      
       
Cash $893,458  $198,500 
Accounts receivable  1,246,814   143,557 
Prepaid expenses  3,600   24,512 
Other current assets  688   5,842 
    Total Current Assets  2,144,560   372,411 
         
Property and Equipment, net  365,017   352,499 
         
Software  258,933   - 
Other assets  8,871   8,865 
Finance costs, net  2,477   2,803 
Total Other Assets  270,281   11,668 
         
Total Assets $2,779,858  $736,578 
         
Liabilities and Stockholders' Equity (Deficit)        
         
Accounts payable $207,741  $195,901 
Due to officer  75,000   - 
Accrued expenses  64,077   23,266 
Accrued payroll  412,186   73,685 
Loan payable to factor  827,075   - 
Accrued interest  4,524   - 
Line of credit, current portion  25,000   98,500 
Capital Leases, current portion  16,923   - 
Notes payable, current portion, net of discount  202,557   - 
Long term debt, current portion  37,513   283,640 
Advances on convertible promissory notes  -   170,000 
Settlement Payable  115,278   - 
Unearned revenue  -   32,988 
Total Current Liabilities  1,987,874   877,980 
Capital Leases (net of current portion)  23,974   - 
Line of credit (net of current portion)  125,000   - 
Notes payable (net of current portion), net of discount  273,751   - 
Long term debt (net of current portion)  181,457   218,417 
Total Liabilities $2,592,056  $1,096,397 
         
Commitments and Contingencies (see Note 11)        
         
Stockholders' Equity (Deficit):        
Common stock ($0.001 par value, 75,000,000 shares authorized, 39,054,867 shares and 16,499,021 issued and outstanding at December 31, 2012 and 2011, respectively)      39,055         16,499   
Additional paid-in capital  2,738,545   751,010 
Subscription receivable  (5,000)  - 
Accumulated deficit  (2,584,798)  (1,127,328)
Total Stockholders' Equity (Deficit)  187,802   (359,819)
         
Total Liabilities and Stockholders' Equity (Deficit) $2,779,858  $736,578 

The accompanying notes are an integral part of these consolidated financial statements.
CONSOLIDATED STATEMENTS OF OPERATIONS
  For the Year-Ended 
  December 31,  December 31, 
  2012  2011 
       
Revenues $5,806,848  $1,432,773 
         
Cost of Revenues  2,830,008   473,719 
Gross Profit  2,976,840   959,054 
         
Operating Expenses        
Selling and administrative expenses (includes stock compensation of $0 and $818,595 in 2012 and 2011, respectively)  3,853,820   1,976,655 
Research and development  64,386   93,489 
Depreciation and amortization  50,765   31,362 
Total Operating Expenses  3,968,971   2,101,506 
         
Operating Loss  (992,131)  (1,142,453)
         
Other Income (Expense)        
Other income  10   - 
Interest expense  (465,349)  (29,468)
Total Other Income (Expense), net  (465,339)  (29,468)
         
Income (Loss) before provision for income taxes  (1,457,470)  (1,171,921)
         
Provision for income taxes  -   - 
         
Net Income (Loss) $(1,457,470) $(1,171,921)
         
Net Loss Per Share        
basic and diluted $(0.04) $(0.08)
Weighted Average Number of Shares Outstanding        
basic and diluted  32,730,809   14,450,235 
The accompanying notes are an integral part of these consolidated financial statements.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)
FOR THE YEARS ENDED DECEMBER 31, 2012 and 2011
  Common Stock  Additional  Subscription  Accumulated  
Total
Stockholders'
 
  Shares  Amount  Paid-in Capital  Receivable  Deficit  Equity (deficit) 
                   
Balance at December 31, 2010  13,199,206  $13,199  $73,210  $-  $44,593  $131,002 
                         
Issuance of stock for services to officer  3,299,815   3,300   815,295   -   -   818,595 
                         
S-corp distributions  -   -   (137,495)  -   -   (137,495)
                         
Net loss 2011  -   -   -   -   (1,171,921)  (1,171,921)
                         
Balance at December 31, 2011  16,499,021   16,499   751,010   -   (1,127,328)  (359,819)
                         
Recapitalization  13,499,226   13,499   (13,499)  -   -   - 
                         
2011 bridge note converted in 2012 related to reverse merger  1,343,729   1,344   248,656   -   -   250,000 
                         
Issuance of common stock for cash  4,352,312   4,352   1,051,742   -   -   1,056,094 
                         
Repayment of advances with shares  1,265,381   1,266   312,642   -   -   313,908 
                         
Value of beneficial conversion feature in convertible debt  -   -   300,000   -   -   300,000 
                         
Repurchase of shares pursuant to settlement agreement  (3,299,802)  (3,300)  (229,200)  -       (232,500)
                         
Conversion of convertible debt  3,000,000   3,000   297,000   -   -   300,000 
                         
Shares issued to lender as fees  2,375,000   2,375   341,125   -   -   343,500 
                         
Offering costs paid  -   -   (325,911)  -   -   (325,911)
                         
Subscription receivable  20,000   20   4,980   (5,000)  -   - 
                         
Net Loss 2012                  (1,457,470)  (1,457,470)
                         
Balance at December 31, 2012  39,054,867  $39,055  $2,738,545  $(5,000) $(2,584,798) $187,802 

The accompanying notes are an integral part of these consolidated financial statements.
CONSOLIDATED STATEMENTS OF CASH FLOWS
  For the Year-Ended 
  December 31,  December 31, 
  2012  2011 
Cash flows from Operating Activities:      
Net loss $(1,457,470) $(1,171,921)
Adjustments to reconcile net loss to net cash used in operating activities:
        
Depreciation and amortization  50,765   31,362 
Stock issued for compensation  -   818,595 
Amortization of debt discount  304,808   - 
Change in operating assets and liabilities:        
Accounts receivable, net  (1,103,257)  50,693 
Prepaid expenses  20,912   (24,512)
Other assets  5,146   (7,389)
Accounts Payable Related Party  75,000   - 
Accounts payable  53,783   204,618 
Unearned revenue  (32,988)  32,988 
Accrued liabilities  383,835   - 
Net Cash used in operating activities  (1,699,466)  (65,566)
         
Cash flows from Investing Activities:        
Capitalization of internally developed software  (258,933)  - 
Purchases of property and equipment  (20,985)  (47,016)
Net Cash used in investing activities  (279,918)  (47,016)
         
Cash flows from Financing Activities:        
Borrowings from long-term debt obligations  51,500   262,500 
Payment for repurchase of common stock  (94,165)  - 
Loan proceeds  1,193,908   - 
Loan proceeds from factor, net  827,075   - 
Repayments of debt obligations  (33,087)  (38,715)
Proceeds from convertible promissory notes  -   170,000 
Issuance of stock for cash net of offering cost  730,183   - 
Payments on  Capital Leases  (1,072)  - 
Payments of stockholder distributions  -   (137,495)
Net Cash provided by (used in) financing activities  2,674,342   256,290 
         
Net Increase (decrease) in cash  694,958   143,708 
Cash at beginning of year  198,500   54,792 
Cash at end of year $893,458  $198,500 
         
Supplemental schedule of cash paid during the year for:        
Interest $36,156  $24,407 
Income Taxes $-  $- 
Supplemental schedule of non-cash investing and financing activities:        
Issuance of stock to repay debt $563,908  $- 
Capital lease obligation incurred for use of equipment $38,704  $- 
Beneficial conversion feature on convertible debt charged to additional paid in capital $300,000  $- 
Shares issued as loan fee $343,500  $- 
Conversion of $300,000 notes to common stock $300,000  $- 
Transfer of accounts payable to notes payable $65,000  $- 
The accompanying notes are an integral part of these consolidated financial statements.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011
1 – NATURE OF BUSINESS AND GOING CONCERN

Overview
Health Revenue Assurance Holdings, Inc. (the “Company”) is a trusted source of timely, accurate and critical resources, technology and information that supports the performance of revenue integrity in assuring the existence of healthcare organizations. The company and its subsidiaries’ products and services include business intelligence technology solutions, contract coding, billing, coding and compliance audits, education, revenue cycle consulting, physician services and ICD-10 transition services. The Company provides customized solutions to its clients with the highest regard for ethical standards and responsibility.
On August 15, 2011, Health Revenue Assurance Associates, Inc. (HRAA) the Company's subsidiary, entered into an Agreement and Plan of Merger with HRM, LLC, a Colorado limited liability corporation. HRAA was the surviving entity with HRM, LLC ceasing to exist.  HRM, LLC was inactive with no assets or liabilities and accordingly the shares issued to the owner of HRM, LLC were accounted for as compensation under an employment agreement with that owner.
Dream Reachers, LLC, owns the Company’s offices and is the borrower on a mortgage loan related to such offices. Dream Reachers, LLC does not engage in real estate rental business. Its offices are occupied by HRAA at no cost and HRAA pays the related mortgage’s principal and interest, taxes and maintenance. The Company’s subsidiary HRAA is the sole member effective May 2011. Dream Reachers has been treated as a Subsidiary for accounting purposes in the Company’s consolidated financial statements for all periods presented. (see Note 2)
On February 10, 2012, HRAA entered into a Merger agreement with Health Revenue Assurance Holdings, Inc. (formerly known as Anvex International, Inc.) "HRAH" (a Nevada incorporated publicly-held company) and its subsidiary Health Revenue Acquisition Corporation (Acquisition Subsidiary) which was treated for accounting purposes as a reverse recapitalization with HRAA considered the accounting acquirer.  Each share of HRAA's common stock was exchanged for the right to receive approximately 1,271 shares of HRAH’s common stock. Before their entry into the Merger Agreement, no material relationship existed between HRAH or Acquisition Sub and HRAA. (see Note 11)

On April 13, 2012, the Company’s Board of Directors unanimously approved a change in the Company’s name from Anvex International, Inc. to Health Revenue Assurance Holdings, Inc.

On April 13, 2012, the Company’s Board of Directors authorized a 12.98 for 1 split of its common stock to stockholders of record as of April 13, 2012. Shares resulting from the split were issued on April 26, 2012. In connection therewith, the Company transferred $32,747 from additional paid in capital to common stock, representing the par value of additional shares issued. As a result of the stock split, fractional shares were rounded up. All share and per share amounts for all periods presented have been retroactively adjusted to reflect the stock split. (see Note 12)

Going Concern

The Company’s future success is dependent upon its ability to achieve profitable operations and generate cash from operating activities, and upon additional financing, management believes they can raise the appropriate funds needed to support their business plan and develop an operating company which is cash flow positive.

However, as of December 31, 2012, the Company has a stockholders' deficit and for the year-ended ended December 31, 2012, incurred substantial net losses, and has used net cash in operations.  The Company has not been able to generate sufficient cash from operating activities to fund its ongoing operations. There is no guarantee that the Company will be able to generate enough revenue and/or raise capital to support its operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

The consolidated financial statements do not include any adjustments relating to the recoverability or classification of recorded assets and liabilities that might result should the Company be unable to continue as a going concern.
As of December 31, 2012 the Company has a cash balance of approximately $894,000, of which $815,000 was received from new loans in December 2012. In January and February 2013, the Company received an additional $1,220,000 in loan proceeds from various investors.
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Health Revenue Assurance Associates, Inc. and Dream Reachers, LLC. All significant inter-company transactions and balances are eliminated in consolidation.
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011
Consolidation of Variable Interest Entities

Effective January 1, 2010, the Company adopted new provisions of the consolidation guidance included in Accounting Standards Codification 810, Consolidations, that amended the consolidation guidance applicable to VIEs and the definition of a VIE, and requires enhanced disclosures to provide more information about an enterprise's involvement in a VIE. Under the consolidation guidance, the Company must make an evaluation of these entities to determine if they meet the definition of a VIE. Generally, a VIE is an entity with one or more of the following characteristics: (a) the total equity investment at risk is not sufficient to permit the entity to finance its activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about an entity's activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests and substantially all of the entity's activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. Dream Reachers became a wholly owned subsidiary in May 2011 but previously was treated as a VIE. The carrying amount and classification of the assets and liabilities of Dream Reachers, LLC included in the Consolidated Balance Sheets are approximately:
  December 31, 
  2012  2011 
Total assets $211,000  $230,000 
Total liabilities $182,000  $185,000 
Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements.  Actual results could differ from those estimates. Significant accounting estimates reflected in the Company’s consolidated financial statements include valuation of accounts receivable, valuation of property and equipment, valuation and amortization period of software, valuation of beneficial conversion features in convertible debt, valuation of equity based instruments issued for other than cash, revenue recognition, and the valuation allowance on deferred tax assets.

Cash

For purposes of the statement of cash flows, the Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company’s cash balances are maintained at various banks that are insured by the Federal Deposit Insurance Corporation subject to certain limitations.

Accounts Receivable and Factoring

Accounts receivable are stated at the amounts management expects to collect.  An allowance for doubtful accounts is recorded using a specific identification method based on a combination of historical experience, aging analysis and information on specific accounts.  Account balances are written off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.  Management has determined that no allowance is required at December 31, 2012 and December 31, 2011. The Company accounts for its factoring arrangements as either a sale or a secured financing based on the criteria in ASC 860 "Transfers and Servicing".  Estimates of allowances for doubtful accounts are reflected as a recourse obligation, a liability, for factor arrangements treated as a sale with recourse or as a contra asset accounts receivable allowance account for arrangements accounted for as a secured financing.

Property and Equipment

Property and equipment is recorded at cost. Depreciation is computed using the straight-line method over estimated useful asset lives, which range from 5 to 39 years.  Repairs and maintenance are expensed, while additions and betterments are capitalized.  The cost and related accumulated depreciation of assets sold or retired are eliminated from the accounts and any gains or losses are reflected in earnings.

Leases

We perform a review of newly acquired leases to determine whether a lease should be treated as a capital or operating lease. Capital lease assets are capitalized and depreciated over the term of the initial lease. A liability equal to the present value of the aggregated lease payments is recorded utilizing the stated lease interest rate. If an interest rate is not stated, we will determine an estimated cost of capital and utilize that rate to calculate the present value. If the lease has an increasing rate over time, and (or) is an operating lease, all leasehold incentives, rent holidays, or other incentives will be considered in determining if a deferred rent liability is required. Leasehold incentives are capitalized and depreciated over the initial term of the lease.
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011
Software

Costs incurred in connection with the development of software products are accounted for in accordance with the Financial Accounting Standards Board Accounting Standards Codification ("ASC") 985   Costs of Software to Be Sold, Leased or Marketed.”   Costs incurred prior to the establishment of technological feasibility are charged to research and development expense. Software development costs are capitalized after a product is determined to be technologically feasible and is in the process of being developed for market and capitalization ceases after the general release of the software. Amortization of capitalized software development costs begins upon initial product shipment. Capitalized software development costs are amortized over the estimated life of the related product (generally thirty-six months) using the straight-line method. The Company evaluates its software assets for impairment whenever events or change in circumstances indicate that the carrying amount of such assets may not be recoverable.  Recoverability of software assets to be held and used is measured by a comparison of the carrying amount of the asset to the future net undiscounted cash flows expected to be generated by the asset.  If such software assets are considered to be impaired, the impairment to be recognized is the excess of the carrying amount over the fair value of the software asset. 
Software maintenance costs are charged to expense as incurred. Expenditures for enhanced functionality are capitalized. The cost of the software and the related accumulated amortization are removed from the accounts upon retirement of the software with any resulting loss being recorded in operations.  No amortization expense was recorded in the accompanying consolidated financial statements as the software had yet to be placed in service.

Long-Lived Assets

The Company reviews the carrying value of its long-lived assets whenever events or changes in circumstances indicate that the carrying values may no longer be appropriate.  Recoverability of carrying values is assessed by estimating future net cash flows from the assets. Impairment assessment inherently involves judgment as to assumptions about expected future cash flows and the impact of market conditions on those assumptions.  Future events and changing market conditions may impact management's assumptions as to sales prices, rental rates, costs, holding periods or other factors that may result in changes in the Company’s estimates of future cash flows.  Although management believes the assumptions used in testing for impairment are reasonable, changes in any one of the assumptions could produce a significantly different result.

Fair Value Measurements and Fair Value of Financial Instruments

Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  The Company classifies assets and liabilities recorded at fair value under the fair value hierarchy based upon the observability of inputs used in valuation techniques.  Observable inputs (highest level) reflect market data obtained from independent sources, while unobservable inputs (lowest level) reflect internally developed market assumptions. The fair value measurements are classified under the following hierarchy:
Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets and liabilities in active markets;
Level 2—Observable inputs, other than quoted market prices, that are either directly or indirectly observable in the marketplace for identical or similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities; and
Level 3—Unobservable inputs that are supported by little or no market activity that are significant to the fair value of the assets or liabilities.


The estimated fair valuecarrying amount of certainthe Company’s financial instruments including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values becausevalue as of December 31, 2021 and December 31, 2022, due to the short-term nature of these instruments.

NOTE 3 – RELATED PARTY RECEIVABLE

On July 7, 2021, the company has entered into an agreement to purchase 100% of the Preferred A-1 Stock of Health Revenue Assurance Holdings, Inc. a SEC registered company for $450,000. In March 2022, Health Revenue Assurance Holdings, Inc. name was changed to Ameriguard Security Services Inc. (AGSS). On December 9, 2022, we signed the definitive merger agreement initiating a reverse merger with AGSS, resulting in the Company becoming a 100% owned subsidiary of AGSS. Prior to the merger, the Company funded the operational expenses of AGSS and treated these expenses as related party expenses. These expenses we eliminated when the two companies were consolidated for the financial statement presentation.

The receivable balances on December 31, 2022, and 2021 were $57,971 and $10,596 respectively.

F-9

Revenue Recognition

NOTE 4 – FIXED ASSETS

Fixed assets consist of the following on December 31, 2022, and 2021:

Schedule of Fixed assets        
  2021  2020 
Leasehold Improvements  224,132   - 
Machinery and Equipment  278,551   246,974 
Vehicles  110,274   131,775 
Total Fixed Assets  612,957   378,749 
Accumulated Depreciation  (314,151)  (245,947)
Fixed Assets, Net $298,806  $132,802 

NOTE 5 – PAYROLL LIABILITY – PENSION

The Company recognizes services revenuecompany offers various pension plans to employee groups based on location of employment. Corporate office employees and guards have an option to participate in a 401K sponsored by the proportional performance methodcompany with a matching program up to 5% of recognizing revenue.

A portionemployee salary. Federal contracts have union agreements that define the pension calculation and due dates. It is the responsibility of the Company’s revenue is generated from medical coding audit services. Auditing revenue is invoiced in accordance withcompany to calculate the contract, generally at three benchmark time periods which coincide with when specific, obligatory field work services have been renderedpension benefit amount each month and completed,contribute the value of this portion of the contract price has been predetermined and agreed upon, and the client has received benefit or value in the form of the independent identification of system weaknesses and risk analysis. Further, collectability is reasonably assuredamount due to the existence of a fixed fee contract and the size and financial health of the Company’s clients. Below is a description of the general benchmarks and work phases associated with the Company’s audit services:

Planning Phase - work commences prior to and as soon as the contract is signed and includes setting the audit scope, scheduling of the job, assignment of audit staff, understanding the client and their systems, determination of sample size and sampling methods to be employed, and other specific items as outlined in the contract. The planning phase includes the determination of deliverables as defined in the contract, generally consisting of a listing of errors, training and a final report. The Company generally invoices and recognizes 50% of the contract value at the completion of the Planning Phase. Although all of the contracts contain a clause making the first 50% of the engagement feeplan designated. The pension balances due and non-refundable at this point, the Company does not deem this initial fee to be recognized as deferred revenue under SAB 104 due to the extensive amount of work to be done prior to accepting the contract.
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011
 ●
Field Work Phase – is performed at the client location and generally lasts one week and encompasses actual testing of sample claims preselected in the Planning Phase. The auditor generally preloads the selected claims into the Company’s proprietary software and audits the claim records by reviewing actual medical records. The software assists the auditor in determining proper classifications and allows the auditor to compare the proper classification against what was filed in the submission made by the client to Medicare. Notes and comments are recorded and audit reports are generated. The Company generally invoices and recognizes 40% of the contract value at the completion of the Field Work Phase.
 ●Reporting Phase – includes a summary of audit findings, exit conference with clients, and any other specific deliverables as determined by the contract. The Company generally invoices and recognizes the remaining 10% of the contract value at the completion of the Report Phase.

A portion of the Company’s revenue is derived from consulting, training and coding services provided. Revenue from these revenue streams is recognized after services are performed based on the quoted and agreed upon fee contained in its contracts.
The Company intends a general release of its first software product in early 2013.  Software sales on a standalone basis will be recognized upon delivery of the software when evidence of the purchase arrangement exists and the price is determinable, and when collectability is reasonably assured.

Arrangements with customers may involve multiple elements including software sales, training, software product maintenance, coding services, coding audit services and other consulting services. Training and maintenance on software products will generally occur after the software product sale while other services may occur before or after the software product sale and may not relate to the software product.  Revenue recognition for multiple element arrangement is as follows:

Each element is accounted for separately when each element has value to the customer on a standalone basis and there is Company specific objective evidence of selling price of each deliverable. For revenue arrangements with multiple deliverables, the Company allocates the total customer arrangement to the separate units of accounting based on their relative selling prices as determined by the price of the items when sold separately. Once the selling price is allocated, the revenue for each element is recognized using the general and specific criteria under GAAP as discussed above for elements sold in non-multiple element arrangements. A delivered item or items that do not qualify as a separate unit of accounting within the arrangement are combined with the other applicable undelivered items within the arrangement. The allocation of arrangement consideration and the recognition of revenue is then determined for those combined deliverables as a single unit of accounting.  The Company has historically sold its services with established rates which it believes is Company specific objective evidence of selling price. For the new software products, management has established selling prices which qualifies as Company specific objective evidence of selling price. Generally all elements in multiple element arrangements with Company customers qualify as separate units of account for revenue recognition purposes.
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011
Cost of Revenues

Cost of revenues includes labor costs. There were no depreciation or amortization costs in 2012 or 2011 that were allocable to cost of sales. In future periods, amortization of capitalized software costs will be included in costs of revenues.
Stock-Based Compensation

Stock-based compensation expense is measured at the grant date fair value of the award and is expensed over the requisite service period.  For employee stock-based awards, the Company calculates the fair value of the award on the date of grant using the Black-Scholes option pricing model.  Determining the fair value of stock-based awards at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates.  The assumptions used in calculating the fair value of stock-based awards represent the Company's best estimates, but these estimates involve inherent uncertainties and the application of management judgment.  For non-employee stock-based awards, the Company calculates the fair value of the award on the date of grant in the same manner as employee awards, however, the awards are revalued at the end of each reporting period and the prorata compensation expense is adjusted accordingly until such time the non-employee award is fully vested, at which time the total compensation recognized to date shall equal the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete.  The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.
Research and Development Costs
In accordance with ASC 730-10, Research and development costs are expensed when incurred.  Total research and development costs for the years ended December 31, 20122022, and 2011 were $64,3862021 for all plans was $453,965 and $93,489$616,579 respectively.
Advertising
The cost of advertising is expensed as incurred. Advertising and marketing expenses amounted to approximately $130,000 and $116,000 for the year ended December 31, 2012 and 2011, respectively and is included

NOTE 6 – NOTES PAYABLE

In June 2020, AmeriGuard Security Services, Inc. received an SBA Loan through Fresno First Bank in selling and administrative expenses.

Income Taxes

The Company elected to convert from a Subchapter S corporation for Federal income tax purposes to a C corporation effective October 21, 2011.  Upon our C coloration election, we began to use the asset and liability method to account for income taxes. Under this method, deferred income taxes are determined based on the differences between the tax basis of assets and liabilities and their reported amounts in the consolidated financial statements which will result in taxable or deductible amounts in future years and are measured using the currently enacted tax rates and laws. A valuation allowance is provided to reduce net deferred tax assets to the amount that, based on available evidence, is more likely than not to be realized.

The Company follows the provisions of ASC 740-10, Accounting for Uncertain Income Tax Positions. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of $1,080,000 that was used to close out the position that would be ultimately sustained. In accordanceCitibank loan in the amount of $312,339 with the guidance of ASC 740-10, the benefit ofremaining balance after expenses held in reserve. The SBA loan is a tax position10-year loan with monthly principal and interest payments. Interest rate is recognized in the financial statements  in the period during which, basedvariable at prime rate plus 2.75%, adjusted every calendar quarter. Interest rate on all available evidence, management believes it is more likely than not that the position will be  sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or  aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest  amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The  portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as  a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interestDecember 31, 2022, and penalties that would  be payable to the taxing authorities upon examination.
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011
Earnings Per Share
The Company computes2021 was 9% and presents earnings or losses per share in accordance with FASB ASC Topic 260, Earnings per share .  Basic earnings or losses per share are computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding.  Diluted earnings or loss per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares and common stock equivalents outstanding, calculated4.01% respectively. Balance remaining on the treasury stock method for optionsSBA loan was $804,387 and warrants using the average market prices during the period.

As the Company incurred a net loss in all periods presented, all potentially dilutive securities were excluded from the computation of diluted loss per share since the effect of including them is anti-dilutive. There were no dilutive securities outstanding at December 31, 2012 and 2011 respectively.

Segment Reporting

Financial Accounting Standards Board (“FASB”) ASC Topic 280, Segment Reporting (“ASC 280”), establishes standards for the way public business enterprises report information about operating segments. ASC 280 also establishes standards for related disclosures about products and services, geographic areas and major customers. The Company has determined that based on these criteria it only operates one segment, consulting services, as all other services do not meet the minimum threshold for separate reporting of a segment.

Contingencies

We accrue for contingent obligations, including legal costs and restructuring costs, when the obligation is probable and the amount can be reasonably estimated. As facts concerning contingencies become known we reassess our position and make appropriate adjustments to the consolidated financial statements. Estimates that are particularly sensitive to future changes include those related to tax, legal, and other regulatory matters that are subject to change as events evolve and additional information becomes available.

Recent Accounting Pronouncements

We have implemented all new accounting standards that are in effect and that may impact our consolidated financial statements and do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our consolidated financial position or results of operations.

3 - ACCOUNTS RECEIVABLE

Accounts receivable at December 31, 2012 and 2011 was as follows:
  2012  2011 
Accounts receivable $1,246,814  $143,557 
Allowance for doubtful accounts  -   - 
 Total $1,246,814  $143,557 

Bad debt expense on trade accounts receivable for 2012 and 2011 was $0, respectively. (See Note 9)
4 - PROPERTY AND EQUIPMENT

Property and equipment consists of the following:

  December 31, 
  2012  2011 
Building and improvements $227,603  $227,603 
Furniture  119,810   118,187 
Computers and Equipment  160,469   99,316 
   507,882   445,106 
Less - Accumulated depreciation  (142,865  (92,607
Total $365,017  $352,499 

Depreciation expense for the years ended December 31, 2012 and 2011 was approximately $51,000 and $31,000, respectively.
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011
5 – RESEARCH AND DEVELOPMENT AND SOFTWARE

Early 2012, the Company started developing the Visualizer™ suite. This intuitive and easy to use business intelligence product is designed to meet the emerging need for healthcare analytics. Customer data is infused into the suite, and the Company uses this to develop pre-defined analytics targeted to address healthcare’s emerging concerns and needs.

HRAA’s Visualizer™ suite will encompass multiple offerings. The first project currently under development is ICD Visualizer™, which assists healthcare leaders with their need to understand the exponential impact of the transition to ICD-10 including work flow, productivity, process changes and documentation and reimbursement risks. The application helps to visualize the reimbursement and operational effects of transitioning organizations to ICD-10 and identify where to focus education and documentation issues. It enables clients to develop a custom work plan to mitigate risks from the highest areas of exposure to the least.

At December 31, 2012, the Company had accumulated $258,933 of capitalized costs related to the development of the Visualizer™ suite which is included as Software on the accompanying consolidated balance sheet.

Amortization expense for software, for the years ended December 31, 2012 and 2011 was $0, respectively as there has not been a general release of the software for sale$888,845 as of December 31, 2012.  Software consisted of the following at December 31, 20122022, and 2011:

  December 31, 2012  December 31, 2011 
Software $258,933  $- 
Accumulated amortization  -   - 
Software, net $258,933  $- 
The following is a schedule of estimated future amortization expense of software at December 31, 2012 (assumes amortization begins2021 respectively.

In January 1, 2013):


Estimated amortization expense of software is as follows:
Year Ending December 31,   
2013 $86,311 
2014  86,311 
2015  86,311 
Total $258,933 
6 – LINE OF CREDIT

The Company has a $150,000 revolving line of credit with a bank, effective in December 2008, for its general working capital needs. The line of credit is secured by all business assets, collateral, and personal guarantees. The line of credit matured on December 18, 2009 and was renewed and was due on December 18, 2012. The revolving line was modified on December 18, 2012 so that the loan no longer has an expiration date of December 18, 2012, but instead, a final maturity date of December 18, 2018. The interest rate per year is equal to the Bank’s Prime Rate plus 6.50 percent. The Bank’s prime rate of interest at December 31, 2012 was 3.25%. The balance due at December 31, 2012 was $150,000 with $25,000 reflected as a current portion. The first of seventy-two payments, being $2,083 was due January 18, 2013.
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011
7 – LONG TERM DEBT AND NOTES PAYABLE

Long Term debt:

Long Term debt consisted of the following at December 31, 2012:
  
December 31,
 2012
  
December 31,
 2011
 
Bank term loan $38,897  $66,245 
Convertible Bridge Loan  -   250,000 
Mortgage loan  180,073   185,812 
   218,970   502,057 
Less current portion  (37,513)  (283,640)
Total long term portion $181,457  $218,417 
On August 23, 2011,2020, the Company entered into a Letter of Intentfinancing agreement with Master Security Company for the purchase of vehicles, guns, and guard equipment for the National Institute of Health USEPA contract which began May 2020. The principal financed was $150,000, with interest of 4% for a private equity group relating toterm of 21 months. Resulting in a possible equity transaction. On September, 13, 2011,monthly principal and interest payment of $7,406. Balance remaining in connection with this contemplated transaction, the Company received a $150,000 bridge loan (the “Initial Bridge Loan”) from the private equity group.  The Initial Bridge Loan is secured by a promissory note for the amount of the loan, incurs interest at 12% per annum$0 and matures on$7,729 as of December 31, 2014.  On October 21, 2011, the Initial Bridge Loan was repaid.

On October 21, 2011,2022, and 2021 respectively.

In December 2021, the Company entered into a second Bridge Loanfinancing agreement (the “Bridge Loan”)with Secure Transportation Inc. for the purchase of three used vehicles in the amount of $250,000$21,500. Note requires 12 equal payments of $1,900 with a third party lender. The primary purpose is to repaycalculated interest rates of 5% with the Initial Bridge Loan and to pay for certain professional fees in connection with a reverse merger with a Public Company. The Bridge Loan incurs interest at the rate of 12% per annum which will be due onlyfirst payment December 15, 2021. Balance remaining in the event the contemplated equity transaction does not materialize. Upon the closing of the transaction, all interest accrued but not paid shall be deemed cancelled and paid in full and the entire principal amount of the note shall be automatically converted into an aggregate of 1,343,749 shares of common stock at a conversion price of $0.19 per share which is equal to a discount of 25% of to the Purchase Price. The loan was converted to stock in February 2012 (See Note 12).


The Company has a term loan with a bank whose proceeds were used for general working capital needs (the “Term Loan”).  The Term Loan was established in March 2009 as a result of a conversion of a revolving line of credit.  The Term Loan is personally guaranteed by one of the Company’s stockholders$0 and is collateralized by the assets of the Company.  Payments of principal and interest are approximately $2,700 per month. The Term Loan matures in five years and incurs interest at the rate of 6.75% per annum.  Balances due$19,615 as of December 31, 2012 was approximately $39,0002022, and is allocated to the current and long term debt line items in the accompanying consolidated balance sheet.

The Company has a mortgage related to certain real estate which houses the Company’s main offices in Plantation, Florida.  The loan originated2021 respectively.

On July 2010 in the amount of $192,500 and matures July 2020, when a balloon principal payment of approximately $129,000 becomes due.  The loan is collateralized by the real estate and is personally guaranteed by the stockholder of the Company. Interest is fixed at 6.625% for the first five years of the loan, and converts to an adjustable rate for the second five years at the Federal Funds Rate plus 3.25%, as established by the United State Federal Reserve. The balance under this mortgage loan as of December 31, 2012 was approximately $180,000 and is allocated to the current and long term debt line items in the accompanying consolidated balance sheet. Monthly payments for principal and interest are approximately $1,500 until July 2015, when the total monthly payment may vary due to the adjustable interest rate provision in the note.


Notes payable:

In December 2012,7, 2022, the Company entered into loan agreementsa buyout agreement with various investors and issued promissory notes upon receipt of $815,000.a shareholder Lillian Flores. The loan agreements have an interest rate of 12% per annum.  Principal and interest is payable over 26 months. Additionally, in connection with the financing, the Company issued 2,375,000 shares of common stock to the lenders as loan fees (See note 12). The fair value per share of $0.28 (based on recent cash sales prices)total buyout amount was used to compute the relative fair value$3,384,950 representing 45% of the shares in accordance with ASC 470-20 which totaled $343,500 which was recorded as a debt discount with a credit to additional paid-in-capital and such discount is being amortized over the term of the loans. The unamortized discount was $338,692 as of December 31, 2012 and the Company recorded $4,524 in accrued interest.

Notes payable consisted of the following at December 31, 2012:
  December 31, 2012 
Principal amount of notes payable $815,000 
Unamortized discount  (338,692
Notes payable, net of discount  476,308 
Less current portion  (202,557
Total long term portion $273,751 
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011
Future annual principal payments on long term debt as of December 31, 2012 are as follows:

2013 $375,564 
2014  420,954 
2015  74,321 
2016  6,848 
2017  7,322 
Thereafter  148,961 
Total $1,033,970 

8 – CAPITAL LEASES
The Company leases its property and equipment from Dell Financial Services L.L.C. under a capital lease. The economic substance of the lease is that the Company is financing the acquisition of the assets through the lease and accordingly, it is recorded in the Company’s assets and liabilities.
The following is an analysis of the leased assets included in Property and Equipment:
  
December 31,
 2012
 
Equipment  41,969 
Less accumulated depreciation  (5,926)
Total $36,043 
The lease agreement contains a bargain purchase option at the end of the lease term.
The following is a schedule by years of future minimum payments required under the lease together with their presentcalculated business value as of December 31, 2012:
Year Ending December 31:   
2013 $16,923 
2014  16,923 
2015  11,282 
Total minimum lease payments  45,128 
Less amount representing interest  (4,231)
     
Present value of minimum lease payments $40,897 
Amortization2020. Following the initial payment of assets held under capital leases$686,990, the company agreed to make 4 equal installments of principal and interest of $739,508 each December 31, starting 2023. Interest is included with depreciation expense and is approximately $9,000 and $0 for the year ended December 2012 and 2011, respectively.
9 – FACTORING AGREEMENT

In June 2012, the Company entered intocalculated at a one-year factoring agreement with a finance company.  The agreement automatically renews annually unless terminated by either party. Under the terms of the agreement, the Company, at its discretion, assigns the collection rights of its receivables to the finance company in exchange for an advancefixed rate of 85%3.110% compounded semi-annually. The company has accrued interest on December 31, 2022, of face value.  The assignments are transacted with recourse only at the option of the finance company$49,035. Balance remaining in the eventamount of non-payment.  $2,697.

The Company's obligations underfollowing schedule details the factor agreement are secured by substantially all assets of the Company.  In accordance with ASC 860 "Transfers and Servicing" regarding transfers of receivables with recourse, this factoring arrangement is accounted for as a secured financing. During 2012, the Company had factored approximately $3,850,000 of receivables and had received cash advances of approximately $3,272,000. Outstanding receivables purchased by the factorloans active as of December 31, 2012 were approximately $950,0002022, and included2021:

 Schedule of the loan active        
  2022  2021 
Current Portion:        
Notes and loans payable $719,563  $127,615 
Total Current Portion  719,563   127,615 
Long term Portion:        
Notes and loans payable  2,782,784   780,845 
Total Long-term Portion  2,782,784   780,845 
  $3,502,347  $908,460 

F-10

NOTE 7 – STOCKHOLDERS’ EQUITY

On December 9, 2022, the Company executed a reverse merger agreement with AGSS resulting in accounts receivablesignificant adjustments to the equity section of both companies. The result of the merger was AGSS became the sole owner of the Company. Although the merger is dated December 9, 2022, for financial statement presentation purposes, we have presented the Equity Section as if the merger occurred in 2021.

The first significant impact on stockholders’ equity was the issuance of 90,000,000 AGSS shares to the shareholders of Ameriguard Security Services, Inc (the Company) in exchange for 1000 shares of the Company, adding a net increase in common shares outstanding of 89,999,000. Next was the cancelation and conversion of series 675,000 A-1 preferred shares held by AGSS on December 31, 2020. The final result in the accompanying consolidated balance sheet,total number of shares outstanding is 93,417,302.

The next part of stockholder’s equity impacted was Additional Paid-in Capital. The impact was a reduction of Paid-in Capital of $579,000. This reduction was caused by an $89,999 impact of issuing new shares, a $10,000 impact form the cancelation of preferred shares and finally the secured loan due to the lender was $827,075. Factor fees in 2012 were approximately $119,000, and are included in interest expenses. (See Note 3)


10 – CONVERTIBLE PROMISSORY NOTES

In December 2011, the Company received a deposit of $170,000.  This deposit was an advance on three convertible promissory notes totaling approximately $314,000 signed on February 2, 2012, automatically convertible into future securities sold at 100% of the sale price and non-interest bearing.  These loans qualify as stock settled debt under ASC 480 with a fixed monetary amount of $314,000.  These loans were to mature in August 2012 but were converted into common stock in February 2012.  (See Note 12)
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011
In May 2012, the Company received $300,000 related to five convertible notes. The term of each note is 12 months. Interest is computed at 6% based on a 360 day year and is payable on the maturity date, and the conversion rate is $0.10 per share. Interest is due and payable only if the notes are repaid in cash. These notes were converted to common stock at their contractual conversion rate of $0.10 per share on July 15, 2012. (See Note 12)

At the note origination date, the Company recorded a debt discount for the beneficial conversion feature value related to the above referenced convertible note in the amount of $300,000 which is based on the intrinsic value between the fair market value$500,000 cost of the Company’s stockpurchase of AGSS, formally Heath Revenue Assurance Holdings, Inc.

There were two other transactions that impacted stockholders’ equity that occurred to the Company’s equity section relating to owner draws and the conversion price. The discount is being amortized to interest expense over the termmerger with a related company. As a part of the note. In accordance with ASC 470-20-40, upon conversion, the remaining unamortized portionnormal activity of the beneficial conversion feature value was expensed.


11 – COMMITMENTS AND CONTINGENCIES

Commitments

Leases:

Until August 2012,privately held Company, an S-Corp, shareholders were distributed funds accounted for as Owner Draws. The owner draw accounts were used primarily for taxes paid by the Company leased certain office equipment under non-cancelable operating lease arrangements.  Monthly payments under the lease agreements were approximately $600 per month. The lease expired in August 2012. In September 2012, the Company started a new non-cancelable operating leaseshareholders due to replace the office equipment.  The lease term is 5 years. Lease payments during the five years are approximately $500 per month.

On September 1, 2011, the Company entered into a commercial lease agreement for additional office space.  The lease term is one year with five successive one year renewal options. Lease payments during the first year were approximately $2,500 for one month and $4,400 for the remaining eleven months.  Starting September 1, 2012, the lease has been renewed for one year with a fixed payment of approximately $5,008 per month. For each year thereafterprofits of the initial year, the rent will be subjectS-Corp being transferred to an incrementtheir personal returns along with some personal expenses and personal cash needs. For 2021, there was approximately $105,000 posted as Owner draw from historical balances of 4%.
Future minimum lease payments under these leases are as follows:

Years Ending December 31:
Years Ending December 31:    
2013 $51,432 
2014  6,360 
2015  6,360 
2016  6,360 
Total $70,512 
Settlement Agreement:

On May 8, 2012, the Company terminated the employment of our Chief Marketing Officer (CMO) and subsequently amended its complaint to enforce certain non-competition clauses contained in the employment agreement. The Company sought a declaration of its obligations to pay severance under the terms of its then-existing employment agreement with the CMO.

On July 9, 2012, the Company and the former CMO entered into a Settlement Agreement to resolve two pending lawsuits arising out of the termination of his employment agreement. The lawsuit was initiated by the Company against the former CMO in the United States District Court for the Southern District of Florida.  In addition, the former CMO sued the Company in the United States District Court of the District of Colorado.
Pursuant to the Settlement Agreement, the former CMO agreed to abolish all claims and lawsuits against the Company and its CEO and COO and resigned any and all positions which he had or presently may have had with the Company.related party receivables. As part of the Settlement Agreement,preparation for merger these inter-company balances were removed through the Company agreed to make eleven (11) payments totaling $232,500 pursuant to the terms of his prior employment agreement. Additionally, the CMO agreed to transfer his 3,299,802 shares to an officer of the Company (see Note 12). These payments commenced July 2012,owner draw accounts. Total owner draw amounts were $473,238 and the outstanding balance as of$62,824 for December 31, 2012 was $115,278. In addition, the Company has agreed to abolish all claims2022, and lawsuits against the former CMO.  2021 respectively.

NOTE 8 – COMMITMENTS AND CONTINGENCIES

The Settlement Agreementcompany has a seven (7) day grace period for payments to the former CMO, after which time, he may seek court intervention to enforce the payments.  The Company's Chief Executive Officer and Chief Operating Officer, respectively, have personally guaranteed the payments of the Settlement Agreement. As a result of the Settlement Agreement, both parties are dismissing their respective filings and have agreed to not enter any more lawsuits concerning the scope of this matter.

HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011
Employment Agreements:

From time to time, the Company enters into employment agreementsmultiple vehicle lease agreement with certain of its employees.  These agreements typically include bonuses, some of which are performance-based in nature.Enterprise Leasing. As of December 31, 2012, no performance bonuses have been earned.2022, the company had 19 vehicles under lease. The Company owes its CEO $75,000 as stated in the February 2012 mergerlease agreement which is accrued in the accompanying consolidated Financial Statements as Due to officer.

Contingencies

From time to time, the Company is involved in litigation matters relating to claims arising from the ordinary course of business. While the results of such claims and legal actions cannot be predicted with certainty, the Company’s management does not believe that there are claims or actions, pending or threatened against the Company, the ultimate disposition of which would have a material adverse effect on our business, results of operations, financial condition or cash flows.

12 – STOCKHOLDERS' EQUITY (DEFICIT)

Recapitalization and Deemed Common Stock Issuance

On February 10, 2012, HRAA entered into a Merger agreement with Health Revenue Assurance Holdings, Inc. "HRAH" (a Nevada incorporated publicly-held company) and its subsidiary Health Revenue Acquisition Corporation (Acquisition Subsidiary) which was treated for accounting purposes as a reverse recapitalization with HRAA considered the accounting acquirer since the shareholders of HRAA obtained voting and management control of HRAH.   Each share of HRAA's common stock was exchanged for the right to receive approximately 1,271 shares of HRAH’s common stock. Before their entry into the Merger Agreement, no material relationship existed between HRAH or Acquisition Sub and HRAA.  As partincludes maintenance services along physical damage insurance. The term of the recapitalization, the Company is deemed to have issued 13,499,226 shares of common stock which represents the common shares outstanding in HRAH just prior to the merger.  There were no recorded assets or liabilities in HRAH just prior to the merger.  All share and per share amounts for all periods presented have been retroactively adjusted to reflect the recapitalization.

Forward Stock Split

On April 13, 2012, the Company’s Board of Directors authorized a 12.98 for 1 split of its common stock to stockholders of record as of April 13, 2012. Shares resulting from the split were issued on April 26, 2012. In connection therewith, the Company transferred $32,747 from additional paid in capital to common stock, representing the par value of additional shares issued. As a result of the stock split, fractional shares were rounded up. All share and per share amounts for all periods presented have been retroactively adjusted to reflect the stock split.

Common Stock
2011:
The Company hired a Chief Marketing Officer and granted 3,299,815 unrestricted shares of Common Stock for his future services. Accordingly, the Company treated the issuance of the shares to its Chief Marketing Officer as Stock Compensation.  At the time of the transaction the Company valued the stock based on current knowledge of the board and during the third quarter of 2011, the board estimated the fair value at approximately $256,000.  Subsequently the Company was able to raise capital at a higher valuation.   As a result of the Private Placement completed in February 2012, and since the grant of stock was within six months of this transaction the Board determined to revalue the stock at the price per share of the private placement and record additional compensation during the fourth quarter of 2011 of approximately $563,000 for total compensation of approximately $819,000.
2012:

On February 10, 2012, upon closing of the reverse merger, a $250,000 convertible bridge loan was automatically converted into an aggregate of 1,343,749 shares of common stock at the contractual conversion price of $0.19 per share.

On February 10, 2012, concurrently with the closing of the reverse merger, the Company sold 1,410,874 shares of the Company’s common stock for gross proceeds of $350,000 at a purchase price of $0.25 per share in a private placement offering.

On February 10, 2012 concurrently with the closing of the reverse merger, convertible promissory notes totaling $313,908 obtained on February 2, 2012 were converted into 1,265,381 shares of common stock or $0.25 per sharelease agreement varies based on the contractual conversion rate.
In April 2012,date vehicle were leased and the Company sold 1,394,909 common sharesrespective terms for each vehicle. The master lease is updated annually and requires annual internal financial reports and company tax return.

NOTE 9 – CONCENTRATION OF SALES

The company generated approximately $349,000 or $0.25 per share.

In May 2012, the Company recorded $300,000 to additional paid-in capital$24,600,000 and $22,100.000 in guard service revenue for the beneficial conversion value of convertible debt (see Note 10).
In July 2012, pursuant to a settlement agreement (see Note 11),years 2022 and 2021 respectively. Of the Company agreed to pay $232,500 and 3,299,802 common shares were returned to the Company.  The Company charged equity for the $232,500 in accordance with the settlement provisions of ASC 718 “Stock Compensation”.
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011
In July 2012, in connection with the settlement agreement discussed in Note 11, upon return of the 3,299,802 shares to the transfer agent, the shares were simultaneously reissued to delegees of the CEO, however, such shares were unvested and subsequently cancelled as a null and void issuance.
On July 15, 2012, the holders of the five convertible notes issuedtotal guard service revenue, approximately 92% was earned from four federal contracts operated by the Company in May 2012 exercisedcompany. The contracts and their rights under the agreement and converted $300,000 into 3,000,000 shares of common stock at the contractual conversion rate of $0.10 per share. 

In August 2012, the company raised approximately $22,000 with the sale of 77,743 shares of common stock at $0.28 per share.

During the period from October 2012 through December 2012, the Company sold 1,468,786 common shares for $335,600 at prices per share between $0.20 and $0.28.

In December 2012, the Company issued 2,375,000 shares of common stock in connection with a financing transaction as more fully described in note 7.
During 2012, the company incurred approximately $326,000 in offering costs that were charged to additional paid-in capital.
13 – CONCENTRATIONS

Sales to thirteen hospitals represented approximately 89% of net sales for the year ended December 31, 2012Wherein, seven and six hospitals respectively are part of two larger health systems.  The company has direct relationships with both the individual hospitals and the health systems.  As such, the strength of the relationship is driven by the individual hospitals.

Sales to two customers were approximately 32% for the year ended December 31, 2011.
Three vendors represented approximately 68% of the outstanding accounts payable balance as of December 31, 2011.
One customer represented approximately 62% of the accounts receivable as of December 31, 2012. Three customers represented approximately 60% of the accounts receivable as of December 31, 2011.
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011
14 - INCOME TAXES

The Company has elected to convert from a Subchapter S corporation for Federal income tax purposes to a C corporation effective October 21, 2011.  Accordingly, the Company's income or losses are passed through to the shareholders of HRAA for the period January 1 to October 21, 2011.  The Company will absorb the tax effects of any income or losses subsequent to the date of conversion to a C Corporation and in future years.
The Company has incurred aggregate cumulative net operating losses of approximately $1,558,862 for C corporation income tax purposes through December 31, 2012. The net operating loss carries forward for income taxes, purposes and may be available to reduce future years’ taxable income. These carry forwards will expire, if not utilized, starting in 2031 through 2032. Management believes that the realization of the benefits from these losses appears not more likely than not due to the Company’s limited operating history and continuing losses for income tax purposes. Accordingly, the Company has provided a 100% valuation allowance on the deferred tax asset to reduce the asset to zero. Management will review this valuation allowance periodically and make adjustments as warranted.
The Company’s income tax expense (benefit) differs from the “expected” tax expense for Federal income tax purposes computed by applying a Federal corporate tax rate of 34% to loss before income taxes as follows:
  
Year ended
December 31,
 2012
  
Year ended
December 31,
 2011
 
U.S. Federal “expected” income tax $(495,540) $(398,453)
State income tax  (52,906)  (58,596)
Non-deductible beneficial conversion interest  102,000   - 
Non-deductible items  24,769   - 
Stock compensation  -   319,252 
S Corp non-deductible/taxable items  -   (31,703)
Change in valuation allowance  421,677   169,500 
Total provision for income taxes $-  $- 

The tax effects of temporary differences that give rise to significant portions of deferred tax assets and liabilities at December 31, 2012 and 2011respective terms are as follows:

  2012  2011 
Deferred tax assets:      
Net operating loss carry forward $586,600  $169,500 
Accrued salary and other  35,821   - 
Total gross deferred tax assets  622,421   169,500 
Deferred tax liabilities:        
Depreciation  (31,244)  - 
Total gross deferred tax liabilities  (31,244)  169,500 
Less valuation allowance  (591,177)  (169,500)
Net deferred tax assets $-  $- 

A deferred tax asset of approximately $169,500 results from the C Corporation taxable losses totaling $434,509 from the period October 22, 2011 through December 31, 2011. The valuation allowance at December 31, 2011 was $169,500.  The increase during 2012 was $421,677.

The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for unrecognized tax benefits. As of December 31, 2012, tax years 2012 and 2011 remain open for IRS audit. The Company has received no notice of audit from the Internal Revenue Service for any of the open tax years.
HEALTH REVENUE ASSURANCE HOLDINGS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011
15 – SUBSEQUENT EVENTS

Through March 2013, the company raised approximately $13,000 through the issuance of 46,429 shares of common stock at a price per share of $0.28.

In January and February 2013, the Company entered into loan agreements with various investors and issued promissory notes upon receipt of $1,220,000. The loan agreements have an interest rate of 12% per annum payable over 26 months. Additionally, in connection with the financing, the Company issued 5,575,000 shares of common stock to the lenders as loan fees. The fair value per share of $0.28 (based on recent cash sales prices) was used to compute the relative fair value in accordance with ASC 470-20 and was recorded as a debt discount with a credit to additional paid-in-capital and such discount is being amortized over the term of the loans.

In January 2013, the company issued 50,266 shares of common stock vesting on July 31, 2013 as compensation to an employee. The shares were valued at $0.28 per share or $14,075 based on recent cash sales prices and such amount will be expensed over the vesting period.
 HEALTH REVENUE ASSURANCE HOLDINGS, INC.
5,125,000 SHARES OF COMMON STOCK

PROSPECTUS

YOU SHOULD RELY ONLY ON THE INFORMATION CONTAINED IN THIS DOCUMENT OR THAT WE HAVE REFERRED YOU TO. WE HAVE NOT AUTHORIZED ANYONE TO PROVIDE YOU WITH INFORMATION THAT IS DIFFERENT. THIS PROSPECTUS IS NOT AN OFFER TO SELL COMMON STOCK AND IS NOT SOLICITING AN OFFER TO BUY COMMON STOCK IN ANY STATE WHERE THE OFFER OR SALE IS NOT PERMITTED.
Until _____________, all dealers that effect transactions in these securities whether or not participating in this offering may be required to deliver a prospectus. This is in addition to the dealer’s obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.
The Date of This Prospectus is ____________, 2014
PART II   INFORMATION NOT REQUIRED IN THE PROSPECTUS
Item 13. Other Expenses of Issuance and Distribution.
Securities and Exchange Commission Registration Fee $165 
Transfer Agent Fees* $-0- 
Accounting fees and expenses* $7,500 
Legal fees and expenses* $5,000 
Blue Sky fees and expenses* $1,000 
Total* $13,665 
* Estimated
Item 14. Indemnification of Directors and Officers.
Our directors and officers are indemnified as provided by the Nevada corporate law and our Bylaws. We have agreed to indemnify each of our directors and certain officers against certain liabilities, including liabilities under the Securities Act. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the provisions described above, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than our payment of expenses incurred or paid by our director, officer or controlling person in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
We have been advised that in the opinion of the Securities and Exchange Commission indemnification for liabilities arising under the Securities Act is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities is asserted by one of our directors, officers, or controlling persons in connection with the securities being registered, we will, unless in the opinion of our legal counsel the matter has been settled by controlling precedent, submit the question of whether such indemnification is against public policy to a court of appropriate jurisdiction. We will then be governed by the court’s decision.

Item 15. Recent Sales of Unregistered Securities.
On April 12, 2012, we closed the offering and issued 107,466 shares of our common stock at a price of $3.22 per share, for a total aggregate amount of $346,040. The securities sold in these transactions were not registered under the Securities Act, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act. Each of the investors who received shares of our common stock in these transactions were accredited investors (as defined by Rule 501 under the Securities Act).
On May 23, 2012 the Company received $300,000 related to five convertible notes. The term of each note is 12 months. Interest is computed at 6% based on a 360 day year and is payable on the maturity date. Interest is due and payable only if the notes are repaid in cash. These notes may be converted to common stock at a conversion rate of $.10 per share at any time after 30 days. The securities sold in these transactions were not registered under the Securities Act, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act. Each of the investors who received shares of our common stock in these transactions were accredited investors (as defined by Rule 501 under the Securities Act).
On February 10, 2012, we sold 206,183 shares of our common stock at a purchase price of $3.22 per share for gross proceeds of $663,909.  In addition, as part of the offering, (i) holders of certain convertible notes of HRAA in an aggregate principal amount of $313,908 (the “HRAA Convertible Notes”) automatically converted into an aggregate of 97,487 shares of our common stock at a conversion price of $3.22 per share which is equal to the purchase price in the Offering, and (ii) holders of certain senior secured bridge loan promissory notes of HRAA in the aggregate principal amount of $250,000 (the “HRAA Notes”) automatically converted into an aggregate of 103,523 shares of our common stock at a conversion price of $2.415 per share which is equal to a discount of 25% to the purchase price in the Offering (collectively, the “Debt Conversions”).The securities sold in these transactions were not registered under the Securities Act, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act provided by Section 4(2) and Regulation D (Rule 506) under the Securities Act. Each of the investors who received shares of our common stock in these transactions were accredited investors (as defined by Rule 501 under the Securities Act).
On February 10, 2012, we issued 1,271,111 shares of our common stock to the former stockholders of HRAA, pursuant to the Merger Agreement. The securities issued in this transaction were not registered under the Securities Act, or the securities laws of any state, and were offered and sold pursuant to the exemption from registration under the Securities Act provided by either Regulation S under the Securities Act, or Section 4(2) and Regulation D (Rule 506) under the Securities Act.  Each of the former stockholders of HRAA who received shares of our common stock pursuant to the Merger Agreement were accredited investors (as defined by Rule 501 under the Securities Act) at the time of the Merger.

In August 2012, the Company raised approximately $22,000 through the issuance of 77,743 shares of common stock at $0.28 per share. These shares of our common stock qualified for exemption under Section 4(2) since the issuance shares by us did not involve a public offering. The offering was not a “public offering” as defined in Section 4(2) due to the insubstantial number of persons involved in the deal, size of the offering, manner of the offering and number of shares offered. We did not undertake an offering in which we sold a high number of shares to a high number of investors. In addition, the investors had the necessary investment intent as required by Section 4(2) since they agreed to and received share certificates bearing a legend stating that such shares are restricted pursuant to Rule 144 of the Securities Act. This restriction ensures that these shares would not be immediately redistributed into the market and therefore not be part of a “public offering.” Based on an analysis of the above factors, we have met the requirements to qualify for exemption under Section 4(2) of the Act for this transaction.
In October 2012, the Company raised approximately $335,000 through the issuance of 1,466,786 shares of common stock at prices ranging from $0.20 to $0.28 per share. These shares of our common stock qualified for exemption under Section 4(2) since the issuance shares by us did not involve a public offering. The offering was not a “public offering” as defined in Section 4(2) due to the insubstantial number of persons involved in the deal, size of the offering, manner of the offering and number of shares offered. We did not undertake an offering in which we sold a high number of shares to a high number of investors. In addition, the investors had the necessary investment intent as required by Section 4(2) since they agreed to and received share certificates bearing a legend stating that such shares are restricted pursuant to Rule 144 of the Act. This restriction ensures that these shares would not be immediately redistributed into the market and therefore not be part of a “public offering.” Based on an analysis of the above factors, we have met the requirements to qualify for exemption under Section 4(2) of the Act for this transaction.
In December 2012, the Company issued 2,375,000 shares of common stock in connection to certain Loan and Promissory Note Agreements with 6 lenders. The shares were issued in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act.  Our reliance on Section 4(2) of the Securities Act was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and us.
On January and February, 2013, we issued 5,575,000 shares of our common stock in connection to certain Loan and Promissory Note Agreements with 12 lenders. The shares were issued in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act of 1933.  Our reliance on Section 4(2) of the Securities Act was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and us.
On January 15, 2013, the Company issued 46,429 shares of our common stock in connection with certain stock purchase agreements among the Company and three purchasers. The Company issued the shares in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act. Our reliance on Section 4(2) of the Securities Act was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and us.
On January 31, 2013, the Company issued 50,266 shares of our common stock in connection with serviced provided to the Company. The Company issued the shares in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act. Our reliance on Section 4(2) of the Securities Act was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and us.

On March 2013, the Company entered into a one-year agreement with a consultant for 230,000 vested shares and cash consideration.  The shares were valued on the agreement date which was the measurement date at $0.35, based on the quoted trading price and the $80,500 is being expensed over the term of the contract.  The shares were issued on April 4, 2013 to the consultant. The shares were issued in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act of 1933.  Our reliance on Section 4(2) of the Securities Act was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and us.
On April 1, 2013, the Company issued 54,847 shares of common stock as compensation to two employees for services rendered through March 31, 2013. The shares were valued at $0.49 per share based on the quoted trading price per share. The shares were issued in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act.  Our reliance on Section 4(2) of the Securities Act was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and us.
On May 19, 2013, the Company raised $250,000 through the issuance of 625,000 shares of common stock at a price per share of $0.40 per share. The shares were issued in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act.  Our reliance on Section 4(2) of the Securities Act was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and us.
On May 24, 2013 and June 21, 2013, the Company raised $50,000 and $300,000 through the issuance of 125,000 and 750,000 shares of common stock at a price of $0.40 per share. The shares were issued in reliance upon the exemption from registration contained in Section 4(2) of the Securities.  Our reliance on Section 4(2) of the Securities Act was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and us.
On June 27, 2013, the Company entered into a financial advisor and agent placement agreement whereby the Company had the option to pay in cash or issue 100,000 shares of common stock valued at $0.51 per share as compensation for services to be rendered. The Company issued the shares on September 2013. The shares were issued in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act. Our reliance on Section 4(2) of the Securities Act was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and us.
On July 8, 2013 and August 7, 2013 pursuant to private placements, the Company issued 1,000,000 shares of common stock in exchange for cash of $400,000 with a per share price of $0.40. The shares were issued in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act of 1933. Our reliance on Section 4(2) of the Securities Act was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and us.
On August 21, 2013, August 27, and August 30, 2013, the Company raised $25,000, $100,000 and $100,000 through the issuance of 100,000, 400,000, and 400,000 shares of common stock at a price of $0.25 per share. The shares were issued in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act.  Our reliance on Section 4(2) of the Securities Act was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and us.

On August 22, 2013 and August 28, 2013, the Company converted $402,083 in unsecured investor promissory notes for five (5) individuals into one million six hundred eight thousand three hundred and thirty three (1,608,333) common shares at a conversion price of $0.25 per share. The shares were valued at $514,666 based on the quoted trading price of $0.32 and accordingly, the company recorded a loss on conversion of $112,583. The shares were issued in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act.  Our reliance on Section 4(2) of the Securities Act was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and us.

In September 2013, the Company issued 95,052 shares of common stock as compensation to three (3) employees for services rendered through June 30, 2013. The shares were valued at $0.48 per share based on the quoted trading price per share. The shares were issued in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act of 1933.  Our reliance on Section 4(2) of the Securities Act was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and us.
On September 6, 2013, the Company entered into a three year agreement with a company to provide consulting and recruiting services. Upon execution of the agreement, the Company issued 50,000 shares of common stock valued at $0.30 per share in consideration of their services to be rendered for the first year of the agreement. The Company issued the shares in September 2013. The shares were issued in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act of 1933.  Our reliance on Section 4(2) of the Securities Act was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and us.
On September 9, 2013, the Company entered into a one year Material Consulting Agreement with Mr. Michael Ciprianni to provide certain consulting services related to the Company’s business in exchange for four million one hundred twenty five thousand (4,125,000) shares of common stock in consideration of the services to be rendered. The shares were issued in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act.  Our reliance on Section 4(2) of the Securities Act was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and us.
On September 30, 2013, the Company issued 187,500 shares of common stock as compensation to two (2) employees for services rendered through September 30, 2013. The shares were valued at $0.23 per share based on the quoted trading price per share. The shares were issued in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act of 1933.  Our reliance on Section 4(2) of the Securities Act was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and us.
On November 12, 2013, we issued and sold an aggregate of 13,500,000 shares of Series A Preferred Stock, and Warrants to purchase an aggregate of 27,000,000 shares of Common Stock for an aggregate purchase price of $5,400,000 in cash. The Company issued the Series A Preferred Shares and Warrants in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act and Rule 506(b) of Regulation D. The Company’s reliance on Section 4(2) of the Securities Act was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by the Company; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and the Company.

On December 31, 2013, the Company issued 75,000 shares of common stock as compensation to one (1) employee for services rendered through December 31, 2013. The shares were valued at $0.25 per share based on the quoted trading price per share. The shares were issued in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act of 1933.  Our reliance on Section 4(2) of the Securities Act was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and us. 
Item 16. Exhibits and Financial Statement Schedules.

EXHIBIT
NUMBER
Social Security Administration, NSC DESCRIPTION-September 2022 through September 2027
   
2.1 Agreement and Plan of Merger and Reorganization, dated February 10, 2012, among Health Revenue Assurance Holdings, Inc., f/k/a Anvex International, Inc., Health Revenue Acquisition Corp. and Health Revenue Assurance Associates, Inc.(1)
2.2Social security Administration, SSC Articles of Merger filed with the State of Nevada on February 10, 2012(1)-June 2022 through June 2027
2.3 Articles of Merger filed with the State of Maryland on February 10, 2012(1)
3.1 
Social Security Administration, WBDOC-June 2021 through July 2026
National Institute of Health- EPA-May 2020 through March 2025

F-11

NOTE 10 – LITIGATION AND CLAIMS

As of December 31, 2022, there was one employment issue pending. The issue involves a terminated employee alleging discrimination and wrongful termination. A lawsuit has not been filed only a demand letter has been presented. Management has been working with the attorneys to find a reasonable settlement to this dispute without going to trial. After several months of discussion and negotiation it appears that the complaint will be settled for $23,000. It is anticipated that an agreement may be reached by the end of March 2023.

Per Attorney letters received there are no other pending cases or legal matters.

NOTE 11 – INCOME TAXES

Prior to the merger the Company had elected, with the consent of its stockholders, to be treated as an S Corporation under the Internal Revenue Code. In lieu of corporate income taxes, the stockholders of an S Corporation are taxed on their proportionate share of the Company’s income. As a result of the merger on December 9, 2022, the S Corporation status ends, and the consolidated 2022 tax return will be filed as a standard corporation. However, due to the losses incurred during the tax year ending 2022, there will be no tax liability for 2022. Therefore, no provision for income taxes has been included in the accompanying financial statements.

NOTE 12 – SUBSEQUENT EVENTS

On March 22, 2023, The Company was notified by the Contracting Officer of National Institute of Health-EPA our contract with them was not continuing and they were invoking the 45 days cancelation clause in the contract. As a result, the company will transition the closure of the contract on or about April 30, 2023. This will reduce on our annual revenue in the amount of approximately $5,122,000 in 2023, along with direct expenses that will be reduced by $4,650,000.

On March 23, 2023, the board of directors approved the purchase of TransportUS, Inc., a California Corporation, with a valuation of approximately $3.72 million, for $3 million. The purchase will be made with restricted common stock only based on market price at the date of closure. Estimated number of shares for purchase is to be 1.5 million. TransportUS Inc. has annual revenues of approximately $4,350,000 with operating net income potential of 10%.

F-12

PART II – INFORMATION NOT REQUIRED IN PROSPECTUS

ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION

The following are our expenses related to our offering:

Securities and Exchange Commission Registration Fee $ 
Legal Fees $25,000.00 
Accounting Fees* $  
Printing and Engraving* $- 
Blue Sky Qualification Fees and Expenses* $- 
Transfer Agent Fee* $- 
Miscellaneous* $ 
TOTAL $ 

*Estimated costs

ITEM 14. INDEMNIFICATION OF DIRECTORS AND OFFICERS

The Registrant is a Nevada corporation, and the provisions of the Nevada Revised Statutes will be applicable to the indemnification the Registrant offers to its officers, directors and agents. In its By-laws the Registrant generally agrees to indemnify each person who is a director or officer of the Registrant or serves at the request of a director or officer as a director, officer, employee or agent of another company, in accordance with the Registrant’s By-laws, to the fullest extent permissible by the Nevada Revised Statutes or other applicable laws. In its By-laws the Registrant indicates that, in connection with any such indemnification, it is within the discretion of the Board of Directors whether to advance any funds in advance of disposition of any action, suit or proceeding.

Under the Articles of Incorporation, the By-laws, and the Nevada Revised Statutes, no director of the Registrant will be personally liable to the Registrant or its stockholders for monetary damages, or expenses in defense of an action, for breach of fiduciary duty as a director or by reason of the fact that he is or was a director, officer, employee or agent of the Registrant, or serving in such capacity for another entity at the request of the Registrant, except for liability (i) for any breach of the director’s duty of loyalty to the Registrant or its stockholders, (ii) for acts or omissions not in good faith or there is reasonable cause to believe it was unlawful, or (iii) for any transaction from which the director derived an improper personal benefit. The Registrant has the power to purchase and maintain insurance on behalf of any persons potentially eligible for indemnification. The rights to indemnification are also applicable to those persons entitled to such rights by virtue of the Registrant’s consummation of a business combination, including such consummations wherein the Registrant is merged into or reorganized as a new entity.

The foregoing description of available indemnification is a summary only and is qualified in its entirety by the complete terms and provisions of the Nevada Revised Statutes and the Registrant’s Articles of Incorporation and By-laws, filed herewith as exhibits.

ITEM 15RECENT SALES OF UNREGISTERED SECURITIES

Below is a chart of all the shareholders who purchased shares since December 31, 2022.

None.

II-1

ITEM 16. EXHIBITS

ExhibitIncorporated by ReferenceFiled Furnished
No.Exhibit DescriptionFormDateHerewith
2.1Definitive Share Exchange Agreement8-K12/14/2022
3.1Amended and Restated Articles of Incorporation (2)of AMERIGUARD SECURITY SERVICES, INC. (Nevada)8-K12/14/2022
3.2Amended and Restated By-Laws (7)Bylaws of AMERIGUARD SECURITY SERVICES, INC. (Nevada)8-K12/14/2022
3.3Certificate of Amendment to Articles of Incorporation (3)Incorporations Ameriguard Security Services, Inc. (Ameriguard)(California)8-K12/14/2022
3.4Certificate of Amendment to Articles of Incorporation (6)Bylaws AGS, Inc. (Ameriguard) (California)8-K12/14/2022
3.55.1Certificate Of Designation Of Preferences And Rights Of Series A Convertible Preferred Stock (7)Opinion of McMurdo Law Group, LLC, legal counsel
4.110.1Form of Warrant issued to the Purchasers under the Securities Purchase Agreement, dated November 12, 2013 (7)Promissory Note (Secured by Stock Pledge)8-K12/14/2022
5.1*10.2Legal Opinion of Szaferman Lakind Blumstein & Blader, PCStock Pledge Agreement8-K12/14/2022
10.123.1FormConsent of Registration Rights Agreement(1)BF Borgers CPA PCFiled
10.223.2Split-Off Agreement, dated February 10, 2012, among Health Revenue Assurance Holdings, Inc., f/k/a Anvex International, Inc., Anvex Split Corp. and Anna Vechera(1)Consent of McMurdo Law Group, LLC (included in Exhibit 5.1)
10.3107General Release Agreement, dated February 10, 2012, among Health Revenue Assurance Holdings, Inc., f/k/a Anvex International, Inc., Anvex Split Corp. and Anna Vechera(1)
10.4Filing fee scheduleHealth Revenue Assurance Holdings, Inc., f/k/a Anvex International , Inc. 2012 Equity Incentive Plan(1)
10.5Form of Convertible Note(3)
10.6Form Loan Agreement and Promissory Note (4)
10.7FiledConsulting Agreement, dated September 9, 2013, by and among Michael Ciprianni and Health revenue Assurance Associates, In. (5)
10.8Employment agreement between the Company and Andrea Clark, effective October 2, 2013 (6)
10.9Addendum to Employment agreement between the Company and Andrea Clark, effective November 12, 2013 (7)
10.10Employment agreement between the Company and Robert Rubinowitz, effective October 2, 2013 (6)
10.11Addendum to Employment agreement between the Company and Robert Rubinowitz, effective November 12, 2013 (7)
10.12Employment agreement between the Company and Evan McKeown, effective October 2, 2013 (6)
10.13Addendum to Employment agreement between the Company and Evan McKeown, effective November 12, 2013 (7)
10.14Employment agreement between the Company and Dean Boyer, effective October 2, 2013 (6)
10.15Addendum to Employment agreement between the Company and Dean Boyer, effective November 12, 2013 (7)
10.16Securities Purchase Agreement, dated November 12, 2013 (7)
10.17Form of Indemnification Agreement (7)
23.1**Consent of Auditor Salberg & Company, PA
23.2**Consent of Auditor Friedman, LLP
23.3**Consent of Szaferman Lakind Blumstein & Blader, PC (filed as Exhibit 5.1)


101.INS**XBRL Instance Document
101.SCH**XBRL Taxonomy Extension Schema Document
101.CAL**XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**XBRL Taxonomy Extension Label Linkbase Document
101.PRE**XBRL Taxonomy Extension Presentation Linkbase Document
(1)Filed as an exhibit to our Current Report on Form 8-K, filed with the SEC on February 13, 2012.
(2)Filed as an exhibit to our Registration Statement on Form S-1, filed with the SEC on March 24, 2011.
(3)Filed as an exhibit to our Registration Statement on Form S-1, filed with the SEC on September 10, 2012.
(4)Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on February 20, 2013.
(5)Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on September 12, 2013.
(6)Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on October 8, 2013.
(7)Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on November 18, 2013.
*To be filed by amendment.
**Filed herewith.

II-2

Item 17. Undertakings.
(A) 

ITEM 17UNDERTAKINGS

UNDERTAKINGS

The undersigned Registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
i.    To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
ii.   To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement.
iii.  To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. 
(4)

1. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

The Registrant is registering securities under Rule 415 of the Securities Act and hereby undertakes:

1. To file, during any period in which it offers or sells securities, a post-effective amendment to this registration statement to:

(i)Include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii)Reflect in the prospectus any facts or events which, individually or together, represent a fundamental change in the information in the registration statement; and notwithstanding the forgoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospects filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in the volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

(iii)Include any additional or changed material information on the plan of distribution.

2. That, for the purposes of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

3. To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

II-3

(5)

4. The undersigned Registrant hereby undertakes that:

A. For determining liability of the undersigned issuer under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned issuer undertakes that in a primary offering of securities of the undersigned issuer pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned issuer will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

i.Any preliminary prospectus or prospectus of the undersigned issuer relating to the offering required to be filed pursuant to Rule 424;

ii.Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned issuer or used or referred to by the undersigned issuer;
iii.The portion of any other free writing prospectus relating to the offering containing material information about the undersigned issuer or its securities provided by or on behalf of the undersigned issuer; and

iv.Any other communication that is an offer in the offering made by the undersigned issuer to the purchaser.

B. That for the purpose of determining liability under the Securities Act to any purchaser:

Each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

“Insofar as indemnification for liabilities arising under the Securities Act of 1933 (the “Act”) may be permitted to directors, officers and controlling persons of the issuer pursuant to the foregoing provisions, or otherwise, the issuer has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.”

In the event that a claim for indemnification against such liabilities (other than the payment by the issuer of expenses incurred or paid by a director, officer or controlling person of the issuer in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the issuer will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

II-4

Pursuant to the requirementrequirements of the Securities Act of 1933, as amended, the registrantRegistrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereuntothereto duly authorized in the City of Plantation, State of Florida,Fresno, California on February 12, 2014.

April 10, 2023.

HEALTH REVENUE ASSURANCE HOLDINGS,AMERIGUARD SECURITY SERVICES, INC.
By:/s/ Andrea ClarkLawrence Garcia
Andrea Clark
Lawrence Garcia

Chairman of the Board,
Chief Executive Officer,
and Director

By:/s/ Evan McKeown
Evan McKeown
Chief Financial Officer/
Principal
Accounting Executive Officer

In accordance with the requirements of the Securities Exchange Act of 1934,1933, this report has beenregistration statement was signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

stated.

Name/s/ Lawrence GarciaTitleDateDated: April 10, 2023
/s/ Andrea Clark

Lawrence Garcia
Chairman of the Board,
Chief Executive Officer,
and Director
Principal Executive Officer

February 12, 2014
Andrea Clark
/s/ Mike GoossenDated: April 10, 2023
/s/ Evan McKeown

Kathy M. Griffin
Chief Financial Officer, Director,
and Principal Accounting Officer

February 12, 2014
Evan McKeown
/s/ Douglas AndersonDated: April 10, 2023
/s/ Robert Rubinowitz

Douglas Anderson

Director

Chief Operating Officer, President, Secretary, Treasurer,
February 12, 2014
Robert Rubinowitzand Director
/s/ Peter RussoDirector
February 12, 2014
Peter Russo
/s/ Michael BrainardDirector
February 12, 2014
Michael Brainard
/s/ David KroinDirector
February 12, 2014
David Kroin
/s/ Mitchell D. Kaye J.D.Director
February 12, 2014
Mitchell D. Kaye J.D.

II-5

II-6